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Posttranslational  modification   by   Small  Ubiquitin-­‐‑like  modifiers   (SUMOs)   affects   the  
behaviour   of   proteins   involved   in  diverse   cellular   processes   and   is   indispensable   for  
cell  survival.  Proteomic  studies  have  identified  hundreds  of  putative  targets  of  SUMO  
conjugation,  but  understanding  the  substrate-­‐‑specific  consequences  of  the  modification  
requires   knowledge   of   precise   target   lysines.   Procedures   for   the   high-­‐‑throughput  
mapping  of  SUMO  modification  sites,  however,  are  lacking.    
A  method  has  been  developed  enabling  global  identification  of  sumoylated  lysines  by  
mass   spectrometry   (MS).   The   workflow   entails   in   vivo   conjugation   to   hexahistidine  
(6His)-­‐‑tagged  SUMO,   in  which   the   residue  preceding   the  C-­‐‑terminal  Gly-­‐‑Gly   (diGly)  
has   been   mutated   to   lysine   (6His-­‐‑SUMOKGG).   Lys-­‐‑C   digestion   of   6His-­‐‑SUMOKGG  
conjugates  yields  a  diGly  remnant  on  modified  lysines  that  cannot  be  attributed  to  any  
other   known  modifier.   This   allows   enrichment   of   SUMO   remnant-­‐‑modified  peptides  
with  a  diGly-­‐‑Lys  (K-­‐‑ε-­‐‑GG)-­‐‑specific  antibody  prior  to  their  MS-­‐‑based  analysis.    
Application   of   the  workflow   enabled   the   unambiguous   identification   of   612   SUMO2  
conjugation  sites  from  the  nuclear  fraction  of  unperturbed  human  cells  and  8262  sites  
from  the  same  fraction  of  heat-­‐‑stressed  cells.  Exposure  to  proteotoxic  stress   increased  
the   extent   of   substrate   sumoylation,   and   targeted   proteins   with   similar   functions   or  
found   within   the   same   macromolecular   complexes.   These   data   provide   a  
comprehensive  resource  for  future  research  on  the  physiological  role  of  sumoylation  in  




Table  of  Contents  
Declaration  ..................................................................................................................................  II	  
Acknowledgements  ..................................................................................................................  III	  
Abstract  ......................................................................................................................................  IV	  
Table  of  Contents  .......................................................................................................................  V	  
Table  of  Figures  .........................................................................................................................  IX	  
Table  of  Tables  ..........................................................................................................................  XII	  
Table  of  Equations  .................................................................................................................  XIII	  
Amino  acids  ............................................................................................................................  XIV	  
Abbreviations  ..........................................................................................................................  XV	  
1.	   Introduction  ..........................................................................................................................  1	  
1.1.	   SUMO  ............................................................................................................................................  2	  
  Characteristics  of  SUMO  proteins  .........................................................................................  2	  1.1.1.
  SUMO  conjugation  pathway  ..................................................................................................  4	  1.1.2.
  SUMO  interaction  motif  ..........................................................................................................  7	  1.1.3.
  Molecular  mechanisms  of  SUMO  modification  ...................................................................  7	  1.1.4.
1.2.	   SUMO  is  essential  for  viability  ................................................................................................  10	  
1.3.	   SUMO  modification  in  proteostasis  ........................................................................................  11	  
1.4.	   SUMO  in  proteopathic  diseases  ..............................................................................................  14	  
  Polyglutamine  diseases  .........................................................................................................  14	  1.4.1.
  Alzheimer’s  disease  ...............................................................................................................  15	  1.4.2.
1.5.	   Identification  of  SUMO  substrates  ..........................................................................................  17	  
2.	   Materials  and  methods  .....................................................................................................  20	  
2.1.	   Cell  culture  procedures  ............................................................................................................  21	  
  Cultured  cell  lines  ..................................................................................................................  21	  2.1.1.
  Generation  of  HEK2936His-­‐‑SUMO2-­‐‑T90K  N3S  cells  .....................................................................  21	  2.1.2.
  Cell  culture  conditions  for  label-­‐‑free  experiments  ............................................................  22	  2.1.3.
  Cell  culture  conditions  for  SILAC-­‐‑based  experiments  .....................................................  23	  2.1.4.
  Cell  proliferation  assay  ..........................................................................................................  24	  2.1.5.
  Cell  lysis  without  subcellular  fractionation  ........................................................................  25	  2.1.6.
  Cell  lysis  with  subcellular  fractionation  .............................................................................  25	  2.1.7.
2.2.	   Protein  techniques  .....................................................................................................................  27	  




  SDS-­‐‑PAGE,  Western  blot  analyses,  and  Coomassie  brilliant  blue  staining  ...................  28	  2.2.2.
  Protein  concentration  estimation  .........................................................................................  29	  2.2.3.
  Antibodies  ...............................................................................................................................  29	  2.2.4.
  Cross-­‐‑linking  of  K-­‐‑ε-­‐‑GG-­‐‑specific  antibody  ........................................................................  30	  2.2.5.
  Protein  precipitation  ..............................................................................................................  31	  2.2.6.
2.3.	   Sample  preparation  for  MS  ......................................................................................................  32	  
  Nickel  affinity  chromatography  ...........................................................................................  32	  2.3.1.
  Filter-­‐‑aided  sample  preparation  and  protein  digestion  ...................................................  32	  2.3.2.
  In  solution  digestion  of  proteins  ..........................................................................................  33	  2.3.3.
  Immunoaffinity  purification  of  diGly-­‐‑Lys-­‐‑containing  peptides  .....................................  34	  2.3.4.
  Desalting  of  peptides  .............................................................................................................  34	  2.3.5.
  SUMOKGG  workflow  ...............................................................................................................  35	  2.3.6.
2.4.	   MS  procedures  ...........................................................................................................................  36	  
  Liquid  chromatography  (LC)-­‐‑tandem  mass  spectrometry  (MSMS)  ...............................  36	  2.4.1.
  Analysis  of  raw  MS  files  ........................................................................................................  38	  2.4.2.
2.5.	   Microscopy  techniques  .............................................................................................................  39	  
  Immunofluorescence  microscopy  ........................................................................................  39	  2.5.1.
  Light  microscopy  ....................................................................................................................  39	  2.5.2.
2.6.	   Bioinformatic  analyses  ..............................................................................................................  40	  
  Alignments  ..............................................................................................................................  40	  2.6.1.
  Sequence  analyses  ..................................................................................................................  40	  2.6.2.
  Pathway  analyses  ...................................................................................................................  40	  2.6.3.
  Protein  secondary  structure  prediction  ..............................................................................  41	  2.6.4.
  Statistical  computing  .............................................................................................................  42	  2.6.5.
3.	   Development  of  a  mass  spectrometry-­‐‑based  method  for  the  system-­‐‑wide  
identification  of  SUMO  modification  sites  ............................................................................  43	  
3.1.	   Introduction  ................................................................................................................................  44	  
  Past  limitations  of  mapping  the  modification  sites  of  the  sumoylated  proteome  ........  45	  3.1.1.
3.2.	   Results  .........................................................................................................................................  48	  
  Selection  of  an  appropriate  cell  lysis  solution  with  a  compatible  protein  affinity  tag  .  48	  3.2.1.
  6His-­‐‑SUMO2T90K  as  a  biochemical  tool  ................................................................................  50	  3.2.2.
  Functional  characterisation  of  SUMO2T90K  ..........................................................................  52	  3.2.3.
  Characterisation  of  HEK293  N3S  cells  stably  expressing  6His-­‐‑SUMO2T90K  ..................  55	  3.2.4.
  Overview  of  the  biochemical  approach  designed  for  the  global  identification  3.2.5.
6His-­‐‑SUMO2T90K  modification  sites  ...............................................................................................  59	  




  Depletion  of  endoproteinases  Lys-­‐‑C  and  Glu-­‐‑C  from  the  solution  of  peptides  ...........  69	  3.2.7.
  Characterisation  of  Lys-­‐‑C  and  Glu-­‐‑C  substrate  specificity  and  proteolytic  efficiency  in  3.2.8.
IAP  buffer  ..........................................................................................................................................  71	  
  Evaluating  the  impact  of  tandem  protein  digestion  on  the  sequence  coverage  of  the  3.2.9.
proteome  ............................................................................................................................................  76	  
  Removal  of  K-­‐‑ε-­‐‑GG-­‐‑specific  antibody  fragments  from  the  mixture  of  purified  3.2.10.
peptides  ..............................................................................................................................................  79	  
  Improving  LC-­‐‑MSMS  settings  for  the  optimal  acquisition  of  low  abundance  peptides3.2.11.
  .............................................................................................................................................................  82	  
  Uncovering  the  false  discovery  rate  of  the  SUMOKGG  workflow  ..................................  90	  3.2.12.
  Benchmarking  the  SUMOKGG  workflow  ...........................................................................  94	  3.2.13.
3.3.	   Discussion  ...................................................................................................................................  98	  
  SUMOKGG  workflow  for  the  global  identification  of  SUMO2  modification  sites  ..........  98	  3.3.1.
  Additional  applications  of  the  SUMOKGG  workflow  .......................................................  100	  3.3.2.
  Comparison  of  the  SUMOKGG  workflow  with  alternative  methods  .............................  103	  3.3.3.
  Future  directions  of  SUMO  site  proteomics  .....................................................................  107	  3.3.4.
4.	   Global  reprogramming  of  SUMO  signalling  in  response  to  heat-­‐‑induced  
proteotoxic  stress  ....................................................................................................................  110	  
4.1.	   Introduction  ..............................................................................................................................  111	  
4.2.	   Results  .......................................................................................................................................  114	  
  Time  course  of  6His-­‐‑SUMO2T90K  conjugation  to  substrate  proteins  in  response  to  4.2.1.
hyperthermic  stress  ........................................................................................................................  114	  
  Overview  of  the  experimental  strategy  .............................................................................  116	  4.2.2.
  Preliminary  examination  of  the  quality  of  fractionated  protein  samples  ....................  120	  4.2.3.
  A  comprehensive  validation  of  the  sample  preparation  workflow  ..............................  122	  4.2.4.
  Uncovering  the  dynamics  of  the  human  proteome  in  response  to  heat-­‐‑induced  4.2.5.
proteotoxic  stress  ............................................................................................................................  131	  
  Spatial  distribution  of  HSF1  and  SUMO2  .........................................................................  137	  4.2.6.
  Subcellular  localisation  and  functional  characterisation  of  targets  of  SUMO2  ...........  141	  4.2.7.
  Extent  of  SUMO2  modification  of  individual  proteins  in  human  cells  ........................  146	  4.2.8.
  Sequence  context  of  SUMO2  modification  sites  ..............................................................  149	  4.2.9.
  Secondary  structure  context  of  the  sumoylated  lysines  ...............................................  157	  4.2.10.
  SUMO2  modification  of  macromolecular  protein  complexes  .....................................  158	  4.2.11.
4.3.	   Discussion  .................................................................................................................................  164	  
  Global  effects  of  heat  on  the  HEK2936His-­‐‑SUMO2-­‐‑T90K  proteome  .........................................  164	  4.3.1.




  Future  perspectives  ..............................................................................................................  169	  4.3.3.
5.	   Bibliography  .....................................................................................................................  171	  
6.	   Appendix  ..........................................................................................................................  201	  
6.1.	   Supplementary  files  and  tables  .............................................................................................  202	  
6.2.	   Publications  ..............................................................................................................................  203	  
  




Table  of  Figures  
Figure  1.1  |  Human  Ubls  share  similar  organisation  of  secondary  structure  elements.  ..  3	  
Figure  1.2  |  The  cycle  of  SUMO  modification.  .......................................................................  5	  
Figure  1.3  |  Downstream  effects  of  SUMO  modification.  ....................................................  9	  
Figure  3.1  |  Digestion  of  human  Ubl-­‐‑conjugated  proteins  with  Lys-­‐‑C  produces  a  
Gly-­‐‑Gly  remnant  on  target  lysines  modified  solely  by  SUMO2T90K.  ..........................  51	  
Figure  3.2  |  SUMO2  and  SUMO2T90K  polymerisation  and  conjugation  to  various  
substrate  proteins  in  vitro  has  a  similar  concentration  dependence.  .........................  53	  
Figure  3.3  |  SUMO2  and  SUMO2T90K  are  deconjugated  from  various  substrate  proteins  
at  similar  rates  in  vitro.  ......................................................................................................  54	  
Figure  3.4  |  SUMO-­‐‑specific  proteases  process  the  inactive  pro-­‐‑forms  of  recombinant  
SUMO2  and  SUMO2T90K  into  functional  mature  proteins  at  a  similar  rate.  ..............  54	  
Figure  3.5  |  Parental  and  6His-­‐‑SUMO2T90K-­‐‑expressing  HEK293  N3S  cells  share  virtually  
identical  morphology.  .......................................................................................................  56	  
Figure  3.6  |  Comparable  doubling  time  can  be  observed  between  parental  and  
6His-­‐‑SUMO2T90K-­‐‑expressing  HEK293  cells.  ...................................................................  57	  
Figure  3.7  |  In  HEK2936His-­‐‑SUMO2-­‐‑T90K,  endogenous  SUMO2/3  and  6His-­‐‑SUMO2T90K  are  
expressed  at  comparable  levels  and  respond  to  heat  stress  similarly.  ......................  59	  
Figure  3.8  |  Depiction  of  the  SUMOKGG  workflow.  ..............................................................  60	  
Figure  3.9  |  6His-­‐‑SUMO2T90K-­‐‑conjugated  proteins  can  be  enriched  using  nickel  affinity  
chromatography.  ...............................................................................................................  66	  
Figure  3.10  |  Sumoylated  or  polyhistidine-­‐‑containing  proteins  in  the  flow-­‐‑through  
fraction  are  not  efficiently  retained  during  the  second  cycle  of  nickel  affinity  
chromatography.  ...............................................................................................................  68	  
Figure  3.11  |  Endoproteinases  Lys-­‐‑C  and  Glu-­‐‑C  are  sufficiently  separated  from  a  
mixture  of  BSA  peptides  using  30  kDa  filter  units.  ......................................................  70	  
Figure  3.12  |  Digestion  of  proteins  in  immunoaffinity  purification  buffer  does  not  alter  
the  efficiency  or  specificity  of  endoproteinases  Lys-­‐‑C  and  Glu-­‐‑C.  ............................  73	  
Figure  3.13  |  In-­‐‑parallel  digestion  of  proteins  with  Lys-­‐‑C,  and  with  Lys-­‐‑C  and  Glu-­‐‑C  




Figure  3.14  |  Chemical  cross-­‐‑linking  of  K-­‐‑ε-­‐‑GG-­‐‑specific  antibody  to  protein  A  agarose  
beads  reduces  the  release  of  antibody  fragments  upon  low-­‐‑pH  elution.  .................  81	  
Figure  3.15  |  Proteome-­‐‑wide  identification  of  sumoylation  sites  is  enabled  by  the  
efficient  enrichment  and  improved  acquisition  of  modified  peptides  by  MS.  .........  83	  
Figure  3.16  |  Acquisition  of  LC-­‐‑MSMS  data  with  ultra  sensitive  instrument  settings  
improves  the  quality  of  MSMS  spectra.  .........................................................................  84	  
Figure  3.17  |  Acquisition  of  MSMS  spectra  with  ultra  sensitive  instrument  settings  
increases  the  number  of  precursor  ions  injected  into  the  Orbitrap,  and  improves  
peptide  sequence  coverage.  .............................................................................................  87	  
Figure  3.18  |  The  majority  of  the  6His-­‐‑SUMO2T90K  modification  sites  are  identified  
using  ultra  sensitive  MS  settings  optimised  for  the  acquisition  of  low  abundance  
peptides.  ..............................................................................................................................  88	  
Figure  3.19  |  Experimental  strategy  to  understand  the  FDR  of  the  SUMOKGG  workflow.
  ..............................................................................................................................................  92	  
Figure  3.20  |  Less  than  1  %  of  the  Gly-­‐‑Gly-­‐‑modified  peptides  identified  using  the  
SUMOKGG  workflow  arise  from  proteins  conjugated  to  a  different  Ubl.  ...................  93	  
Figure  3.21  |  Reproducibility  of  the  SUMOKGG  workflow.  .................................................  95	  
Figure  3.22  |  The  SUMOKGG  workflow  increases  the  known  number  of  sumoylation  
sites  by  more  than  tenfold.  ...............................................................................................  97	  
Figure  3.23  |  The  phenotype  of  S.  pombe  strain  expressing  solely  6His-­‐‑SUMOL109K  is  
indistinguishable  from  wild-­‐‑type  counterpart.  ...........................................................  101	  
Figure  4.1  |  The  apex  of  6His-­‐‑SUMO2T90K  conjugation  is  reached  in  30–60  minutes  of  
exposure  to  acute  heat  stress.  .........................................................................................  115	  
Figure  4.2  |  Experimental  strategy.  ......................................................................................  117	  
Figure  4.3  |  Increased  SUMO2  conjugation  in  the  nuclear  fraction  of  heat-­‐‑stressed  cells.
  ............................................................................................................................................  121	  
Figure  4.4  |  Reproducibility  of  subcellular  fractionation.  ................................................  125	  
Figure  4.5  |  Efficiency  of  subcellular  fractionation.  ...........................................................  128	  
Figure  4.6  |  Spatial  distribution  of  the  HEK2936His-­‐‑SUMO2-­‐‑T90K  proteome  grouped  by  the  
IF-­‐‑based  location  annotation.  .........................................................................................  130	  
Figure  4.7  |  The  abundance  of  proteins  remains  unaltered  in  cells  exposed  to  heat  




Figure  4.8  |  The  abundance  of  1129  proteins  is  increased  in  the  nuclear  fraction  by  
more  than  twofold  in  response  to  heat  shock.  ............................................................  135	  
Figure  4.9  |  The  cytoplasmic  abundance  of  1231  proteins  decreased  by  more  than  
twofold  in  heat-­‐‑stressed  human  cells.  ..........................................................................  136	  
Figure  4.10  |  HSF1  accumulates  in  subnuclear  foci  in  response  to  heat  stress.  .............  139	  
Figure  4.11  |  SUMO2/3  accumulates  in  subnuclear  foci  in  response  to  heat  stress.  .....  140	  
Figure  4.12  |  6His-­‐‑SUMO2T90K  conjugates  localise  to  the  nuclear  fraction  of  unstressed  
cells.  ...................................................................................................................................  142	  
Figure  4.13  |  Substrates  of  6His-­‐‑SUMO2T90K  are  functionally  related.  ............................  143	  
Figure  4.14  |  SUMO2-­‐‑modified  proteins  segregate  into  the  nuclear  fraction  of  heat-­‐‑
stressed  human  cells.  ......................................................................................................  145	  
Figure  4.15  |  Number  of  SUMO2  modification  sites  identified  per  target  protein  
increases  after  acute  heat  stress.  ....................................................................................  147	  
Figure  4.16  |  Lysines  residing  in  two  distinct  sequence  motifs  are  preferentially  
targeted  for  SUMO2  conjugation  after  heat  shock.  ....................................................  150	  
Figure  4.17  |  Distribution  of  the  sequence  motifs  targeted  by  SUMO2  modification.  .  151	  
Figure  4.18  |  Occurrence  of  phosphorylated  residues  in  proximity  to  the  sumoylated  
lysine.  .................................................................................................................................  154	  
Figure  4.19  |  Sequence  context  of  a  phosphate-­‐‑modified  sumoylated  peptide  of  Myb  
conforms  to  PDSM  motif.  ...............................................................................................  156	  
Figure  4.20  |  Majority  of  6His-­‐‑SUMO2T90K-­‐‑conjugated  lysines  reside  outside  regular  
secondary  structure  elements.  .......................................................................................  158	  
Figure  4.21  |  Multiple  members  of  macromolecular  protein  complexes  involved  in  
DNA  transcription  or  RNA  processing  are  conjugated  to  SUMO2T90K  in  response  to  
heat  stress.  .........................................................................................................................  160	  
Figure  4.22  |  Multiple  members  of  protein  complexes  involved  in  DNA  replication  or  
chromatin  remodelling  are  conjugated  to  SUMO2T90K  in  response  to  heat  stress.  .  161	  
Figure  4.23  |  SUMO2T90K-­‐‑modified  lysines  locate  to  the  interface  of  individual  subunits  
of  MCM  complex.  ............................................................................................................  163	  
  




Table  of  Tables  
Table  2.1  |  Cell  lines.  ................................................................................................................  21	  
Table  2.2  |  Antibodies.  .............................................................................................................  30	  
Table  3.1  |  Summary  statistics  of  raw  files  acquired  with  standard  MS  settings  ...........  84	  
Table  3.2  |  Summary  statistics  of  raw  files  acquired  with  ultra  sensitive  MS  settings  ..  89	  
Table  3.3  |  False  positive  identifications  ...............................................................................  94	  
Table  4.1  |  Precision  and  accuracy  of  spiking  procedure.  ................................................  124	  
Table  4.2  |  Proteins  with  greater  than  twofold  change  in  absolute  abundance.  ...........  133	  
  




Table  of  Equations  
Equation  4.1  |  Strategy  for  the  spiking  of  standard  protein.  ............................................  119	  
Equation  4.2  |  Strategy  for  the  assessment  of  the  spiking  accuracy.  ..............................  123	  
Equation  4.3  |  Calculation  of  culture-­‐‑specific  "ʺNuclear  fr."ʺ-­‐‑to-­‐‑"ʺCytoplasmic  fr."ʺ  protein  
ratios.  .................................................................................................................................  124	  
  










Alanine   Ala   A  
Arginine   Arg   R  
Asparagine   Asn   N  
Aspartic  acid   Asp   D  
Cysteine   Cys   C  
Glutamine   Gln   Q  
Glutamic  acid   Glu   E  
Glycine   Gly   G  
Histidine   His   H  
Isoleucine   Ile   I    
Leucine   Leu   L  
Lysine   Lys   K  
Methionine   Met   M  
Phenylalanine   Phe   F    
Proline   Pro   P  
Serine   Ser   S  
Threonine   Thr   T  
Tryptophan   Trp   W  
Tyrosine   Tyr   Y  
Valine   Val   V  
Hydrophobic   —   ψ  
Any   —   x  
  






6His   Hexahistidine  
  
10His   Decahistidine  
  
AMP   Adenosine  monophosphate  
  
APP   Amyloid  precursor  protein  
  
Appl.   Application  
  
ATP   Adenosine  triphosphate  
  
Aβ   Amyloid-­‐‑β  
  
BCA   Bicinchoninic  acid  
  
BS3   Bis(sulfosuccinimidyl)suberate  
  
BSA   Bovine  serum  albumin  
  
C-­‐‑   Carboxyl-­‐‑  
  
Cat.   Catalog  
  
COP9   Constitutive  photomorphogenesis  9  
  
DAPI   4'ʹ,6-­‐‑diamidino-­‐‑2-­‐‑phenylindole  
  
DeSI   Desumoylating  isopeptidase  
  
diGly   Gly-­‐‑Gly  
  
DMEM   Dulbecco'ʹs  modified  Eagle  medium  
  
DMP   Dimethyl  pimelimidate  
  
DMSO   Dimethyl  sulfoxide  
  
DPBS   Dulbecco'ʹs  phosphate  buffered  saline  
  
DTT   Dithiothreitol  
  
E2-­‐‑25K   Ubiquitin-­‐‑conjugating  enzyme  E2  K  
  
ECL   Enhanced  chemiluminescence  
  
eYFP   Enhanced  Yellow  fluorescent  protein  
  
FASP   Filter  aided  sample  preparation  
  
FBS   Fetal  bovine  serum  
  
FDR   False  discovery  rate  
  
Fr.   Fraction  
  
GTF2I   General  transcription  factor  II-­‐‑I  
  
Gu-­‐‑HCl   Guanidine  hydrochloride  
  
HA   Human  influenza  virus  hemagglutinin  
  
HCD   Higher  energy  collisional  dissociation  
  
HEPES   4-­‐‑(2-­‐‑hydroxyethyl)-­‐‑1-­‐‑piperazineethanesulfonic  acid  
  
hnRNP   Heterogenous  nuclear  ribonucleoprotein  
  
HPA   Human  Protein  Atlas  database  
  
HSF1   Heat  shock  factor  protein  1  
  





IAP  buffer   Immunoaffinity  purification  buffer:  50  mM  NaCl,  
  
  
50  mM  MOPS-­‐‑NaOH  pH  7.2,  10  mM  Na2HPO4  
  
IF   Immunofluorescence  microscopy  
  
IMAC   Immobilised  metal  affinity  chromatography  
  
IPA   Qiagen'ʹs  Ingenuity  Pathway  Analysis  
  
IRF-­‐‑2   Interferon  regulatory  factor  2  
  
IT   Injection  time  
  
IκBα   NF-­‐‑kappa-­‐‑B  inhibitor  alpha  
  
K-­‐‑ε-­‐‑GG   Gly-­‐‑Gly-­‐‑modified  Lys  
  
K0   L-­‐‑Lys  (12C6,  14N2)  
  
K8   L-­‐‑Lys  (13C6,  15N2)  
  
LC   Liquid  chromatography  
  
Lys-­‐‑C   Lysyl  endopeptidase  
  
m/z   Mass-­‐‑to-­‐‑charge  ratio  
  
MCM   Minichromosome  maintenance  
  
MEF2   Myocyte-­‐‑specific  enhancer  factor  2  
  
MES   2-­‐‑(N-­‐‑morpholino)ethanesulfonic  acid  
  
mHTT   Pathogenic  variant  of  Huntingtin  
  
MOPS   3-­‐‑(N-­‐‑morpholino)propanesulfonic  acid  
  
MS   Mass  spectrometry  
  
MSMS   Tandem  mass  spectrometry  
  
N-­‐‑   Amino-­‐‑  
  
NF-­‐‑κB   Nuclear  factor  NF-­‐‑kappa-­‐‑B  
  
Ni2+-­‐‑NTA   Nickel-­‐‑nitriloacetic  acid  
  
No.   Number  
  
NONO   Non-­‐‑POU  domain-­‐‑containing  octamer-­‐‑binding  protein  
  
PAGE   Polyacrylamide  gel  electrophoresis  
  
PARP1   Poly  [ADP-­‐‑ribose]  polymerase  1  
  
PBS   Phosphate  buffered  saline  
  
PcG   Polycomb  group  
  
PCNA   Proliferating  cell  nuclear  antigen  
  
PCR   Polymerase  chain  reaction  
  
PDSM   Phosphorylation-­‐‑dependent  sumoylation  motif  
  
Pen-­‐‑Strep   Penicillin  and  streptomycin  
  
PIAS   Protein  inhibitor  of  activated  STAT  
  
PML   Promyelocytic  leukemia  protein  
  
PPAR-­‐‑γ   Peroxisome  proliferator-­‐‑activated  receptor  gamma  
  
ppm   Parts  per  million  
  
PRC   Polycomb  repressive  complex  
  





PSM   Peptide-­‐‑to-­‐‑spectrum  match  
  
PTM   Posttranslational  modification  
  
PVDF   Polyvinylidene  difluoride  
  
R0   L-­‐‑Arg  (12C6,  14N4)  
  
R10   L-­‐‑Arg  (13C6,  15N4)  
  
RanBP2   Ran-­‐‑binding  protein  2  
  
RanGAP1   Ran  GTPase-­‐‑activating  protein  1  
  
RMSD   Root  mean  square  deviation  
  
S-­‐‑   Sulfur  
  
SAE   SUMO-­‐‑activating  enzyme  
  
SAFB2   Scaffold  attachment  factor  B2  
  
SAX   Strong  anion  exchange  
  
SDS   Sodium  dodecyl  sulfate  
  
SENP   Sentrin/SUMO-­‐‑specific  protease  
  
SF   Subcellular  fractionation  
  
SHMT1   Serine  hydroxymethyltransferase  
  
SILAC   Stable  isotope  labelling  by  amino  acids  in  a  cell  culture  
  
SIM   SUMO  interaction  motif  
  
Smad4   Mothers  against  decapentaplegic  homolog  4  
  
SMEM   Minimum  Essential  medium  Eagle  
  
snRNP   Small  nuclear  ribonucleoprotein  
  
Sp100   Nuclear  autoantigen  Sp-­‐‑100  
  
StageTip   Stop  and  Go  Extraction  Tip  
  
STUbL   SUMO-­‐‑targeted  ubiquitin  ligase  
  
Sulfo-­‐‑NHS-­‐‑acetate   Sulfosuccinimidyl  acetate  
  
SUMO   Small  Ubiquitin-­‐‑like  modifier  
  
TAP   Tandem  affinity  purification  
  
TCA   Trichloroacetic  acid  
  
TCEP   Tris(2-­‐‑carboxyethyl)phosphine  
  
TDG   G/T  mismatch-­‐‑specific  thymine  DNA  glycosylase  
  
TFA   Trifluoroacetic  acid  
  
TIC   Total  ion  current  
  
TRIM28   Transcription  intermediary  factor  1-­‐‑β  
  
Ubl   Ubiquitin-­‐‑like  protein  
  
Ufd1   Ubiquitin  fusion  degradation  protein  1  
  
WaLP   Wild-­‐‑type  α-­‐‑lytic  protease  
  
WB   Western  blot  
  















 Characteristics  of  SUMO  proteins  1.1.1.
Small  Ubiquitin-­‐‑like  modifiers   (SUMOs)  are  proteins  named  after  and  belonging   to  a  
family  of  Ubiquitin-­‐‑like  proteins  (Ubls)  (Mahajan  et  al.,  1997).  All  members  of  the  Ubl  
family   are   characterised   by   a   remarkably   similar   three-­‐‑dimensional   core   structure,  
which  adopts  a  globular  β-­‐‑grasp  ubiquitin-­‐‑related  fold  despite  the  large  differences  in  
the  amino  acid  sequences  of  individual  proteins  (Figure  1.1)  (Bayer  et  al.,  1998;  Huang  
et  al.,  2004;  Hochstrasser,  2009).  A  distinctive  structural  feature  of  SUMO  is  the  flexible  
amino  (N)-­‐‑terminal  extension  that  is  absent  in  the  founding  member  of  the  Ubl  family:  
Ubiquitin   (Figure   1.1A)   (Bayer   et   al.,   1998;   Muller   et   al.,   2001;   Huang   et   al.,   2004).  
However,  most  Ubls  can  be  posttranslationally  covalently  bound  to  other  proteins  via  
their   carboxyl   (C)-­‐‑terminus   (Muller   et   al.,   2001).   At   the   C-­‐‑terminus   of   most   mature  
human  Ubls  are  two  conserved  glycines  known  as  the  Gly-­‐‑Gly  or  diGly  motif  (Figure  
1.1A)  (Flotho  and  Melchior,  2013).    
Orthologs   of   SUMO   proteins   have   been   identified   throughout   the   eukaryotic  
kingdoms,   with   most   higher   eukaryotes   expressing   multiple   SUMO   paralogs.   In  
humans,   three  SUMO  paralogs  are  expressed  ubiquitously:  SUMO1  (Small  ubiquitin-­‐‑
related  modifier  1,  or  Smt3C),  SUMO2  (Small  ubiquitin-­‐‑related  modifier  2,  or  Smt3A)  
and  SUMO3  (Small  ubiquitin-­‐‑related  modifier  3,  or  Smt3B)  (Saitoh  and  Hinchey,  2000;  
Flotho  and  Melchior,  2013).  Primary  structures  of  mature  SUMO2  and  SUMO3  proteins  






Figure  1.1  |  Human  Ubls  share  similar  organisation  of  secondary  structure  elements.    
(A)   Sequence   alignment   of   Ubiquitin,   SUMO1,   SUMO2   and   SUMO3   coloured   by   identity.  
Amino  acids  conserved  between  two,  three  or  all  four  Ubls  are  shown  in  yellow,  light  green  or  
dark   green,   respectively.   The   alignment  was   created   using  Clustal  Omega  multiple   sequence  
alignment  tool   integrated  into  Jalview,  version  2  editor  (Waterhouse  et  al.,  2009;  Sievers  et  al.,  
2011).   (B)   Structural   alignment   of   Ubiquitin   (grey;   PDB   entry:   1UBQ),   SUMO1   (orange;   PDB  
entry:   4WJQ),   and   SUMO3   (blue;   PDB   entry:   1WM2)   (Vijay-­‐‑Kumar   et   al.,   1987;  Huang   et   al.,  
2004;  Cappadocia  et  al.,  2015a).  The  overall  root  mean  square  deviation  (RMSD)  over  72  aligned  
residues  is  1.2640  Å.  The  alignment  was  generated  using  a  protein  structure  comparison  service  
PDBeFold,  version  2.59  (Krissinel  and  Henrick,  2004).  
  
contrast,  only  ~47  %  sequence  identity   is  shared  between  SUMO1  and  SUMO2,  hence  
the   classification   of   SUMO   proteins   into   two   subfamilies:   SUMO1   or   SUMO2/3.  
Western   blot   images   of   human   cell   lysates   indicate   that   the   majority   of   SUMO1   is  
engaged  in  conjugates.  In  comparison,  a  large  proportion  of  SUMO2/3  is  unconjugated  




damaging   stimuli,   such   as   ethanol,   hydrogen  peroxide,   or  heat   (Saitoh   and  Hinchey,  
2000).   Furthermore,   SUMO   has   the   ability   to   target   itself   for   modification   and  
polymerise   into  chains,  although   incorporation  of  SUMO1  into  poly-­‐‑SUMO2/3  chains  
appears   to   impede   further   chain   elongation   in  vitro   (Tatham  et   al.,   2001;  Matic   et   al.,  
2008;  Hsiao  et  al.,  2009).    
 SUMO  conjugation  pathway  1.1.2.
Each  SUMO  paralog  is  synthesized  as  a  precursor  molecule,  which  is  processed  into  an  
active   form  by   cleaving   the   carboxyl-­‐‑terminal   extension  and  exposing   the  C-­‐‑terminal  
glycine  of  the  conserved  diGly  motif  (Figure  1.1A).  Enzymes  responsible  for  the  SUMO  
maturation   are   generically   termed   SUMO   proteases   (Hickey   et   al.,   2012).   Protein  
sumoylation   is   a   process   in   which   an   isopeptide   bond   is   formed   between   the  
C-­‐‑terminal   carboxylate   of   SUMO   and   the   ε-­‐‑amino   group   of   a   lysine   residue   of   a  
substrate  (Figure  1.2).  The  SUMO  conjugation  pathway  is  initialised  by  a  heterodimeric  
E1   composed   of   SUMO-­‐‑activating   enzyme   subunits   1   and   2   (SAE1/SAE2),   which  
catalyses   the   adenosine   triphosphate   (ATP)-­‐‑dependent   adenylation   of   the  C-­‐‑terminal  
carboxyl  group  of  SUMO.  Consequent  release  of  adenosine  monophosphate  (AMP)  is  
accompanied  by  the  formation  of  a  thioester  bond  between  the  sulfhydryl  group  of  the  
catalytic   Cys   residue   of   SAE2   and   the   C-­‐‑terminus   of   SUMO   (Johnson   et   al.,   1997;  
Desterro   et   al.,   1999;   Gong   et   al.,   1999;   Okuma   et   al.,   1999).   Subsequently,   upon  
interaction  with  E2   SUMO-­‐‑conjugating   enzyme  Ubc9,   SUMO   is   transesterified   to   the  
catalytic  Cys  residue  of   the  E2   (Desterro  et  al.,  1997;   Johnson  and  Blobel,  1997).  Ubc9  






Figure  1.2  |  The  cycle  of  SUMO  modification.    
The   nascent   SUMO   precursor   is   processed   by   SUMO-­‐‑specific   proteases   (SUP)   to   reveal   the  
conserved  C-­‐‑terminal  Gly-­‐‑Gly  motif.  The  mature  molecule   is   then  activated  by  an  E1  SUMO-­‐‑
activating   enzyme   SAE1/SAE2   and   subsequently   transesterified   to   an   E2   SUMO-­‐‑conjugating  
enzyme  Ubc9.   E2   facilitates   the   transfer   of   SUMO   to   target   proteins,   however   the   process   is  
often  catalysed  by  the  actions  of  E3  SUMO-­‐‑protein  ligases.  Substrate  sumoylation  can  occur  on  
a  single  (monosumoylation)  or  multiple   lysine  residues  (multi-­‐‑monosumoylation),  and  SUMO  
can   form   chains   (polysumoylation).   The   cycle   is   completed   by   SUMO-­‐‑specific   protease-­‐‑
dependent   desumoylation   of   substrates.   “XX”   represents   the   C-­‐‑terminal   extension   of   the  
nascent   SUMO  molecule;   wavy   and   straight   lines   correspond   to   thioester   or   peptide   bonds,  





the   SUMO   molecule   to   the   ε-­‐‑amino   group   of   the   Lys   residue   of   the   substrate  
(Rodriguez  et  al.,   2001;  Sampson  et  al.,   2001;  Bernier-­‐‑Villamor  et  al.,   2002).  However,  
this  step   is  often  catalysed  by  E3  SUMO-­‐‑protein   ligases   (Figure  1.2).  Most  E3s  recruit  
the   substrate,   bind   charged   Ubc9   and   promote   SUMO   transfer   by   coordinating   the  
thioester   in   an   optimal   orientation   for   the   isopeptide   bond   formation   (Reverter   and  
Lima,   2005;   Flotho   and   Melchior,   2013).   In   a   recent   structural   study,   the   molecular  
mechanism  by  which   an  E3   SUMO-­‐‑protein   ligase   can   neglect   the   specificity   of  Ubc9  
and  force-­‐‑feed  the  target  Lys  into  the  active  site  of  the  E2,  was  also  illustrated  (Streich  
and   Lima,   2016).   Importantly,   SUMO   conjugation   can   occur   on   a   single   lysine  
(monosumoylation)  or  multiple   lysine  residues  (multi-­‐‑monosumoylation)  of   the  same  
substrate  protein  (Figure  1.2).    
The   largest   family   of   mammalian   E3   SUMO-­‐‑protein   ligases   includes   NSE2   and   the  
Protein   inhibitor   of   activated   STAT   (PIAS)   proteins,   which   are   characterised   by   an  
Ubc9-­‐‑binding  SP-­‐‑RING  domain  (Kahyo  et  al.,  2001;  Sachdev  et  al.,  2001;  Potts  and  Yu,  
2005;  Streich  and  Lima,  2016).  However,  a  few  unrelated  E3s  have  also  been  identified,  
such  as  the  Ran-­‐‑binding  protein  2  (RanBP2)  (Pichler  et  al.,  2002;  Pichler  et  al.,  2004)  or  
the  ZNF451  (Cappadocia  et  al.,  2015b;  Eisenhardt  et  al.,  2015).  
SUMO  modification  is  reversible  and  proteases  involved  in  SUMO  maturation  are  also  
required  for  its  deconjugation  from  substrate  proteins  (Hickey  et  al.,  2012).  So  far,  nine  
human   SUMO-­‐‑specific   cysteine   proteases   have   been   identified   and   categorised   into  
three  structural  families:  six  Sentrin/SUMO-­‐‑specific  proteases  (SENP1,  -­‐‑2,  -­‐‑3,  -­‐‑5,  -­‐‑6,  -­‐‑7)  
(Yeh  et  al.,  2000),  two  Desumoylating  isopeptidases  (DeSI-­‐‑1  and  -­‐‑2)  (Shin  et  al.,  2012),  




 SUMO  interaction  motif  1.1.3.
A   requirement   for   SUMO   to   act   as   a  molecular  marker   triggering   the   recruitment   of  
other   proteins   is   the   ability   of   these   downstream   effectors   to   recognise   SUMO.   In  
general,   this   specificity   is   found   in  a  particular   sequence  element  known  as  a  SUMO  
interaction  motif   (SIM).  The   SIM   is   a   short   repeat   of   branched  hydrophobic   residues  
generally   conforming   to   one   of   the   two   sequence   motifs:   [V/I]x[V/I][V/I]   or  
[V/I][V/I]x[V/I],  where  x  represents  any  amino  acid  and  residues  in  square  brackets  are  
interchangeable.   SIMs   are   often   N-­‐‑   or   C-­‐‑terminally   flanked   by   a   stretch   of   serines,  
acidic   or   both   types   of   residues,   which   appear   to   enhance   the   binding   affinity   for  
SUMO.  SIMs   form  non-­‐‑covalent   interactions  with  SUMO  paralogs  by  adopting   short  
β-­‐‑strand   conformations   that   insert   into   the   groove   between   the   β2-­‐‑strand   and   the  
α-­‐‑helix  of  the  SUMO  molecule  (Song  et  al.,  2004;  Song  et  al.,  2005;  Hecker  et  al.,  2006).    
Two  additional  binding  modules,  which  have  thus  far  been  characterised  in  a  limited  
number   of   proteins,   form   non-­‐‑covalent   interactions   preferentially   with   SUMO1:   the  
ZZ-­‐‑type  zinc  finger  domain  of  the  E3  ubiquitin-­‐‑protein  ligase  HERC2  and  the  extended  
arm  structure  of  the  Dipeptidyl  peptidase  9  (Danielsen  et  al.,  2012;  Pilla  et  al.,  2012).  
 Molecular  mechanisms  of  SUMO  modification  1.1.4.
The   downstream   effects   of   protein   sumoylation   are   often   substrate   specific,   but   in  
general   can  be   categorised   into   three   types  of   events.  First,   SUMO  can  compete  with  
other   Lys-­‐‑targeting   posttranslational   modifications   (PTMs),   such   as   methylation,  
acetylation  or  conjugation  to  other  Ubls  (Figure  1.3A).  For  instance,  transcription  factor  




inhibitor  alpha  (IκBα)  via  its  ubiquitination  at  Lys21.  However,  sumoylation  of  Lys21  of  
IκBα   prevents   its   ubiquitination,   rendering   the   molecule   partially   resistant   to  
proteasomal   degradation,   and   thus   facilitating   the   inhibition   of   NF-­‐‑κB-­‐‑dependent  
transcription  (Desterro  et  al.,  1998).  Furthermore,  competition  between  acetylation  and  
sumoylation  has  been  described  for  Myocyte-­‐‑specific  enhancer  factor  2A  (MEF2A).  In  
this   situation,   sumoylation  of  Lys403   has  been   suggested   to  hinder   its   acetylation   and  
lead  to  repression  of  MEF2-­‐‑mediated  transcription  (Shalizi  et  al.,  2006).    
SUMO  modification  is  a  large  PTM  and  can  thus  prevent  the  interactions  of  substrate  
proteins   with   their   binding   partners   through   steric   hindrance   (Figure   1.3B).   For  
instance,   sumoylation   of   Lys14   of   Ubiquitin-­‐‑conjugating   enzyme   E2  K   (E2-­‐‑25K)  
competes  with  the  binding  of  E2-­‐‑25K  to  E1  Ubiquitin-­‐‑like  modifier-­‐‑activating  enzyme,  
and   thus   interferes  with   the   thioester   bond   formation   between   the  E2   and  Ubiquitin  
(Pichler  et  al.,  2005).  Through  steric  hindrance,  conjugation   to  SUMO  can  also   inhibit  
the  posttranslational  modification  of  residues  neighbouring  the  modified  lysine.  In  the  
case   of   Cellular   tumor   antigen   p53,   sumoylation   at   Lys386   appears   to   inhibit   its  
subsequent   in   vitro   Histone   acetyltransferase   p300-­‐‑dependent   acetylation   at   adjacent  
residues:  Lys382  and  Lys373  (Wu  and  Chiang,  2009).    
The  most  prevalent  molecular   function  of   sumoylation  appears   to  be   the  SUMO-­‐‑SIM  
interaction-­‐‑dependent   recruitment   of   downstream   effectors   (Figure   1.3C).   Although  
the  affinities  of  SIMs  for  SUMOs  are  in  the  low  micromolar  range  (Hecker  et  al.,  2006),  
several   cooperative   SUMO-­‐‑SIM   interactions   can   enhance   the   efficiency   of   substrate  






Figure  1.3  |  Downstream  effects  of  SUMO  modification.    
The  molecular   consequences   of   sumoylation   (S;   blue)   are   divided   into   three   types   of   events.  
SUMO  modification  can:  (A:  competition)  compete  for  acceptor  lysines  with  other  Lys-­‐‑specific  
PTMs,  such  as  methylation,  acetylation  or  conjugation  to  Ubiquitin  (Ub;  red),   (B:   interference)  
sterically  hinder  either  protein-­‐‑protein  interactions  or  posttranslational  modification  of  adjacent  
residues,   or   (C:   non-­‐‑covalent   interactions)   bind   non-­‐‑covalently   to   inter-­‐‑   or   intramolecular  
SUMO   interaction   motifs   (SIMs)   and   thus   induce   physical   associations   or   conformational  
changes.  Figure  is  adapted  from  (Jentsch  and  Psakhye,  2013).  
  
E3   Ubiquitin-­‐‑protein   ligase   RNF4,   which   through   specific   binding   of   poly-­‐‑SUMO  
chains   promotes   the   ubiquitination   and   subsequent   proteasomal   degradation   of  
several   substrate   proteins,   including   the   promyelocytic   leukemia   protein   (PML)  
(Tatham  et  al.,  2008).  SUMO-­‐‑SIM  binding  can  also  induce  intramolecular  interactions.  
Upon   sumoylation   at   Lys330,   the   G/T   mismatch-­‐‑specific   thymine   DNA   glycosylase  
(TDG)  undergoes  a  conformational  change  that  enables  its  dissociation  from  the  abasic  




1.2. SUMO  is  essential  for  viability  
Most  eukaryotic  organisms  require  a  functional  sumoylation  pathway  for  survival.  The  
sole  murine  SUMO-­‐‑conjugating  enzyme  Ubc9  is  essential  for  the  early  development  of  
mouse  embryos,  with  Ubc9-­‐‑deficient  mice  suffering  from  premature  embryonic  death  
at   the  post-­‐‑implantation   stage   (Nacerddine  et   al.,   2005).  Moreover,   adult  mice  with  a  
conditional   knock-­‐‑out   of   Ubc9   in   the   gastrointestinal   tract   die   within   six   days  
(Demarque  et  al.,  2011).  Mice  deficient  in  SUMO1  are  fertile  and  demonstrate  no  overt  
phenotype   although   increased   conjugation   of   SUMO2/3   has   been   suggested   to  
compensate   for   the   lack   of   SUMO1   (Evdokimov   et   al.,   2008;   Zhang   et   al.,   2008).  
Likewise,   SUMO2   is   dispensable   for   the   development   of   mouse   embryos   and   the  
appearance  of  postnatal  mice   lacking  SUMO2  is   indistinguishable   from  the  wild-­‐‑type  
littermates.   In  contrast,  deficiency   in  murine  SUMO3  results   in  severe  developmental  
delay   and   has   an   embryonic   lethal   phenotype.   Considering   that   the   sequence   and  
structure   of   SUMO3   is   nearly   identical   to   SUMO2,   but   SUMO3   is   the   primarily  
expressed   paralog   during   mouse   embryogenesis,   it   has   been   suggested   that   the  
apparent  developmental  differences  are  inflicted  by  an  extreme  decrease  in  the  overall  
SUMO   production   (Wang   et   al.,   2014).   Inactivation   of   murine   SENP1   leads   to  
embryonic  lethality  in  midgestation  as  a  consequence  of  severe  defects  in  erythro-­‐‑  or  T  
and  B  cell  lymphopoiesis  (Cheng  et  al.,  2007;  Van  Nguyen  et  al.,  2012).  These  findings  
demonstrate  the  importance  of  balanced,  dynamic  SUMO  conjugation  for  the  viability  
of  higher  eukaryotes,  and  suggests  at  least  partial  functional  redundancy  of  individual  




1.3. SUMO  modification  in  proteostasis  
The   homeostasis   of   the   proteome   (proteostasis)   is   achieved   by   a   balanced   and  
coordinated  synthesis,  folding,  disaggregation,  and  degradation  of  proteins  (Labbadia  
and   Morimoto,   2015).   SUMO   conjugation   increases   under   conditions   of   proteotoxic  
stress  (Saitoh  and  Hinchey,  2000;  Golebiowski  et  al.,  2009;  Tatham  et  al.,  2011),  and  the  
modification   is   involved   in  several  cellular  processes  required  for   the  maintenance  of  
proteostasis  (Liebelt  and  Vertegaal,  2016).    
Nucleotide-­‐‑binding  proteins   are   common   targets   of   sumoylation   in  unperturbed   and  
stressed   human   cells,   and   the   modification   of   chromatin-­‐‑binding   proteins   occurs  
predominantly  at  the  promoters  of  actively  transcribed  genes  (Golebiowski  et  al.,  2009;  
Liu   et   al.,   2012;   Becker   et   al.,   2013;   Neyret-­‐‑Kahn   et   al.,   2013;   Niskanen   et   al.,   2015;  
Seifert   et   al.,   2015).  However,   the  general  physiological   role  of   SUMO  recruitment   to  
chromatin   is   still   unclear,   as   it   has   been   suggested   to   either  maintain   or   restrain   the  
transcription  of  target  genes  (Liu  et  al.,  2012;  Neyret-­‐‑Kahn  et  al.,  2013;  Niskanen  et  al.,  
2015;  Seifert  et  al.,  2015).  Coordinated  sumoylation  and  desumoylation  of  substrates  is  
also   required   for   the   biogenesis   of   ribosomes,   where   it   facilitates   the   assembly   of  
eukaryotic  pre-­‐‑ribosomal  particles  (Panse  et  al.,  2006;  Haindl  et  al.,  2008;  Finkbeiner  et  
al.,  2011).  Furthermore,  SUMO  appears  to  be  required  for  mRNA  processing  (Vassileva  
and  Matunis,  2004;  Vethantham  et  al.,  2008;  Pelisch  et  al.,  2010;  Liu  et  al.,  2015).    
Sumoylation  has  also  been  suggested  to  promote  protein  solubility,  as  the  aggregation  
propensity  of   several  natively  unfolded  polypeptides   is   reduced  by   the  modification.  




misfolding  disorders  (proteopathic  diseases)  (Mukherjee  et  al.,  2009;  Janer  et  al.,  2010;  
Krumova  et  al.,  2011).    
The  involvement  of  SUMO  in  protein  degradation  is  mostly  mediated  by  its  crosstalk  
with  Ubiquitin.  As  demonstrated  in  Chapter  1.1.4  competition  between  the  Ubls  for  the  
same  acceptor  lysine  alters  the  stability  of  IκBα.  However,  several  other  proteins  have  
been   suggested   to   be   under   similar   regulation,   such   as   the   Serine  
hydroxymethyltransferase   (SHMT1)   (Anderson   et   al.,   2012)   or   Mothers   against  
decapentaplegic   homolog   4   (Smad4)   (Lin   et   al.,   2003).   For   instance,   the   stability   of  
Smad4  appears  to  increase  through  sumoylation  at  Lys113  and  Lys159,  which  prevent  its  
Ubiquitin-­‐‑mediated  degradation  (Lin  et  al.,  2003).    
Through  SUMO-­‐‑SIM  interactions,  polysumoylation  of  substrates  can  serve  as  a  signal  
for   the  recruitment  of  SUMO-­‐‑targeted  E3  Ubiquitin-­‐‑protein   ligases   (STUbLs),   such  as  
RNF4  (Tatham  et  al.,  2008).  The  stability  of  many  proteins  functioning  in  fundamental  
cellular  processes,  including  the  assembly  of  kinetochores  (Mukhopadhyay  and  Dasso,  
2010)   or   survival   after   exposure   to   hyperthermia   (Martin   et   al.,   2009),   hypoxia   (van  
Hagen   et   al.,   2010),   or   DNA   damage   (Nie   and   Boddy,   2016),   are   targets   of   RNF4-­‐‑
mediated   ubiquitination   and   subsequent   degradation.   In   some   cases,   the   STUbL-­‐‑
dependent   processing   of   substrates   is   assisted   by   p97   (Cdc48   in   yeast)-­‐‑Ufd1-­‐‑Npl4  
segregase,  which  facilitates  the  extraction  of  ubiquitinated  proteins  from  higher  order  
complexes  (Meyer  et  al.,  2012;  Baek  et  al.,  2013).  For  instance,  one  of  the  known  targets  
of  the  combined  action  of  STUbL  and  p97-­‐‑Ufd1-­‐‑Npl4  segregase  is  the  Fanconi  anemia  




SUMO   modification,   RNF4-­‐‑catalysed   ubiquitination,   and   p97-­‐‑mediated   extraction  
(Gibbs-­‐‑Seymour  et  al.,  2015).    
  




1.4. SUMO  in  proteopathic  diseases  
The   involvement   of   SUMO  modification   in   human  diseases   is   gradually   becoming   a  
topic   of   interest,   as  many   proteins  with   a   fundamental   function   in   pathogenesis   are  
substrates   of   sumoylation.   Thus,   SUMO   conjugation   has   been   suggested   to   affect  
carcinogenesis  (Eifler  and  Vertegaal,  2015),  cardiac  disease  (Mendler  et  al.,  2016),  viral  
infection   (Everett   et   al.,   2013),   or   several   proteopathic   diseases   (Steffan   et   al.,   2004;  
Eckermann,  2013;  Lee  et  al.,  2013).  
 Polyglutamine  diseases  1.4.1.
Polyglutamine   diseases   are   a   family   of   neurodegenerative   conditions   caused   by   an  
expansion  of   trinucleotide   repeat   that   induces   the  production  of   a   toxic   aggregation-­‐‑
prone  protein  with  an  elongated  polyglutamine  track.  Neurological  disorders  affected  
by  the  repeat  expansion  include  spinobulbar  muscular  atrophy,  Huntington’s  disease,  
and  various  types  of  spinocerebellar  ataxias  (Zoghbi  and  Orr,  2000).  Interestingly,  the  
solubility   of   several   of   these   disease-­‐‑inducing   proteins   is   altered   by   conjugation   to  
SUMO  (Mukherjee  et  al.,  2009;  Janer  et  al.,  2010).    
Huntington’s   disease   is   a   hereditary   disorder   characterised   by   a   progressive  
degeneration   of   brain   cells,   resulting   in   involuntary   movements,   memory   loss,   and  
personality  changes  (Orr  and  Zoghbi,  2007).  The  disease  is  caused  by  an  expansion  of  a  
polyglutamine   repeat   at   the   N-­‐‑terminal   region   of   Huntingtin   that   promotes   its  
assembly   into   intermediate   oligomers   before   inclusion   into   higher-­‐‑order   aggregates  
(The   Huntington'ʹs   Disease   Collaborative   Research   Group,   1993;   Labbadia   and  




SUMO1   and   SUMO3   (Steffan   et   al.,   2004;   Subramaniam   et   al.,   2009;  O'ʹRourke   et   al.,  
2013).  Modification  by  SUMO3  is  facilitated  by  the  E3  SUMO-­‐‑protein  ligase  PIAS1  and  
results   in   an   accumulation   of   toxic   insoluble   mHTT   (O'ʹRourke   et   al.,   2013).  
Conjugation   to   SUMO1   is  mediated   by   a   GTP-­‐‑binding   protein   Rhes   and   reduces   its  
aggregation   propensity   (Subramaniam   et   al.,   2009).   However,   in   each   case,   the  
sumoylation   of   mHTT   appears   to   increase   cytotoxicity   (Subramaniam   et   al.,   2009;  
O'ʹRourke   et   al.,   2013).   The   tissue-­‐‑specific   expression   of   Rhes   could   also   explain   the  
localised  neuropathology  of  the  Huntington’s  disease  (Subramaniam  et  al.,  2009).  
 Alzheimer’s  disease  1.4.2.
Alzheimer’s   disease   is   an   age-­‐‑related   neurodegenerative   disorder   manifested   in  
patient’s   progressive   cognitive   impairment.   The   symptoms   of   the   condition   are  
inflicted   by   the   aggregation   of   either   a   small   polypeptide   Amyloid-­‐‑β   (Aβ)   or   a  
microtubule-­‐‑associated   protein   Tau   that   form   plaques   or   neurofibrillary   tangles,  
respectively  (LaFerla  et  al.,  2007).    
Aβ  is  generated  by  the  endoproteolysis  of  an  Amyloid  precursor  protein  (APP)  via  the  
amyloidogenic  pathway  (LaFerla  et  al.,  2007).  In  close  proximity  to  the  endoproteolytic  
cleavage  site  of  APP  are  two  lysine  residues  that  appear  to  be  covalently  conjugated  to  
SUMO.  Sumoylation  of  APP  leads  to  the  reduced  accumulation  of  Aβ  aggregates  and  
has  been  suggested  to  sterically  hinder  the  processing  of  APP  (Zhang  and  Sarge,  2008).  
Remarkably,  some  patients  with  Alzheimer’s  disease  carry  a  mutation  that  is  predicted  
to   produce   an   APP   protein   with   one   of   the   SUMO   target   lysines   replaced   by   an  
asparagine   (Mullan   et   al.,   1992;   Zhang   and   Sarge,   2008).   However,   conflicting  




SUMO  paralogs  individually  or  SUMO3  exclusively  increased  either  the  production  of  
APP  or  the  secretion  of  Aβ  or  both.  Furthermore,  sumoylation  was  suggested  to  have  
an  indirect  role  through  non-­‐‑covalent  interactions  (Dorval  et  al.,  2007;  Yun  et  al.,  2013).    
Toxic   neurofibrillary   tangle-­‐‑forming   Tau   is   also   subjected   to   sumoylation,   which  
appears  to  inhibit  its  Ubiquitin-­‐‑mediated  degradation  (Dorval  and  Fraser,  2006;  Luo  et  
al.,  2014).  SUMO  is  preferentially  conjugated   to   the  soluble  pool  of  Tau,  however   the  
physiological   role   of   this   modification   requires   further   investigation   (Dorval   and  
Fraser,  2006;  Lee  et  al.,  2013).  
These  examples  illustrate  the  involvement  and  importance  of  covalent  modification  by  
SUMO   in   proteopathic   diseases,   although   many   underlying   mechanisms   and  
physiological  roles  of  sumoylation  remain  to  be  elucidated.  




1.5. Identification  of  SUMO  substrates  
In   general,   the   identity   of   SUMO   conjugates   is   inferred   either   on   a   scale   of   a   single  
protein  using  substrate-­‐‑specific  methods,  or  en  masse  by  large-­‐‑scale  proteomic  analyses  
of   sumoylation.   Both   approaches   are   hindered   by   the   low   abundance   of   targets   and  
limited  occupancy  of  sumoylation  (Hay,  2005;  Wohlschlegel  et  al.,  2006;  Tatham  et  al.,  
2009).   To   improve   the  detection   of  modified   substrates,   SUMO   is   often  N-­‐‑terminally  
fused  to  an  affinity  tag,  and  proteins  conjugated  to  the  exogenously  expressed  SUMO  
are  purified  by  affinity   chromatography.  Various  protein   tags  have  been  successfully  
used  for  the  enrichment  of  mammalian  sumoylated  substrates,  including  polyhistidine  
(Rodriguez  et  al.,  1999;  Vertegaal  et  al.,  2004;  Vertegaal  et  al.,  2006),  Human  influenza  
virus   hemagglutinin   (HA)   (Zhao   et   al.,   2004;   Blomster   et   al.,   2009),   tandem   affinity  
purification  (TAP)  tag  (Golebiowski  et  al.,  2009;  Tatham  et  al.,  2011;  Domingues  et  al.,  
2015),  FLAG  (Schimmel  et  al.,  2014),  and  Strep-­‐‑tag  (Bursomanno  et  al.,  2015).  In  some  
instances,   the   best   strategy   has   been   the   combined   utilisation   of   immobilised  
metal-­‐‑   and   immunoaffinity   chromatography   (Schou   et   al.,   2014).   In   addition   to  
cultured  cell  lysates,  affinity  purification  techniques  have  also  been  used  to  enrich  and  
identify  SUMO  conjugates  from  knock-­‐‑in  mice  (Tirard  et  al.,  2012).    
Hitherto,   only   a   limited   number   of   studies   have   accomplished   the   high-­‐‑throughput  
identification   of   endogenous   SUMO   substrates.   These   methods   still   require   the  
enrichment  of  sumoylated  proteins  and  thus  include  immunoaffinity  chromatography  
techniques   using   either   SUMO   paralog-­‐‑specific   antibodies   (Matafora   et   al.,   2009;  
Becker   et   al.,   2013;   Cubenas-­‐‑Potts   et   al.,   2015)   or   a   fragment   of   RNF4   that   binds   to  




The   modification   status   of   a   specific   putative   target   protein   is   often   determined   by  
Western  blot  analyses  (Desterro  et  al.,  1998;  Rodriguez  et  al.,  1999;  Muller  et  al.,  2000).  
High-­‐‑throughput   identification   of   sumoylated   substrates   is   facilitated   by   mass  
spectrometry   (MS)-­‐‑based   proteomics.   The   extensive   global   investigations   have  
altogether   revealed  hundreds  of  putative  SUMO-­‐‑modified  proteins   from  human  cells  
cultured  either  unperturbed  (Vertegaal  et  al.,  2006;  Becker  et  al.,  2013)  or  in  response  to  
various  cellular  stresses,  such  as  DNA  damage  (Bursomanno  et  al.,  2015;  Hendriks  et  
al.,  2015b),  proteasome  inhibition  (Schimmel  et  al.,  2008;  Matafora  et  al.,  2009;  Tatham  
et  al.,  2011),  exposure   to  heat   (Golebiowski  et  al.,  2009;  Bruderer  et  al.,  2011),  or  viral  
infection  (Domingues  et  al.,  2015;  Sloan  et  al.,  2015).    
One   of   the   key   challenges   of   the   proteomic   studies   of   sumoylation   has   been   the  
separation  of  genuine  SUMO-­‐‑modified  substrates  from  the  co-­‐‑purified  “contaminant”  
proteins  that  are   identified  in  the  same  experiment  (Golebiowski  et  al.,  2009).  Lack  of  
consideration  for  this  technical  issue  could  lead  to  a  false  conclusion  and  an  inclusion  
of   many   contaminants   to   a   list   of   SUMO   substrates.   As   the   direct   evidence   of  
sumoylation  is  often  absent,  the  target  proteins  are  inferred  indirectly  by  a  process  of  
elimination  (Vertegaal  et  al.,  2006;  Golebiowski  et  al.,  2009;  Bruderer  et  al.,  2011).  Direct  
evidence   of   modification   would   be   provided   by   the   identification   of   sequences  
containing   the   modified   lysine(s)   attached   to   the   C-­‐‑terminal   peptide   of   the   SUMO  
itself.   Methods   for   the   high-­‐‑throughput   mapping   of   SUMO   modification   sites,  
however,  are  lacking.  In  many  investigations,  the  lysines  most  likely  to  be  targeted  for  
SUMO   conjugation   are   systematically   mutated   to   chemically   similar   non-­‐‑modifiable  
residues,  and  genuine  substrates  are   inferred  by  assessing   the  ability  of   these  mutant  




1999;   Muller   et   al.,   2000).   However,   these   mutational   studies   identify   the   residues  
required   for   modification,   but   do   not   provide   direct   evidence   at   the   mutated   site.  
Several   independent   research   groups   have   also   acknowledged   the   benefits   of   MS-­‐‑
based   proteomics   for   the   high-­‐‑throughput,   unbiased,   and   direct   identification   of  
SUMO  modification   sites,   but   the  developed   strategies   encountered   several   technical  
challenges  (discussed  in  Chapter  3.1.1)  (Cooper  et  al.,  2005;  Blomster  et  al.,  2010;  Matic  
et  al.,  2010;  Galisson  et  al.,  2011;  Lamoliatte  et  al.,  2013).  Therefore,  prior  to  the  launch  
of   this  PhD  project,   the   largest   site-­‐‑specific   study  of  protein   sumoylation  determined  
only   103   sumoylated   lysines   (Matic   et   al.,   2010),  which  was   far   fewer   than   expected  












2.1. Cell  culture  procedures  
 Cultured  cell  lines  2.1.1.
Cell  lines  used  in  this  study  are  listed  in  Table  2.1.    
Table  2.1  |  Cell  lines.    
	  	   Name   Description   Source   Cat.  no.  
	  
HEK293  N3S  
Human  embryonic  kidney  
293  suspension  cells  




human  embryonic  kidney  
293  suspension  cells  






human  embryonic  kidney  





Human  cervix  epitheloid  
carcinoma  cells  
Hay  lab  stock       
  
 Generation  of  HEK2936His-­‐‑SUMO2-­‐‑T90K  N3S  cells  2.1.2.
HEK2936His-­‐‑SUMO2-­‐‑T90K  N3S  cell   line  was  generated  by  Adel  F.  M.  Ibrahim  (University  of  
Dundee).   A   bicistronic   pEFIRESpuro-­‐‑6His-­‐‑SUMO2T90K   plasmid   was   created   by  
replacing   the   coding   sequence   of   enhanced   Yellow   fluorescent   protein   (eYFP)   of   a  
vector   pEFIRESpuro-­‐‑eYFP-­‐‑C1   with   a   polymerase   chain   reaction   (PCR)-­‐‑produced  
6His-­‐‑SUMO2   fusion   sequence   (Hobbs   et   al.,   1998).  NheI   restriction   enzyme   site  was  
coded   between   the   sequences   for   SUMO2   and   the   6His-­‐‑tag.   T90K   mutation   was  




the   region   encoding   6His-­‐‑SUMO2T90K   was   submitted   for   sequencing   to   the   DNA  
Sequencing  facility  at  the  University  of  Dundee.    
HEK293   N3S   cells   cultured   in   suspension   were   transfected   with   a   plasmid  
pEFIRESpuro-­‐‑6His-­‐‑SUMO2T90K  using  Lipofectamine  2000  (Thermo  Fisher  Scientific,  cat.  
no.   11668019)   and   the   selection   of   stably-­‐‑transfected   cells   was   performed   by  
supplementation   with   2  µμg/ml   puromycin.   The   generated   stable   HEK2936His-­‐‑SUMO2-­‐‑T90K  
N3S  cell   line  was  maintained  in  a  puromycin-­‐‑containing  (1  µμg/ml)  culture  medium  at  
37  °C  in  5  %  CO2.    
The  amino  acid  sequence  of  the  stably-­‐‑expressed  6His-­‐‑SUMO2T90K  is:  
MHHHHHHASMSEEKPKEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKA
YCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQKGG  
 Cell  culture  conditions  for  label-­‐‑free  experiments  2.1.3.
Adherent   HEK2936His-­‐‑SUMO2-­‐‑T90K   N3S   or   HEK2936His-­‐‑SUMO2   N3S   cells   were   cultured   in  
Dulbecco’s   modified   Eagle   medium   (DMEM;   Thermo   Fisher   Scientific,   cat.   no.  
61965026)  supplemented  with  10  %  fetal  bovine  serum  (FBS;  Biosera,  cat.  no.  FB-­‐‑1090),  
1  µμg/ml   puromycin   (Melford,   cat.   no.   P0121),   and   50  U/ml   penicillin   with   50  µμg/ml  
streptomycin   (100  U/ml   Pen-­‐‑Strep;   Thermo   Fisher   Scientific,   cat.   no.   15140122).  
Adherent  HeLa  or  HEK293  N3S  cells  were  cultured  in  DMEM  supplemented  with  10  %  
FBS  and  100  U/ml  Pen-­‐‑Strep,  and  maintained  at  37  °C  in  5  %  CO2.    
For   the   label-­‐‑free   experiments   using   SUMOKGG   workflow,   HEK2936His-­‐‑SUMO2-­‐‑T90K   N3S  




into   Minimum   Essential   medium   Eagle   (SMEM;   Sigma-­‐‑Aldrich,   cat.   no.   M8167)  
supplemented  with  10  %  FBS,  1  µμg/ml  puromycin,  2  mM  L-­‐‑glutamine  (Thermo  Fisher  
Scientific,   cat.   no.   25030024),   and   100  U/ml   Pen-­‐‑Strep.   Approximately   375  ml   of  
suspension   culture   corresponding   to   ~1.75  ×  108  cells   was   cultured   per   experiment,  
stimulated   by   heat   shock   at   43  °C   for   30  minutes,   harvested   by   centrifugation,   and  
washed   with   cold   1  ×   Dulbecco’s   phosphate   buffered   saline   (DPBS;   Thermo   Fisher  
Scientific,  cat.  no.  14190094).    
The  time  course  experiments  of  the  heat  shock  response  were  performed  with  adherent  
cultures  of  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  incubated  at  43  °C  for  0,  15,  30,  60,  or  120  minutes.  
Cells  were  scraped  into  the  culture  medium,  harvested  by  centrifugation  and  washed  
twice  with  cold  1  ×  DPBS.    
Immunofluorescence   microscopy   experiments   were   performed   with   adherent   HeLa  
cells  cultured  in  two  24-­‐‑well  plates,  and  one  of  the  plates  was  incubated  at  43  °C  for  30  
minutes.  Unperturbed  and  heat-­‐‑stressed  HeLa  cells  were  washed  twice  with  1  ×  DPBS  
at  either  37  °C  or  43  °C,  respectively.    
 Cell  culture  conditions  for  SILAC-­‐‑based  experiments  2.1.4.
For   quantitive   proteomic   experiments,   the   adherent   HEK2936His-­‐‑SUMO2   N3S   or  
HEK2936His-­‐‑SUMO2-­‐‑T90K  N3S  cells  were  cultured  in  DMEM  lacking  L-­‐‑lysine,  L-­‐‑arginine  and  
L-­‐‑glutamine  (Biosera;  cat.  no.  SM-­‐‑D0550),  and  supplemented  with  10  %  dialysed  FBS,  
1  µμg/ml  puromycin,  100  U/ml  Pen-­‐‑Strep,  2  mM  L-­‐‑glutamine,  and  either  natural  [Sigma-­‐‑
Aldrich,   cat.   nos.   L8662   (12C6,   14N2;   K0)   and   A8094   (12C6,   14N4;   R0)]   or   heavy   stable  




K8)  and  CNLM-­‐‑539-­‐‑H  (13C6,   15N4;  R10)]  0.8  mM  L-­‐‑lysine  and  0.14  mM  L-­‐‑arginine.  Five  
175  cm2   dishes   of   either   light-­‐‑   or   heavy-­‐‑labelled   cells   at   ~90  %   confluency   were  
transferred   into  SMEM  lacking  L-­‐‑lysine,  L-­‐‑arginine  and  L-­‐‑glutamine   (Biosera;   cat.  no.  
SM-­‐‑M0538),  and  supplemented  with  10  %  dialysed  FBS,  1  µμg/ml  puromycin,  100  U/ml  
Pen-­‐‑Strep,   2  mM   L-­‐‑glutamine,   and   either   natural   or   heavy   stable   isotope-­‐‑containing  
0.8  mM   L-­‐‑lysine   and   0.14  mM   L-­‐‑arginine,   respectively.   Approximately   0.5–1.0  L   of  
suspension   culture   corresponding   to   ~2.35–4.70  ×  108  cells   was   cultured   per  
experimental   condition,   and   either   heat-­‐‑stressed   at   43  °C   for   30  minutes,   treated   by  
supplementation  with  GRE010   to   20  µμM   for   8  hours,   or   left   unperturbed.  Cells  were  
harvested  by  centrifugation  and  washed  twice  with  cold  1  ×  DPBS.    
Proteomic   experiments   involving   subcellular   fractionation   were   performed   with  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   cultured   as   above,   and   ~3  L   of   suspension   culture   was  
harvested  per  experimental  condition.    
 Cell  proliferation  assay  2.1.5.
The   growth   rates   of   parental   or   6His-­‐‑SUMO2T90K-­‐‑expressing  HEK293  N3S   cells  were  
determined   in   collaboration   with   Adel.   F.   M.   Ibrahim   (University   of   Dundee).  
Adherent  cultures  of  HEK293  N3S  or  HEK2936His-­‐‑SUMO2-­‐‑T90K  N3S  cells  were  subcultured  
at  a  low  density  (<1000  cells/well)  into  96-­‐‑well  plates  (Greiner  Bio-­‐‑one,  cat.  no.  655090).  
The  6His-­‐‑SUMO2T90K-­‐‑expressing  cells  were  analysed  twice,  either  with  or  without   the  
supplementation   with   1  µμg/ml   puromycin.   Both   cell   lines   were   subcultured   in   32  
replicates  per   time  point,   and   after   2,   3,   4,   or   5  days   of   incubation   at   37  °C,   the   cells  
were  fixed  with  4  %  formaldehyde  followed  by  staining  with  0.1  µμg/ml  4’,6-­‐‑diamidino-­‐‑




high-­‐‑content  IN  Cell  Analyzer  2000  imaging  system  (GE  Healthcare  Life  Sciences),  and  
the   cells  were   counted  using   the   IN  Cell   Investigator  Developer  Toolbox   1.9.1,   build  
2206  (GE  Healthcare  Life  Sciences).    
 Cell  lysis  without  subcellular  fractionation  2.1.6.
Cells  for  proteomic  experiments,  which  did  not  require  subcellular  fractionation,  were  
collected   by   centrifugation,   lysed   in   fresh   cell   lysis   buffer   containing   6  M   guanidine  
hydrochloride   (Gu-­‐‑HCl),   100  mM   sodium   phosphate   buffer   pH   8.0   [5.3  %   (vol/vol)  
NaH2PO4   in   Na2HPO4],   10  mM   Tris-­‐‑HCl   pH  8.0,   10  mM   imidazole,   and   5  mM  
2-­‐‑mercaptoethanol.   Lysis   buffer   was   added   to   cell   pellets   in   a   ratio   of   5:1   (vol/wt).  
DNA  was   sheared  by   short   pulses   of   sonication,   insoluble  material  was   removed  by  
centrifugation  and  filtration   through  sterile  Minisart  NML  syringe   filters  with  0.2  µμm  
pore   size   (Sartorius,   cat.   no.   16534),   and   protein   concentration   was   estimated   using  
Pierce  bicinchoninic  acid  (BCA)  protein  assay  (Thermo  Fisher  Scientific,  cat.  nos.  23223  
and  23224).  Cells  cultured   for  Western  blot  analysis-­‐‑based  experiments  were   lysed   in  
4  %  sodium  dodecyl  sulfate  (SDS),  100  mM  Tris-­‐‑HCl  pH  7.5  and  incubated  at  95  °C  for  
1–2  minutes.    
 Cell  lysis  with  subcellular  fractionation  2.1.7.
Cells  harvested  for  the  proteomic  analyses  that  involved  subcellular  fractionation  (SF)  
were   resuspended   in   cold   SF   buffer   containing   10  mM   HEPES   [4-­‐‑(2-­‐‑hydroxyethyl)-­‐‑
1-­‐‑piperazineethanesulfonic   acid]   pH   7.9,   1.5  mM   MgCl2,   10  mM   KCl,   0.08  %   NP-­‐‑40,  
100  mM  2-­‐‑chloroacetamide,   and   cOmplete  protease   inhibitor   cocktail   (Sigma-­‐‑Aldrich,  




by   30-­‐‑minute   rotation   at   4  °C.   Nuclei   were   separated   from   cytoplasmic   material   by  
centrifugation   at   2000  g   for   ~5  minutes,  washed  with   cold   SF   buffer,   and   subcellular  
compartments   and   protein   structures   in   each   fraction   were   disrupted   by  
supplementation   with   6  M   Gu-­‐‑HCl,   10  mM   imidazole.   DNA   was   sheared   by  
sonication,   insoluble   material   was   removed   by   centrifugation   and   filtration   through  
sterile  Minisart  NML  syringe   filters  with  0.2  µμm  pore   size,   and  protein  concentration  
was   estimated   using   Pierce   BCA   protein   assay.   Cells   cultured   for   Western   blot  
analysis-­‐‑based   experiments   were   prepared   as   above,   but   6  M   Gu-­‐‑HCl   was   replaced  
with  2  %  SDS.    




2.2. Protein  techniques  
 In  vitro  SUMO  conjugation,  deconjugation  and  processing  2.2.1.
In  vitro  assays  were  performed  by  Ellis  G.  Jaffray  (University  of  Dundee).  All  reactions  
were   buffered   in   50  mM   Tris-­‐‑HCl   pH  7.5,   and   samples   were   analysed   by   SDS-­‐‑
polyacrylamide  gel  electrophoresis  (PAGE).    
Conjugation   assays   contained   5  mM   dithiothreitol   (DTT),   5  mM  MgCl2,   2  mM   ATP,  
110  nM  SAE1/SAE2,  0.5–2  µμM  Ubc9,  ~10  µμM  substrate  protein  and  a   range  of  mature  
recombinant  SUMO:  0,  40,  80,  or  200  µμM.  The  reactions  were   incubated  at  37  °C  for  4  
hours.    
Deconjugation   assays   were   prepared   as   above   using   200  µμM   SUMO   followed   by   a  
supplementation  with  SENP1  to  10  nM,  and  the  reactions  were  monitored  at  0,  0.5,  1,  
2.5,  5  and  10  minutes  at  20  °C.    
Precursor   SUMO   processing   assays   contained   150  mM   NaCl,   0.5  mM  
Tris(2-­‐‑carboxyethyl)phosphine   (TCEP),   600  µμM   SUMO2,   and   100  nM   or   200  nM   of  
recombinant  catalytic  domain  of  SENP1  or  SENP2,  respectively  (Shen  et  al.,  2006).  The  
reactions   were   incubated   at   20  °C   for   0,   5,   10,   20,   30,   60,   90,   120,   180,   240   and   960  
minutes.    
The   amino   acid   sequences   of   the   precursor   or   mature   recombinant   SUMO2   and  




• Precursor  SUMO2:  
GSEEKPKEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQ
IRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGGVPESSLAGHSF  
• Mature  SUMO2:  
GSEEKPKEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQ
IRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG  
• Precursor  SUMO2T90K:  
GSEEKPKEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQ
IRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQKGGVPESSLAGHSF  
• Mature  SUMO2T90K:  
GSEEKPKEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQ
IRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQKGG  
 SDS-­‐‑PAGE,  Western  blot  analyses,  and  Coomassie  brilliant  2.2.2.
blue  staining    
SDS-­‐‑PAGE   was   performed   using   either   10  %   or   4–12  %   NuPAGE   Novex   Bis-­‐‑Tris  
precast   protein   gels   (Thermo   Fisher   Scientific,   cat.   nos.   NP0301–NP0303,   NP0321–
NP0323,   or   WG1402–WG1403)   in   MOPS   [3-­‐‑(N-­‐‑morpholino)propanesulfonic   acid]   or  
MES  [2-­‐‑(N-­‐‑morpholino)ethanesulfonic  acid]  SDS  running  buffer,  and  macromolecules  




Western   blot   images   were   prepared   using   Immobilon-­‐‑P   polyvinylidene   difluoride  
(PVDF)   transfer   membrane   (Merck   Millipore,   cat.   no.   IPVH00010),   Pierce   enhanced  
chemiluminescence  (ECL)  Western  blotting  substrate  (Thermo  Fisher  Scientific,  cat.  no  
32106),  and  antibodies  specified  in  Table  2.2.  
Coomassie  brilliant  blue  staining  of  protein  gels  or  Western  blot  PVDF  membranes  was  
performed  with  0.18  %  (wt/vol)  Coomassie  brilliant  blue  R-­‐‑250  in  9.1  %  (vol/vol)  acetic  
acid,   45.5  %   (vol/vol)   ethanol,   followed   by   destaining   with   7  %   acetic   acid   in   40  %  
ethanol  and  short-­‐‑term  storage  in  7  %  acetic  acid,  5  %  ethanol.  
 Protein  concentration  estimation  2.2.3.
Cell   lysate   proteins   diluted   either   two-­‐‑,   five-­‐‑   or   tenfold   into   water   were   mixed   in  
triplicate   with   a   solution   of   Pierce   BCA   protein   assay   reagents   in   a   ratio   of  
~1:30  (vol/vol).  A  range  of  concentrations  (0.05,  0.1,  0.25,  0.5,  and  1.0  mg/ml)  of  bovine  
serum   albumin      (BSA;   Sigma-­‐‑Aldrich,   cat.   no.   A7906)   was   used   to   generate   the  
calibration   curve.   Mixtures   were   incubated   at   60  °C   for   25   minutes,   at   4  °C   for  
30  minutes,  and  protein  concentration  in  each  cell   lysate  was  estimated  by  UV-­‐‑visible  
spectrophotometry  at  ~570  nm.  
 Antibodies  2.2.4.
Antibodies  used  in  this  study  are  listed  in  Table  2.2.    




Table  2.2  |  Antibodies.    
	  	   Name   Species   Source   Catalog  no.   Appl.   Dilution  
	  
6×His   Mouse   Clontech   631212   WB   1:3000  
	  





WB   1:1500  
	  
SUMO-­‐‑2/3  (18H8)   Rabbit  
Cell  Signaling  
Technology  
#4971S   IF   1:100  
	  
HSF1   Rabbit  
Cell  Signaling  
Technology  







MA1-­‐‑80189   WB   1:5000  
	  
Lamin  A/C  (636)   Mouse  
Santa  Cruz  
Biotechnology  





peroxidase      
secondary  antibody  
Goat   Sigma-­‐‑Aldrich   A6154   WB   1:3000  
	  
Anti-­‐‑mouse-­‐‑
peroxidase      
secondary  antibody  
Goat   Sigma-­‐‑Aldrich   A9917   WB   1:3000  
	  







A11034   IF   1:500  
	  	  
PTMScan  Ubiquitin  





#5562   IAP       
	  
WB,  Western  blot;  IF,  immunofluorescence  microscopy;  IAP,  immunoaffinity  purification  
  
  
 Cross-­‐‑linking  of  K-­‐‑ε-­‐‑GG-­‐‑specific  antibody  2.2.5.
Chemical  cross-­‐‑linking  of  diGly-­‐‑modified  lysine  (K-­‐‑ε-­‐‑GG)-­‐‑specific  antibody  (Table  2.2)  
was   performed  with   a   fresh   solution   of   bis(sulfosuccinimidyl)suberate   (BS3;   Thermo  
Fisher   Scientific,   cat.   no.   21585).   The   antibody-­‐‑conjugated   protein  A   agarose   beads  
were  washed   twice  with   20   resin   volumes   of   conjugation   buffer   containing   150  mM  




Na2HPO4],   resuspended   in   25   resin  volumes  of   5  mM  BS3   in   conjugation  buffer,   and  
rotated   at   room   temperature   (~22  °C)   for   30  minutes.   The   cross-­‐‑linking   reaction  was  
quenched  by  supplementation  with  Tris-­‐‑HCl  pH  7.5  to  50  mM  and  cross-­‐‑linked  beads  
were  washed   three   times  with   20   resin   volumes   of   cold   immunoaffinity   purification  
(IAP)   buffer   (50  mM   MOPS-­‐‑NaOH   pH  7.2,   10  mM   Na2HPO4,   50  mM   NaCl),  
resuspended  in  cold  IAP  buffer  in  a  final  concentration  of  50  %  (vol/vol),  and  stored  at  
4  °C.    
 Protein  precipitation  2.2.6.
Up   to   200  µμg   of   proteins  were   supplemented  with   cold   10  %   (vol/vol)   trichloroacetic  
acid  (TCA;  Sigma-­‐‑Aldrich,  cat.  no.  T6508)  in  a  final  volume  of  200  µμl,  and  incubated  on  
ice   for   one   hour.   Proteins   were   collected   by   centrifugation,   washed   twice   with   cold  
ethanol   and   resuspended   in   buffer   solutions   compatible   with   specific   downstream  
analyses.  




2.3. Sample  preparation  for  MS  
 Nickel  affinity  chromatography  2.3.1.
Nickel  affinity  purification  of  6His-­‐‑SUMO2T90K  conjugates  was  performed  according  to  
a   protocol   adapted   from   (Tatham   et   al.,   2011).   Cell   lysate   proteins  were  mixed  with  
pre-­‐‑equilibrated   nickel-­‐‑nitriloacetic   acid   (Ni2+-­‐‑NTA)   agarose   resin   (Qiagen,   cat.   no.  
30210)  in  a  ratio  of  200:1  (wt/vol),  and  the  slurry  was  mixed  overnight  (14–18  hours)  at  
4  °C.  Beads  were  collected   into  an  empty  spin  chromatography  column  (Bio-­‐‑Rad,  cat.  
no.  7326204)  and  washed  with  five  resin  volumes  of  cell  lysis  buffer,  ten  resin  volumes  
of   wash   buffer   pH  8.0   (8  M   urea,   100  mM   sodium   phosphate   buffer   pH  8.0,   10  mM  
Tris-­‐‑HCl   pH  8.0,   10  mM   imidazole,   5  mM   2-­‐‑mercaptoethanol),   ten   resin   volumes   of  
wash   buffer   pH  6.3   (8  M   urea,   100  mM   sodium   phosphate   buffer   pH  6.3   [77.5  %  
(vol/vol)   NaH2PO4   in   Na2HPO4],   10  mM   Tris-­‐‑HCl   pH  8.0,   10  mM   imidazole,   5  mM  
2-­‐‑mercaptoethanol),   and   ten   resin   volumes   of   wash   buffer   pH  8.0.   Conjugates   were  
eluted   in   three   sequencial   steps   with   two   resin   volumes   of   elution   buffer   (200  mM  
imidazole   in   wash   buffer   pH  8.0)   and   protein   concentration   was   estimated   by  
UV-­‐‑visible  spectrophotometry  at  280  nm.    
 Filter-­‐‑aided  sample  preparation  and  protein  digestion  2.3.2.
Protein   digestion   was   performed   on   an   ultrafiltration   spin   column   with   a   30  kDa  
nominal   molecular   weight   cutoff   limit   (Sartorius,   cat.   no.   VN01H22)   according   to   a  
protocol   adapted   from   (Manza   et   al.,   2005;   Wisniewski   et   al.,   2009b).   Denatured  
proteins   were   concentrated   on   the   device,   washed   twice   with   8  M   urea,   100  mM  




Tris-­‐‑HCl  pH  7.5  at  room  temperature  for  20  minutes  in  the  dark.  Samples  were  washed  
twice  with  IAP  buffer  and  digested  overnight  with  Lysyl  endopeptidase  (Lys-­‐‑C;  Wako,  
cat.   no.   129-­‐‑02541)   in   IAP   buffer   at   37  °C   [enzyme-­‐‑to-­‐‑protein   ratio   1:50   (wt/wt)].  
Peptides  were  collected  and  the  device  was  washed  with  IAP  buffer  to  increase  the  the  
yield   of   Lys-­‐‑C   digested   peptides.   High-­‐‑molecular-­‐‑weight   peptides   retained   on   the  
30  kDa   ultrafiltration   spin   column   were   subsequently   digested   with   endoproteinase  
Glu-­‐‑C  (Sigma-­‐‑Aldrich,  cat.  no.  11047817001)  overnight  in  IAP  buffer  at  25  °C  [enzyme-­‐‑
to-­‐‑protein   ratio   1:100   (wt/wt)],   and   after   the   collection   of   peptides,   the   device   was  
washed  with  IAP  buffer.    
Experiments   evaluating   the   specificity   of   endoproteinases  were   performed   as   above,  
but   digestion   with   Lys-­‐‑C   was   performed   under   two   conditions,   either   25  mM  
ammonium  bicarbonate  (NH4HCO3)  or  IAP  buffer.  After  Lys-­‐‑C  digestion,  the  samples  
were  supplemented  with  either  Glu-­‐‑C  or  trypsin  (Promega,  cat.  no.  V5280)  at  enzyme-­‐‑
to-­‐‑protein  ratio  of  1:50   (wt/wt)  and  digested  overnight  at  either   room  temperature  or  
37  °C,  respectively.    
 In  solution  digestion  of  proteins  2.3.3.
Complete  proteome  analyses  were  performed  with  cell  lysate  proteins  dissolved  in  6  M  
urea,   2  M   thiourea   after   TCA-­‐‑based   precipitation.   The   proteins   were   treated   with  
10  mM   DTT   for   1   hour   and   50  mM   2-­‐‑chloroacetamide   for   1.5   hours   at   room  
temperature  in  the  dark,  prior  to  2.5-­‐‑fold  dilution  into  50  mM  ammonium  bicarbonate  
and  digestion  with  Lys-­‐‑C  at  enzyme-­‐‑to-­‐‑protein  ratio  1:50  (wt/wt)  at  room  temperature  
for  4.5  hours.  Lys-­‐‑C  digested  samples  were  then  equally  divided  in  two,  and  one  of  the  




supplementation  with   trypsin   at   enzyme-­‐‑to-­‐‑protein   ratio   1:50   (wt/wt).   Both   samples  
were  digested  overnight  at  room  temperature.  When  stated,  resulting  peptide  mixtures  
were  fractionated  into  six  fractions  based  on  the  pH  of  the  solution  (pH  11.0,  8.0,  6.0,  
5.0,   4.0,   and   3.0)   used   to   elute   the   peptides   from   a   pipette   tip-­‐‑based   Empore   anion  
exchanger  (Agilent  Technologies,  cat.  no.  12145012)  according  to  a  protocol  described  
in  (Wisniewski  et  al.,  2009a).  
 Immunoaffinity   purification   of   diGly-­‐‑Lys-­‐‑containing  2.3.4.
peptides  
The   enrichment   of   diGly-­‐‑Lys-­‐‑containing   peptides   was   performed   according   to   a  
protocol   adapted   from   (Udeshi   et   al.,   2013a).   Peptides   in   IAP   buffer   were  
supplemented   with   ~18.75  µμg   of   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody   cross-­‐‑linked   to   3  µμl   of  
protein  A   agarose   resin,   and   rotated   overnight   at   4  °C.   Agarose   beads  were  washed  
twice   with   cold   IAP   buffer   and   peptides   were   eluted   in   two   sequencial   steps   with  
0.15  %  (vol/vol)  trifluoroacetic  acid  (TFA).    
 Desalting  of  peptides  2.3.5.
Prior  to  MS  analyses,  all  peptide  samples  were  concentrated  and  desalted  on  Empore  
C18  (Agilent  Technologies,  cat.  no.  12145004)  Stop  and  Go  Extraction  Tips  (StageTips)  
according   to   a   protocol   adapted   from   (Rappsilber   et   al.,   2007).   Self-­‐‑made   StageTips  
stacked   with   three   layers   of   C18-­‐‑bonded   silica   extraction   disks   were   washed   with  
methanol,   conditioned   with   80  %   (vol/vol)   acetonitrile,   0.1  %   (vol/vol)   TFA,   and  




loaded  onto  StageTips,  washed  with  0.1  %  TFA,  extracted  with  80  %  acetonitrile,  0.1  %  
TFA,  and  vacuum  concentrated  at  30  °C  prior  to  the  reconstitution  in  0.1  %  TFA.    
 SUMOKGG  workflow  2.3.6.
A  detailed  protocol  of  SUMOKGG  workflow  is  provided  in  Appendix  6.2  (Tammsalu  et  
al.,  2015)  and  summarised  in  Figure  3.8.  




2.4. MS  procedures  
 Liquid   chromatography   (LC)-­‐‑tandem   mass   spectrometry  2.4.1.
(MSMS)  
All  desalted  peptide  samples  were  analysed  using  EASY-­‐‑nLC  1000  nano-­‐‑flow  UHPLC  
system,   EASY-­‐‑Spray   ion   source   and   Q   Exactive   hybrid   quadrupole-­‐‑Orbitrap   mass  
spectrometer   (all   Thermo  Fisher   Scientific).   Peptides  were   loaded   onto   2  cm  Acclaim  
PepMap  100  C18  nanoViper  pre-­‐‑column   (75  µμm   inner  diameter;   3  µμm  particles;   100  Å  
pore   size)   at   a   constant   pressure   of   800  bar   and   separated   using   50  cm   EASY-­‐‑Spray  
PepMap   RSLC   C18   analytical   column   (75  µμm   inner   diameter;   2  µμm   particles;   100  Å  
pore  size)  maintained  at  45  °C.  
DiGly-­‐‑Lys-­‐‑enriched   samples  were  analysed  at   least   twice.  Exploratory  analysis  using  
standard  MS  settings  was  in  general  performed  with  10  %  of  the  sample  and  peptides  
were  separated  with  60-­‐‑minute  linear  gradient  of  5−22  %  (vol/vol)  acetonitrile  in  0.1  %  
(vol/vol)   formic   acid   at   a   flow   rate   of   250  nl/min,   followed   by   a   12-­‐‑minute   linear  
increase  of  acetonitrile  to  40  %  (vol/vol).  Total  length  of  the  gradient  including  column  
washout   and   re-­‐‑equilibration  was   90  minutes.  Comprehensive  peptide   analyses  were  
performed  using  either  identical  conditions  or  a  120-­‐‑minute  linear  gradient  of  5−22  %  
(vol/vol)  acetonitrile   in  0.1  %  (vol/vol)   formic  acid  at  a  flow  rate  of  250  nl/min,  with  a  
subsequent  15-­‐‑minute  linear  increase  of  acetonitrile  to  40  %  (vol/vol).  Thus,  the  overall  
lengths  of  the  gradients  during  comprehensive  analyses  were  either  90  or  150  minutes,  
respectively.  Peptides  corresponding  to  the  complete  human  proteome  were  in  general  




at  a  flow  rate  of  250  nl/min,  with  the  majority  of  peptides  eluting  during  a  220-­‐‑minute  
acetonitrile  window  from  5  %  to  50  %  (vol/vol).    
Peptides   eluting   from   the   liquid   chromatography   (LC)   column   were   charged   using  
electrospray   ionisation   and  MS   data  was   acquired   online   in   a   profile   spectrum   data  
format.  Full  MS  scan  covered  a  mass  range  of  mass-­‐‑to-­‐‑charge  ratio   (m/z)  300−1800  or  
300−1600   during   standard   or   comprehensive   peptide   analyses,   respectively.   Target  
value  was  set   to  1  000  000   ions  with  a  maximum  injection   time  (IT)  of  20  ms  and  full  
MS  was  acquired  at  a  mass  resolution  of  70  000  at  m/z  200.  Data  dependent  MSMS  scan  
was  initiated  if  the  intensity  of  a  mass  peak  reached  a  minimum  of  20  000  ions.  During  
standard   LC-­‐‑MSMS   analyses,   up   to   10   most   abundant   ions   (Top  10)   were   selected  
using   2  Th   mass   isolation   range   when   centered   at   the   parent   ion   of   interest.   For  
comprehensive  analyses,   either  up   to  5   (Top  5)  or   the  most   abundant   ion  exclusively  
(Top  1)   were   picked   for   MSMS.   Selection   of   molecules   with   peptide-­‐‑like   isotopic  
distribution  was  preferred.  Target  value  for  MSMS  scan  was  set  to  500  000  ions  with  a  
maximum  IT  of  60  ms  and  resolution  of  17  500  at  m/z  200  for  standard,  or  maximum  IT  
of   1000  ms   (Top  1)   or   300  ms   (Top  5),   and   a   resolution   35  000   at   m/z  200   for  
comprehensive   peptide   analyses.   Precursor   ions   were   fragmented   by   higher   energy  
collisional  dissociation   (HCD)  using  normalised   collision   energy  of   30   and   fixed   first  
mass  was  set  to  m/z  100.  Precursor  ions  with  undetermined,  single,  or  high  (>8)  charge  
state  were   rejected.   Ions   triggering  a  data-­‐‑dependent  MSMS  scan  were  placed  on   the  
dynamic   exclusion   list   for   40  s   (standard   analyses)   or   60  s   (comprehensive   analyses)  




 Analysis  of  raw  MS  files  2.4.2.
Raw  mass  spectrometric  data  files  were  processed  with  MaxQuant  software  (versions  
1.3.0.5  or  1.5.2.8)  (Cox  and  Mann,  2008)  and  peak  lists  were  searched  with  an  integrated  
Andromeda   search   engine   (Cox   et   al.,   2011)   against   an   entire   human   UniprotKB  
proteome   containing   canonical   and   isoform   sequences   (The   UniProt   Consortium,  
2015).   Raw   files   were   divided   into   parameter   groups   based   on   the   specificity   of  
proteolysis   applied   during   sample   preparation.   Hydrolysis   of   peptide   bonds  
C-­‐‑terminal   to   Lys,   or   Lys   and  Arg  with   a  maximum   of   three  missed   cleavages  was  
allowed   for   peptides   processed   with   Lys-­‐‑C,   or   Lys-­‐‑C   and   trypsin,   respectively.  
Samples   acquired   after   an   additional   Glu-­‐‑C   digestion   were   analysed   with   enzyme  
specificity   set   to   C-­‐‑terminal   to   Lys,   Glu   and   Asp   with   a   maximum   of   five   missed  
cleavages.   Carbamidomethylation   of   cysteine   residues   was   specified   as   a   fixed  
modification   and   oxidation   of   methionines,   acetylation   of   protein   N-­‐‑termini,   and  
where  applicable,  Gly-­‐‑Gly  adduct  on  internal  lysine  residues  were  selected  as  variable  
modifications.  When  required,  phosphorylation  of  Ser,  Thr  and  Tyr  was  also  included  
as   a   variable   modification.   Maximum   peptide   mass   of   10  000   Da   was   allowed,  
multiplicity  was  set  to  1  and  re-­‐‑quantify  option  was  disabled.  Decoy  sequence  database  
was  generated  using  Lys  as  a  special  amino  acid.  Default  values  were  chosen   for   the  
rest   of   the   parameters.   For   SILAC-­‐‑based   samples,   multiplicity   was   set   to   two,   and  
K8R10  were  selected  as  heavy-­‐‑labelled  counterparts.  Match  between  runs  option  was  
enabled  with  a  match   time  window  of  1  min  and  alignment   time  window  of  20  min.  
All   data   sets  were   filtered   by  posterior   error   probability   to   achieve   a   false  discovery  




2.5. Microscopy  techniques  
 Immunofluorescence  microscopy  2.5.1.
Immunofluorescence   microscopy   experiments   were   performed   in   collaboration   with  
Ellis  G.  Jaffray  and  Federico  Pelisch  (both  University  of  Dundee).  Unperturbed  or  heat-­‐‑
stressed  HeLa  cells  in  24-­‐‑well  plates  were  fixed  with  3.8  %  formaldehyde  in  phosphate  
buffered  saline  (PBS),  permeabilised  with  0.2  %  Triton  X-­‐‑100  in  PBS,  blocked  with  5  %  
BSA   in   0.1  %   Tween  20,   PBS,   incubated   with   antibodies   specified   in   Table   2.2,   and  
stained  with  0.1  µμg/ml  DAPI.  The  samples  were  mounted  on  microscope  slides  (VWR,  
cat.   no.   631-­‐‑0116)   and   images   were   acquired   using   a   widefield   DeltaVision   Elite  
imaging  system  (GE  Healthcare  Life  Sciences),  an  Olympus  IX71  inverted  microscope  
with   a   60  ×/1.42   Plan   Apochromat   oil   immersion   lens   (Olympus),   a   CoolSNAP   HQ  
camera   (Photometrics),   and   softWoRx   software.   Non-­‐‑deconvolved   images   were  
processed  using  ImageJ  1.50b  (Schneider  et  al.,  2012),  maintaining  all  parameters  when  
comparing  unperturbed  or  heat-­‐‑stressed  cells.      
 Light  microscopy  2.5.2.
Photographs   of   adherent   HEK293   N3S   or   HEK2936His-­‐‑SUMO2-­‐‑T90K   N3S   cells   cultured   in  
75  cm2  flask  were  taken  using  an  Axiovert  40  CFL  inverted  microscope,  an  LD  A-­‐‑Plan  





2.6. Bioinformatic  analyses  
 Alignments  2.6.1.
Sequence   alignments   were   generated   with   a   Clustal   Omega   multiple   sequence  
alignment  tool  (Sievers  et  al.,  2011)  using  Jalview,  version  2  editor  (Waterhouse  et  al.,  
2009).    
Structural   alingments   were   created   with   a   protein   structure   comparison   service  
PDBeFold,   version   2.59   at   European   Bioinformatics   Institute   (http://www.ebi.ac.uk/  
msd-­‐‑srv/ssm)  (Krissinel  and  Henrick,  2004).    
 Sequence  analyses  2.6.2.
Primary   structure   motif   analyses   were   performed   with   pLogo   (O'ʹShea   et   al.,   2013).  
Sequence  windows  of  13  amino  acids  centered  at  the  modified  lysine  were  used  as  an  
input,   and   N-­‐‑   or   C-­‐‑terminal   sequences   not   covering   the   13   residue   window   were  
omitted   from   the   output.   Residues  were   scaled   relative   to   their   Bonferroni-­‐‑corrected  
statistical  significance  using  human  proteome  as  a  background  data  set  (645  531  lysine  
residues).    
 Pathway  analyses  2.6.3.
Protein   function   annotation   and   network   analyses   were   generated   using   Qiagen’s  




Cellular   component-­‐‑based   annotations  were   retrieved   from  Gene  Ontology   database  
(released  in  August  2016)  using  PANTHER  Classification  System  (The  Gene  Ontology  
Consortium,  2015;  Mi  et  al.,  2016)  and  analysed  with  PANTHER  overrepresention  tool  
(released  in  July  2016)  using  Bonferroni-­‐‑correction  for  multiple  testing.    
 Protein  secondary  structure  prediction  2.6.4.
Secondary  structure  predictions  were  performed   in  collaboration  with  Christian  Cole  
(University  of  Dundee).  All  modified  peptides  were  expanded   to   their  whole  protein  
“parent”   and   submitted   to   JPred4   for   protein   secondary   structure   prediction  
(Drozdetskiy  et  al.,  2015).  JPred4  had  length  and  time  limits  for  making  predictions,  so  
proteins   longer   than  800  or  shorter   than  20  amino  acids,  or  predictions   taking   longer  
than  one  hour  were  omitted.  DisEMBL  disorder  prediction   (Linding  et  al.,   2003)  was  
performed   via   JABAWS   (Troshin   et   al.,   2011).   The   central   lysine   residue   for   each  
peptide   was   then   interrogated   in   its   parent   protein   for   its   secondary   structure   and  
disorder   prediction,   and   assigned   as   being   either   in   α-­‐‑helical,   β-­‐‑strand   or   coil,   and  
disordered   or   non-­‐‑disordered   region.   The   counts   for   each   of   the   five   states   were  
summed   and   compared   between   experimental   conditions.   As   the   JPred4-­‐‑predicted  
secondary  structures  can  only  be  one  of  three  states,  the  comparison  was  performed  at  
the   level   of   proportion   of   each   state   between   experimental   conditions.   The   Wald  
method  was  used  to  determine  the  95  %  confidence  interval  of  the  proportions  of  each  




 Statistical  computing  2.6.5.
Statistical   analyses   were   performed   and   graphics   were   generated   using   either  
GraphPad  Prism  version  6.0e  for  Mac  OS  X  (GraphPad  Software,  www.graphpad.com)  
or   R   programming   language   (R   Core   Team,   2015)   via   RStudio   interface   (version  
0.99.484)   (RStudio   Team,   2015)   and   implementing  R   packages   ”stats”   (R  Core   Team,  






Development  of  a  mass  spectrometry-­‐‑based  
method  for  the  system-­‐‑wide  identification  of  









The   aim   of   this   project   was   to   establish   a   high-­‐‑throughput   approach   for   the   global  
identification  of  SUMO  modification  sites  from  a  diverse  collection  of  complex  protein  
mixtures.   As   a   consequence   of   the   remarkable   advances   in   instrumentation   and  
methodology,  mass  spectrometry  (MS)-­‐‑based  proteomics  has  become  the  technique  of  
choice   for   comprehensive   identification   and   quantification   of   entire   proteomes   (Cox  
and  Mann,  2007;  Wilhelm  et  al.,  2014).  With  current  MS-­‐‑based  proteomics  tools,  high-­‐‑
accuracy   qualitative   and   quantitative   information   on   thousands   of   proteins   can   be  
rapidly  collected  with  a  single  study  (Nilsson  et  al.,  2010).  Moreover,  numerous  robust  
MS-­‐‑based  techniques  have  also  been  developed  for  the  large-­‐‑scale  detection,  mapping  
and  quantification  of  protein  posttranslational  modifications   (PTMs)   (Cox  and  Mann,  
2007).   For   these   reasons,   the   workflow   for   the   global   identification   of   SUMO  
modification   sites   was   also   designed   to   utilise   the   advanced   equipment   and  
methodology  of  mass  spectrometry-­‐‑based  proteomics.    
In   this   chapter,   the   development   of   an   experimental   strategy   that   enables   high-­‐‑
throughput  identification  of  sumoylated  proteins  and  allows  mapping  of  exact  sites  of  
modification,  is  described.  The  importance  of  each  stage  of  the  workflow  is  evaluated,  
and   if   applicable,   compared   with   alternative   techniques   that   can   be   utilised   for   a  
similar   purpose.   In   addition,   the   eligibility   of   individual   cell   lines,   reagents   and  
equipment  is  examined.  A  number  of  small-­‐‑scale  studies  on  SUMO2  modification  sites  
in   human   kidney   cells   are   performed   to   investigate   and   validate   the   robustness,  




 Past   limitations   of   mapping   the   modification   sites   of   the  3.1.1.
sumoylated  proteome  
The  reversible  nature  of   sumoylation   is  achieved  by  a  unique  group  of  enzymes   that  
can   attach   or   remove   SUMO   from   substrate   proteins.   The   activity   and   specificity   of  
deconjugating  enzymes,  universally   termed  as  SUMO  proteases,   is   largely   influenced  
by   their   subcellular   localisation   (Hickey   et   al.,   2012).   The   spatial   separation   of   these  
isopeptidases  from  their  substrates,  however,  is  lost  upon  cell  disruption.  Therefore,  if  
SUMO-­‐‑specific   proteases   are   not   rapidly   inactivated,   a   general   decrease   in   protein  
sumoylation   is   observed   and   consequently,   the   identification   of   target   proteins   and  
sites  is  hampered  (Vertegaal  et  al.,  2006).    
Many   studies   focusing   on   individual   SUMO   substrates   have   shown   that   the   steady-­‐‑
state  stoichiometry  of  protein  sumoylation  is  very  low  (<  1  %)  (Hay,  2005;  Wohlschlegel  
et   al.,   2006;   Tatham   et   al.,   2009).   The   identification   of   such   low   abundance   target  
proteins   by   liquid   chromatography   (LC)-­‐‑tandem  mass   spectrometry   (MSMS)   is   often  
challenging,  because  of  the  wide  dynamic  range  of  individual  protein  abundances  in  a  
cell   lysate   (Nilsson   et   al.,   2010).  As  discussed   in  Chapter  1.5,   a   collection  of  methods  
have  been  developed   that  address   this   issue  by  enriching  SUMO-­‐‑modified  molecules  
from   the   rest   of   the   proteome.   However,   none   of   them   provide   direct   evidence   of  
sumoylation,  as  the  exact  location  of  modified  lysine(s)  is  not  provided.    
Prior   to   the  LC-­‐‑MSMS  analysis,  proteins  are  generally  hydrolysed   into  peptides.  This  
type   of   approach,   where   MS-­‐‑based   detection   and   sequencing   is   performed   at   the  
peptide   level,   is   known   as   bottom-­‐‑up   or   shotgun   proteomics.   Although   mass  




accuracy   is  much  higher   for   low-­‐‑molecular-­‐‑weight  molecules,  and   the  success   rate  of  
obtaining   complete   sequence   information   is   better   with   peptides   (Steen   and   Mann,  
2004;   Cox   and   Mann,   2011).   On   the   other   hand,   proteolysis   increases   the   sample  
complexity,   as   proteins   are   generally   digested   into   multiple   peptides.   Importantly,  
individual   sumoylated  molecules   of   a   substrate   protein   can   be  modified   on   distinct  
lysine(s)   and  most   residues   are   not   sumoylated   at   any   particular   time.   Digestion   of  
these  heterogenic   samples  of  SUMO  conjugates  will   thus  generate  complex  mixtures,  
which   are   characterised   by   an   excess   of   unmodified   over   modification-­‐‑specific  
peptides.   Therefore,   analogous   to   the   complications   inherent   in   protein-­‐‑level  
sumoylation   analysis,   MS-­‐‑based   identification   of   low   abundance   modified   peptides  
without   prior   enrichment   is   challenging,   because   of   the   wide   dynamic   range   of   the  
peptide  abundances  in  the  arising  samples.    
SUMO  is  a  large  PTM,  and  a  single  sumoylation  event  will  increase  the  mass  of  a  target  
protein  by  ~11  kDa  (The  UniProt  Consortium,  2015).  Like  other  proteins,  SUMO  can  be  
proteolytically   cleaved,   and   the   C-­‐‑terminal   peptide   of   a   substrate-­‐‑bound   SUMO  
molecule   will   remain   attached   to   the   target   lysine.   In   most   cases   of   bottom-­‐‑up  
proteomics,  peptides  are  generated  using  trypsin  (Steen  and  Mann,  2004;  Tsiatsiani  and  
Heck,   2015),  which   is   a   highly   specific   endoproteinase   that   cleaves   at   the  C-­‐‑terminal  
side  of  arginines  and  lysines  (Olsen  et  al.,  2004).  Inspection  of  the  primary  sequences  of  
all   SUMO   paralogs,   however,   reveals   a   dearth   of   these   residues   in   their   C-­‐‑terminal  
regions.  Consequently,  the  digestion  of  sumoylated  proteins  with  trypsin  will  generate  
long   remnants   attached   to   target   lysines.   In   particular,   substrate-­‐‑bound   tryptic  
remnants  of  human  SUMO1  or  SUMO2/3   contain   19  or   32   amino  acids,   respectively,  




remnant-­‐‑modified  peptides  with  two  N-­‐‑termini,  termed  “branched  peptides”,  generate  
intricate   MSMS   fragmentation   spectra   and   to   date   can   only   be   processed   using  
specialist   software,   which   appear   to   have   limited   applicability   to   complex   peptide  
mixtures  (Pedrioli  et  al.,  2006;  Matic  et  al.,  2008;  Hsiao  et  al.,  2009).    
In   this  chapter  an  MS-­‐‑based  approach  was  developed   to  address  all  abovementioned  







 Selection   of   an   appropriate   cell   lysis   solution   with   a  3.2.1.
compatible  protein  affinity  tag  
An  important  consideration  for  the  successful  isolation  of  SUMO-­‐‑modified  proteins  is  
the   formulation  of   the   cell   lysis  buffer.  A  major   complication   that  has   to  be   resolved  
during  the  enrichment  of  sumoylated  proteins  is  the  presence  of  highly  active  SUMO-­‐‑
specific  proteases  in  the  cell  lysate.  If  no  action  is  taken,  these  will  rapidly  deconjugate  
SUMO   from   its   substrates   (Vertegaal   et   al.,   2006).   Although   SUMO-­‐‑specific   cysteine  
isopeptidases   can   be   chemically   inhibited   by   sulfur   (S)-­‐‑alkylating   agents,   denaturing  
buffer   conditions   have   been   successfully   utilised   to   promptly   unfold   and   inactivate  
proteases,  and  thus  prevent  SUMO  deconjugation  (Vertegaal  et  al.,  2006;  Tatham  et  al.,  
2009;   Bruderer   et   al.,   2011).   In   addition,   these   buffer   conditions   can   disrupt   the  
non-­‐‑covalent   interactions   between   conjugates   and   residual   non-­‐‑sumoylated   proteins,  
and  reduce  the  proportion  of  co-­‐‑purifying  proteins,  often  referred  to  as  “contaminants”  
(Vertegaal  et  al.,  2006;  Tatham  et  al.,  2009).    
The  range  of  protein  affinity  tags  compatible  with  strong  denaturing  agents  is  limited  
(Andersen   et   al.,   2009).   Therefore,   a   well-­‐‑characterised   hexahistidine   (6His)-­‐‑tag   was  
selected   to   generate   a   version   of   SUMO   that   enables   the   enrichment   of   modified  
proteins  under  denaturing   conditions  by   immobilised  metal   affinity   chromatography  
(IMAC).  As  the  isopeptide  bond  with  a  substrate  is  formed  via  the  C-­‐‑terminal  glycine  
of   SUMO,   the   6His-­‐‑tag  was   linked   to   the  N-­‐‑terminus  of   the  protein   (Kamitani   et   al.,  




tags  do  not  interfere  with  the  functionality  of  SUMO  (Vertegaal  et  al.,  2004;  Tatham  et  
al.,  2009).    
Nickel-­‐‑nitriloacetic  acid  (Ni2+-­‐‑NTA)  agarose  matrix  facilitates  the  purification  of  6His-­‐‑
tagged  recombinant  proteins  and  has  been  used  for  the  enrichment  of  SUMO-­‐‑modified  
substrates.   However,   conventional   detergent-­‐‑based   cell   lysis   buffers   cannot   be  
employed,   as   Ni2+-­‐‑NTA   agarose   is   incompatible   with   the   amount   of   detergents  
required   to  prevent  desumoylation.   Instead,  high   concentration  of   chaotropic   agents,  
such   as   8  M  urea   or   6  M   guanidine   hydrochloride   (Gu-­‐‑HCl)   have   been   utilised  with  
Ni2+-­‐‑NTA   resin   (Vertegaal   et   al.,   2004;   Tatham   et   al.,   2009).   Lysis   of   cells   was   thus  
performed  using  a  Gu-­‐‑HCl-­‐‑based  buffer,  which  was  selected  over  urea  because  of   its  
higher  denaturing  properties,   chemical   inertness,   thermostability,   and  high   solubility  
at  a  low  temperature  (Poulsen  et  al.,  2013).    
In   conclusion,   purification   of   6His-­‐‑tagged   SUMO   conjugates   by   nickel   affinity  
chromatography   under   denaturing   conditions   solves   two   major   complications   of  
sumoylation  proteomics:  
1) Aggressive  SUMO  proteases  are  inactivated  rapidly,  as  the  cell  lysis  procedure  
is  carried  out  using  strong  denaturing  Gu-­‐‑HCl-­‐‑based  buffer  solutions.  
2) The  detection  of  SUMO  substrates  by  LC-­‐‑MSMS  is  achieved,  as  the  enrichment  





 6His-­‐‑SUMO2T90K  as  a  biochemical  tool    3.2.2.
To   enable   the   system-­‐‑wide   identification  of   the   exact   sites   of   SUMO  modification  by  
LC-­‐‑MSMS,  three  additional  problems  have  to  be  addressed:  
1) Derivatisation,  substitution  or  truncation  of  the  long  SUMO  remnant  peptide  is  
required   to   enable   the   mapping   of   sumoylation   sites   using   conventional   MS  
software.  
2) The   newly   designed   remnant   sequence   of   SUMO   should   represent   a   unique  
mass-­‐‑to-­‐‑charge  (m/z)  signature  to  allow  its  discrimination  from  other  PTMs.  
3) The  remnant  sequence  of  SUMO  should  also  enable  the  specific  enrichment  of  
low  abundance  modified  peptides.  
To   address   these   points,   a   6His-­‐‑SUMO2T90K   construct  was   generated   by   site-­‐‑directed  
mutagenesis   (implemented   by   Adel   F.   M.   Ibrahim).   By   replacing   threonine90,   which  
precedes  the  conserved  Gly-­‐‑Gly  motif  at  the  C-­‐‑terminus  of  SUMO2,  with  lysine  (Figure  
3.1;   red),   a   new   cleavage   site   for   two   highly   specific   endoproteinases,   trypsin   and  
Lys-­‐‑C,  was   created.  Considering   that   trypsin   cleaves   substrates  C-­‐‑terminal   to   lysines  
and   arginines   (Olsen   et   al.,   2004),   it   cannot   be   utilised   to   generate   SUMO   remnants  
with   a  unique  mass.   In  particular,   three  human  Ubls   (Ubiquitin,   ISG15   and  NEDD8)  
have   an   arginine   in   the   equivalent   position   to   T90K  mutation   (Figure   3.1),   so   all   of  
them  will  be  cleaved  by  trypsin  and  thus  produce  identical  Gly-­‐‑Gly  remnants  attached  
to  target  lysines.  In  contrast,  Lys-­‐‑C  hydrolyses  peptide  bonds  at  the  C-­‐‑terminal  side  of  
lysines  alone  (Raijmakers  et  al.,  2010).  Notably,  none  of  the  other  known  human  Ubls  






Figure   3.1   |   Digestion   of   human  Ubl-­‐‑conjugated   proteins  with   Lys-­‐‑C   produces   a  Gly-­‐‑Gly  
remnant  on  target  lysines  modified  solely  by  SUMO2T90K.    
Alignment   of   human   Ubl-­‐‑family   proteins   that   contain   C-­‐‑terminal   Gly-­‐‑Gly   (diGly).   Remnant  
peptides   attached   to   the   target   lysines   after   Lys-­‐‑C   digestion   (blue)   show   that   mutating   the  
residue  before  Gly-­‐‑Gly  sequence  to  lysine  (red)  as  in  SUMO2T90K  creates  an  additional  cleavage  
site   for   Lys-­‐‑C,   which   generates   a   diGly   remnant   on   modified   lysines   with   a   unique  
mass-­‐‑to-­‐‑charge  (m/z)  signature.  Lysines  targeted  by  Lys-­‐‑C  are  underlined.  
  
digestion  of  sumoylated  proteins  will  generate  a  Gly-­‐‑Gly  remnant  that  can  be  assumed  
to  be  unique  to  6His-­‐‑SUMO2T90K.  
Importantly,   the   T90K   variant   of   SUMO2   can   also   be   exploited   to   reduce   the  
complexity  of  the  peptide  mixture.  A  monoclonal  antibody  that  specifically  recognises  
Gly-­‐‑Gly-­‐‑modified   lysines   has   been   developed   and   can   thus   be   utilised   for   the  
enrichment  of  low  abundance  6His-­‐‑SUMO2T90K  remnant-­‐‑modified  peptides  after  Lys-­‐‑C  
digestion   (Kim   et   al.,   2011).   The   purified   lower   complexity   sample   is   then   readily  
analysed   by   LC-­‐‑MSMS.   Furthermore,   as   the   Gly-­‐‑Gly   modification   (114.0429  Da)   is  
considerably   smaller   than   the   remnant   of   endogenous   wild-­‐‑type   SUMO2  
(3549.5367  Da),   conventional  MS   software   can  be   efficiently  utilised   to  determine   the  




 Functional  characterisation  of  SUMO2T90K  3.2.3.
To  assess  the  effect  of  T90K  mutation  on  SUMO2  function,  the  activities  of  recombinant  
SUMO2  and  SUMO2T90K  were  compared   in  multiple   in  vitro  enzyme  assays   (data  and  
images   generated   by   Ellis   G.   Jaffray).   Four   well-­‐‑established   targets   of   SUMO  
conjugation:   Sp100   (Nuclear   autoantigen   Sp-­‐‑100)   (Sternsdorf   et   al.,   1997),   RanGAP1  
(Ran   GTPase-­‐‑activating   protein  1)   (Matunis   et   al.,   1996;   Mahajan   et   al.,   1997),   PML  
(Protein  PML)  (Sternsdorf  et  al.,  1997),  and  IRF-­‐‑2  (Interferon  regulatory  factor  2)  (Han  
et   al.,   2008)   were   purified   and   subjected   to   in   vitro   sumoylation   analyses   with  
increasing  amount  of  either  SUMO2  or  SUMO2T90K   (Figure  3.2).  These  assays  showed  
little   substrate-­‐‑dependent   variation   between   SUMO2   and   SUMO2T90K   in   terms   of  
polymerisation   or   conjugation   to   target   proteins.   Separation   of   the   two   variants   of  
SUMO2  was  also  accomplished,  provided  that  the  SDS-­‐‑PAGE  was  performed  using  a  
10  %  Bis-­‐‑Tris  protein  gel  in  a  MES  buffer  solution,  which  resulted  in  a  slightly  slower  
migration  rate  of  SUMO2T90K  (Figure  3.2;  control  lanes).    
Desumoylation  assays  with  10  nM  of  SENP1  (Sentrin/SUMO-­‐‑specific  protease  SENP1)  
over   a   time   period   of   10   minutes   demonstrated   that   both   variants   of   SUMO2   were  
deconjugated  from  the  same  set  of  well-­‐‑established  substrate  proteins  at  similar  rates  
(Figure  3.3).  





Figure   3.2   |   SUMO2   and   SUMO2T90K   polymerisation   and   conjugation   to   various   substrate  
proteins  in  vitro  has  a  similar  concentration  dependence.    
Images   of   Coomassie   brilliant   blue-­‐‑stained   SDS-­‐‑PAGE   protein   gels   comparing   the   in   vitro  
sumoylation   of   recombinant   SUMO2   or   SUMO2T90K   to   four   distinct   substrate   proteins:  
(A)  Sp100,  (B)  RanGAP1,  (C)  PML,  and  (D)  IRF-­‐‑2.  Courtesy  of  Ellis  G.  Jaffray.    
  
Finally,   processing   of   full-­‐‑length   pro-­‐‑forms   of   SUMO2   and   SUMO2T90K   into   active  
mature  proteins  using  100  nM  of  SENP1  or  200  nM  of  SENP2  (Sentrin/SUMO-­‐‑specific  
protease  SENP2)  showed  no  significant  difference  irrespective  of  the  protease  utilised  
for  the  assay  (Figure  3.4).  These  data  confirmed  the  ability  of  SUMO2T90K  to  participate  
in   in   vitro   modification,   deconjugation   and   maturation   reactions   in   a   comparable  
manner  to  the  wild-­‐‑type  counterpart.    





Figure   3.3   |   SUMO2   and   SUMO2T90K   are   deconjugated   from   various   substrate   proteins   at  
similar  rates  in  vitro.    
Images   of   Coomassie   brilliant   blue-­‐‑stained   SDS-­‐‑PAGE   protein   gels   comparing   the   in   vitro  
deconjugation  of  SUMO2  and  SUMO2T90K  with  SENP1  from  four  distinct  sumoylated  substrate  
proteins:  (A)  Sp100,  (B)  RanGAP1,  (C)  PML,  and  (D)  IRF-­‐‑2.  Courtesy  of  Ellis  G.  Jaffray.  
  
  
Figure  3.4  |  SUMO-­‐‑specific  proteases  process  the  inactive  pro-­‐‑forms  of  recombinant  SUMO2  
and  SUMO2T90K  into  functional  mature  proteins  at  a  similar  rate.    
Images   of   Coomassie   brilliant   blue-­‐‑stained   SDS-­‐‑PAGE   proteins   gels   comparing   the   in   vitro  
maturation  of   recombinant  SUMO2   (top)  or   SUMO2T90K   (bottom)  with  SENP1   (left)   or   SENP2  
(right).  Courtesy  of  Ellis  G.  Jaffray.  




 Characterisation   of   HEK293   N3S   cells   stably   expressing  3.2.4.
6His-­‐‑SUMO2T90K  
To  express  SUMO2T90K   in  vivo,   human  embryonic  kidney  293   (HEK293)   cells   adapted  
for  growth  in  suspension  were  used  as  a  parental  cell  line  and  stably  transfected  with  a  
bicistronic  eukaryotic  expression  vector  pEFIRESpuro  (Hobbs  et  al.,  1998)   to  generate  
6His-­‐‑SUMO2T90K-­‐‑expressing   HEK293   cells   (HEK2936His-­‐‑SUMO2-­‐‑T90K  N3S;   implemented   by  
Adel  F.  M.  Ibrahim).  Plasmid  pEFIRESpuro  contains  a  bicistronic  transcription  cassette  
with  complementary  DNAs  encoding  the  protein  of  interest  (6His-­‐‑SUMO2T90K)  and  the  
selectable  marker  Puromycin  N-­‐‑acetyltransferase.  Transcription  will  generate  a  single  
mRNA  molecule  with  an  internal  ribosome  entry  site  of  an  encephalomyocarditis  virus  
downstream   of   the   coding   sequence   of   the   desired   protein.   The   expression   of  
6His-­‐‑SUMO2T90K  is  thus  ensured  in  clones  that  are  resistant  to  the  antibiotic  puromycin  
(Hobbs  et  al.,  1998).  Using  this  approach,  stable  cells  expressing  6His-­‐‑SUMO2T90K  were  
isolated.    
Light   microscopy   was   utilised   to   compare   the   morphologies   of   parental   and   newly  
generated   6His-­‐‑SUMO2T90K-­‐‑expressing   HEK293   cells.   Photographs   of   adherent   cell  
cultures   with   20   times   optical   magnification   demonstrated   that   they   were  
indistinguishable  (Figure  3.5).    
Growth   rates  were  determined  by   subculturing   both   of   the   cell   lines   in   32   replicates  
and  counting  the  cells  daily  over  a  time  period  of  2–5  days  (Figure  3.6).  Irrespective  of  
the  utilised  culturing  conditions,   the  replicate  values  of  all  data  points   from  both  cell  






Figure   3.5   |   Parental   and   6His-­‐‑SUMO2T90K-­‐‑expressing   HEK293   N3S   cells   share   virtually  
identical  morphology.    
Comparison   between   adherent   wild-­‐‑type   HEK293   cells   (left)   and   those   stably   expressing  
6His-­‐‑SUMO2T90K  (right)  visualised  using  light  microscopy.  Scale  bars  represent  20  µμm.  
  
standard  deviation  with  higher  number   of   cells   (Figure   3.6A).  However,   variation   in  
the   initial   number   of   subcultured   cells   meant   that   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   grown  
under  puromycin  selection  reached  nearly  maximum  confluency  after  96  hours  (Figure  
3.6B).  The  last  measurement  of  this  cell  culture  was  thus  omitted  from  the  downstream  
analyses   to   allow   fitting   of   an   exponential   model.   Best-­‐‑fit   curves   describing   the  
exponential   growth  were   then  modelled   based   on   the   replicate   values   of   individual  
data   points   using   nonlinear   weighted   least   squares   regression.   As   the   variability   of  
replicate  data  points  across   the  measured  time  period  was  heteroscedastic,  weighting  
factor   1/Y2   was   selected   to  minimise   the   sum   of   the   squares   of   relative   distances   of  
replicate  values  from  the  curve  (Figure  3.6).  Doubling  times  of  both  cell  lines  were  then  
calculated   from   these   best-­‐‑fit   curves   and   appeared   to   be   comparable  –   16.1   or   18.5  






Figure   3.6   |   Comparable   doubling   time   can   be   observed   between   parental   and  
6His-­‐‑SUMO2T90K-­‐‑expressing  HEK293  cells.    
The   number   of   cells   was   counted   daily   in   32   biological   replicates   for   adherent   wild-­‐‑type  
HEK293  cells  (black)  or  for  those  stably  expressing  6His-­‐‑SUMO2T90K  cultured  either  without  (–;  
blue)   or   under   puromycin   selection   (+;   orange)   over   a   time   period   of   2–5   days   after  
subculturing.   (A)  Scatter  plot  of   individual   cell   count  values.   (B)  Graph  of  average  number  of  
cells  with  y-­‐‑axis  in  logarithmic  scale  (base  2).  All  series  of  data  points  were  fitted  with  a  curve  
describing  exponential  growth  modelled  using  nonlinear  least  squares  regression  weighted  by  a  
factor  1/Y2.  Error  bars  correspond  to  standard  deviations  and  the  omitted  data  point  is  indicated  
by  a  red  arrow.  
  
supplementation  with   the   selection   antibiotic   puromycin   (1  µμg/ml)   had   a   cumulative  
effect   on   the   growth   rate   as   indicated   by   the   increase   in   the   doubling   time   of  
6His-­‐‑SUMO2T90K-­‐‑expressing  cells  to  20.0  hours.  
Finally,  the  abundance  of  6His-­‐‑SUMO2T90K  was  evaluated  together  with  its  conjugation  




either  unperturbed  or  after  heat  stress  at  43  °C  for  30  minutes.  Equivalent  amounts  of  
cell   lysates   (protein   wt/wt)   were   then   subjected   to   Western   blot   analyses   using  
antibodies   recognising  either  SUMO2/3  or   the  6His   tag   (Figure  3.7).  The   immunoblot  
image   with   SUMO2/3-­‐‑specific   antibody   highlighted   the   near   identical   amounts   of  
endogenous   wild-­‐‑type   and   exogenous   6His-­‐‑SUMO2T90K   produced   by   the  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (Figure   3.7A;   lanes  3   and   4).   Moreover,   enhanced  
polymerisation   and   conjugation   of   6His-­‐‑SUMO2T90K   to   substrate   proteins   in   cells  
exposed  to  the  elevated  temperature  was  consistent  with  the  response  of  endogenous  
SUMO2/3   produced   by   the   parental   cells   (Figure   3.7).   This   was   confirmed   by   the  
Western   blot   analysis   utilising   6His-­‐‑specific   antibody,   which   enabled   to   exclusively  
detect   the   response   of   6His-­‐‑SUMO2T90K   (Figure   3.7B).   HEK2936His-­‐‑SUMO2-­‐‑T90K   N3S   cells  
were   thus   approved   as   a   suitable   tool   for   the   identification   of   SUMO2  modification  
sites  by  mass  spectrometry.    





Figure   3.7   |   In   HEK2936His-­‐‑SUMO2-­‐‑T90K,   endogenous   SUMO2/3   and   6His-­‐‑SUMO2T90K   are  
expressed  at  comparable  levels  and  respond  to  heat  stress  similarly.    
Lysates   from   parental   (–)   or   stable   6His-­‐‑SUMO2T90K-­‐‑expressing   (+)   HEK293   cells   either  
unstressed   (37  °C)  or   in   response   to  heat   stress   (43  °C,  30  min)  were  subjected   to  western  blot  
analysis   for   the   detection   of:   (A)  SUMO2/3,   or   (B)  6His.   Nonspecific   immunoreaction   is  
indicated  by  asterisk.  
  
 Overview   of   the   biochemical   approach   designed   for   the  3.2.5.
global  identification  6His-­‐‑SUMO2T90K  modification  sites  
To   enable   proteome-­‐‑wide   identification   of   SUMO2  modification   sites,   a   biochemical  
enrichment   approach   was   developed   exploiting   the   newly   characterised  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   together   with   the   high   sensitivity   and   throughput   of   MS-­‐‑
based   proteomics.   The   method   (hereafter   referred   to   as   the   SUMOKGG   workflow)  
employs   two   tandem   purification   steps   involving   the   enrichment   of   sumoylated  
proteins   followed   by   an   affinity   purification   of   peptides   modified   by   the   Gly-­‐‑Gly  





Figure  3.8  |  Depiction  of  the  SUMOKGG  workflow.    
››  




‹‹  Figure  3.8  |  Depiction  of  the  SUMOKGG  workflow.    
Proteins   conjugated   to   6His-­‐‑SUMO2T90K   are   purified   using   nickel   affinity   chromatography,  
digested   with   Lys-­‐‑C   and   resulting   peptides   are   separated   from   the   protease   using   a   30  kDa  
filter  device.  High-­‐‑molecular-­‐‑weight  peptides  retained  on  the  device  are  subsequently  cleaved  
with  Glu-­‐‑C,   filtered   through   the  membrane   and   samples   are   kept   separately.   Finally,   SUMO  
remnant-­‐‑containing  peptides  are  enriched  from  each  sample  using  a  K-­‐‑ε-­‐‑GG-­‐‑specific  antibody  
and  analysed  by  LC-­‐‑MSMS.  
  
In  this  strategy,  proteins  are  extracted  by  cell  lysis  under  strong  denaturing  conditions  
to   inactivate   SUMO   proteases   and   prevent   desumoylation   of   substrates.   Cell   lysate  
proteins  are   then  mixed  with  Ni2+-­‐‑NTA  agarose  resin  and  stirred  overnight  at  4  °C  to  
allow   specific   binding  of   the  polyhistidine   stretch   of   6His-­‐‑SUMO2T90K   to   the  divalent  
nickel   ion   (Ni2+),   immobilised   to   an   agarose  matrix   via   a   coordination   complex  with  
nitriloacetic   acid   (NTA)   (Hochuli   et   al.,   1987;   Bornhorst   and   Falke,   2000).   Next,   the  
slurry  of  Ni2+-­‐‑NTA  agarose  with  cell   lysate  proteins   is   transferred  into  an  empty  spin  
chromatography  column  and  agarose  beads  are  allowed  to  settle  to  the  bottom  of  the  
container  by  gravity.  Packed  Ni2+-­‐‑NTA  resin  is  then  stringently  washed  while  altering  
the   pH   of   the   buffer   solutions   for   the   elution   of   nonspecifically   bound   proteins.  
Importantly,  the  pH  of  these  buffers  should  not  be  adjusted  below  6.0,  as  the  imidazole  
ring   of   the   histidine   residue   becomes   protonated.   This   phenomenon   disrupts   the  
coordination  complex  and  results   in  a  premature  dissociation  of  polyhistidine-­‐‑tagged  
proteins   from   the   resin   (Bornhorst   and   Falke,   2000).   Finally,   6His-­‐‑SUMO2T90K  
conjugates  are  separated  from  the  Ni2+-­‐‑NTA  stationary  phase  using  an  imidazole-­‐‑based  
eluent  that  competes  with  the  imidazole  rings  of  the  histidines  and  enables  the  efficient  




Proteins   eluted   from   the   Ni2+-­‐‑NTA   agarose   resin   are   then   concentrated   in   an  
ultrafiltration  device   (Figure  3.8;   second  panel).  This  device  acts   as  a   container  while  
subsequent   sample   preparation   procedures   are   applied,   including   proteolysis   into  
peptides.  The  nominal  molecular  weight  cutoff  limit  should  thus  be  carefully  selected  
to   obtain   the   desired   properties   of   separation.   An   appropriate   cutoff   assists   a   rapid  
buffer   exchange   for   the   complete   removal   of   chemicals   incompatible   with   the  
subsequent   stages   of   the   protocol,   and   ultimately   facilitates   the   efficient   elution   of  
derivative   peptides.   On   the   other   hand,   partially   or   undigested   proteins,   and   high-­‐‑
molecular-­‐‑weight  peptides  should  be  retained  on  the  filter  device,  as  they  can  interfere  
the  eventual  analysis  by  LC-­‐‑MSMS  (Manza  et  al.,  2005;  Wisniewski  et  al.,  2009b).  Most  
importantly,   utilised   proteases   should   be   efficiently   separated   from   the   peptide  
mixture   to  prevent   cleavage  of  diGly-­‐‑Lys   (K-­‐‑ε-­‐‑GG)-­‐‑specific   antibody.  Thus,   a   30  kDa  
ultrafiltration  device  was  employed  and  its  suitability  was  comprehensively  examined  
in  Chapter  3.2.7.    
Prior  to  proteolytic  digestion,  the  concentrated  denatured  proteins  in  the  ultrafiltration  
device   are   treated   with   2-­‐‑chloroacetamide   to   carbamidomethylate   the   reduced   thiol  
groups   of   cysteine   residues   and   block   the   subsequent   formation   of   disulfide   bonds  
(Figure   3.8;   second   panel).   The   advantage   of   2-­‐‑chloroacetamide   over   the   routinely  
utilised   2-­‐‑iodoacetamide   is   its   high   substrate   selectivity,   which   prevents   the  
derivatisation   of   lysine   residues   with   2-­‐‑acetamidoacetamide   adducts   that   have   an  
identical  atomic  composition  to  Gly-­‐‑Gly  remnant  (C4H6N2O2;  114.0429  Da)  and  are  thus  
not   distinguished   by   MS   (Nielsen   et   al.,   2008).   The   excess   of   2-­‐‑chloroacetamide   is  
removed  by  applying  stringent  washes  and  eventually  replaced  with   immunoaffinity  




and  ultimately   improves   the  yield  of  peptides,   as   the   arising  mixture   can  be  directly  
subjected  to  the  second  enrichment  procedure.  
Lys-­‐‑C  is  essential  to  the  SUMOKGG  workflow  owing  to  its  high  specificity  towards  the  
hydrolysis  of  the  peptide  bonds  at  the  C-­‐‑terminal  side  of   lysines  alone  (Raijmakers  et  
al.,   2010).   This  will   ensure   that   substrates   conjugated   to   6His-­‐‑SUMO2T90K  will   be   left  
with  the  Gly-­‐‑Gly  remnant  attached  to  the  target  lysines.  As  other  human  Ubls  do  not  
contain   a   lysine   in   the   equivalent   position   (Figure   3.1),   diGly-­‐‑modified   peptides   can  
only   originate   from   6His-­‐‑SUMO2T90K.   Finally,   these   Lys-­‐‑C-­‐‑digested   peptides   in   IAP  
buffer  are  eluted  from  the  ultrafiltration  device  (Figure  3.8;  second  panel).    
Covalent   modification   of   lysine   ε-­‐‑amino   groups   renders   the   sites   resistant   to   Lys-­‐‑C  
digestion   (Giansanti  et  al.,  2016).   It  was   thus  expected   that   lysine-­‐‑deficient   regions  of  
proteins   could   generate   peptides   too   large   to   pass   through   the   membrane   of   the  
ultrafiltration   device   or   for   reliable   identification   by   LC-­‐‑MSMS.   To   increase   the  
proteome  coverage,  a  second  endoproteinase  Glu-­‐‑C  was  introduced  into  the  workflow  
(Figure   3.8;   second   panel),   which   cleaves   at   the   C-­‐‑terminal   side   of   glutamic   and  
aspartic   acids   (Drapeau   et   al.,   1972).   Glu-­‐‑C   will   not   affect   the   Gly-­‐‑Gly   remnant   of  
6His-­‐‑SUMO2T90K,  but  can  shorten   the  high-­‐‑molecular-­‐‑weight  peptides  retained  on   the  
membrane.  These  truncated  peptides  generated  by  the  subsequent  Glu-­‐‑C  digestion  are  
also  eluted  from  the  filter  device,  but  stored  separately  from  the   initial  subfraction  of  
Lys-­‐‑C  cleaved  peptides  (Figure  3.8;  second  panel).    
Both   subfractions   of   peptides   are   then   independently   subjected   to   the   second  




Gly-­‐‑Gly-­‐‑modified   lysines   (Kim   et   al.,   2011).   Selective   separation   of   diGly-­‐‑modified  
species  from  the  excess  of  unmodified  peptides  is  required  to  reduce  the  complexity  of  
the   samples   (Figure   3.8;   third   panel).   Finally,   these   purified   Gly-­‐‑Gly-­‐‑Lys-­‐‑containing  
peptide   sequences   are   identified   and   the   modification   sites   are   determined   using  
LC-­‐‑MSMS  (Figure  3.8;  bottom  panel).    
 Purification  of  proteins  conjugated  to  6His-­‐‑SUMO2T90K    3.2.6.
Three  members  of  the  human  Ubl  family  contain  an  arginine  at  the  equivalent  position  
to   the   T90K   mutation   in   6His-­‐‑SUMO2T90K   (Figure   3.1).   Considering   the   low  
stoichiometry  of  sumoylated  proteins,  it  was  speculated  that  their  separation  from  the  
excess   of   proteins   conjugated   to   any   of   the   residual   Ubls   could   be   beneficial.   In  
particular,   if  unspecific  digestion  of  Lys-­‐‑C  at   the  C-­‐‑terminal  side  of  arginine  residues  
occurs   even   with   low   efficiency,   a   considerable   number   of   identified   Gly-­‐‑Gly  
modification  sites  could  in  reality  emerge  from  Ubiquitin,  ISG15  or  NEDD8,  instead  of  
6His-­‐‑SUMO2T90K.    
Secondly,   the  K-­‐‑ε-­‐‑GG-­‐‑specific  monoclonal   antibody   that   is  utilised   in   the   subsequent  
stage   of   the   SUMOKGG   workflow,   was   originally   designed   for   the   enrichment  
diGly-­‐‑Lys-­‐‑containing   peptides   of   trypsin-­‐‑digested   ubiquitinated   proteins   (Kim   et   al.,  
2011).  Numerous  valuable  characteristics  of  the  antibody,  such  as  specificity  or  binding  
capacity  have  thus  been  determined,  and  the  established  protocols  can  be  adjusted  for  
the   enrichment   of   SUMO   remnant-­‐‑modified   peptides.   For   instance,   merely   31  µμg   of  
K-­‐‑ε-­‐‑GG-­‐‑specific   antibody   conjugated   to   5  µμl   of   protein  A   beads   is   required   for   the  
enrichment  of  ubiquitinated  peptides  from  10  mg  of  MG132-­‐‑treated  cell  lysate  proteins.  




increases   the   proportion   of   nonspecifically   bound   unmodified   peptides,   which   then  
hamper   the   identification   of   genuine   targets   (Udeshi   et   al.,   2013b).   In   human   cells,  
Ubiquitin   is   present   in   approximately   20-­‐‑fold   excess   compared   to   the   absolute  
abundance  of  SUMO  paralogs  (Kaiser  et  al.,  2011;  Matic  et  al.,  2011;  Wisniewski  et  al.,  
2014).  It  was  thus  predicted  that  less  than  31  µμg  of  antibody  is  required  for  the  optimal  
enrichment  of  SUMO2T90K  remnant-­‐‑modified  peptides.  Therefore,  the  lowest  amount  of  
antibody-­‐‑conjugated   resin   that   could   be   reproducibly   handled   was   established   and  
corresponded   to   3  µμl   of   protein  A   beads   conjugated   to   ~19  µμg   of   K-­‐‑ε-­‐‑GG-­‐‑specific  
antibody.   Such   a   low  quantity   of   resin,   however,   generated   a   demand   to  work  with  
low-­‐‑volume  peptide  samples  to  prevent  the  loss  of  antibody-­‐‑bound  beads  to  the  sides  
of   a   large   container.   The   efficient   enrichment   of   SUMO2T90K   conjugates   could  
simultaneously  decrease  the  complexity  and  reduce  the  volume  of  protein  samples.    
To   evaluate   the   suitability   of   nickel   affinity   chromatography   for   the   enrichment   of  
6His-­‐‑SUMO2T90K  conjugates,  proteins  extracted  from  heat-­‐‑stressed  HEK2936His-­‐‑SUMO2-­‐‑T90K  
cells  were  combined  with  Ni2+-­‐‑NTA  resin  in  a  ratio  of  200:1  (wt/vol).  After  an  overnight  
rotation  at  4  °C,  the  slurry  was  transferred  into  an  empty  spin  chromatography  column  
and   the   residual   solution   of   unbound   proteins   was   collected   by   gravity.  
Nonspecifically  bound  proteins  were  removed  by  repeatedly  washing  the  column  with  
buffer   solutions   at   different   pH,   and   6His-­‐‑SUMO2T90K-­‐‑bound  proteins  were   eluted   in  
three  sequencial  steps  (a  detailed  protocol  is  provided  in  Chapter  2.3.1).  An  equivalent  
proportion  of  the  volume  of  each  fraction  was  then  loaded  onto  an  SDS-­‐‑PAGE  protein  
gel   and   subjected   to   Western   blot   analyses   for   the   detection   of   SUMO2/3   or   6His  





Figure   3.9   |   6His-­‐‑SUMO2T90K-­‐‑conjugated   proteins   can   be   enriched   using   nickel   affinity  
chromatography.    
Equal   proportion   (~0.04  %;   vol/vol)   of  HEK2936His-­‐‑SUMO2-­‐‑T90K   cell   lysate   (input)   and   each   nickel  
affinity   chromatography   fraction   (flow-­‐‑through;   washes   1–4;   elutions   1–3)   were   subjected   to  
Western  blot  analysis   for   the  detection  of:   (A)  SUMO2/3  or   (B)  6His.  Approximately  0.04  %  of  
input  material  corresponds  to  20  µμg  of  protein.  Empty  lane  (_).  
  
A   SUMO2/3-­‐‑specific   immunoblot   image   illustrated   the   reduced   abundance   of  
sumoylated  proteins  in  the  high-­‐‑molecular-­‐‑weight  area  of  the  flow-­‐‑through  fraction  of  
the  nickel  affinity  chromatography.  Likewise,  the  amount  unconjugated  SUMO2/3  was  
also   decreased   (Figure   3.9A).   Notably,   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   express   endogenous  
SUMO2/3  and  6His-­‐‑SUMO2T90K,  which  compete  for  conjugation.  Therefore,  the  residual  
sumoylated   proteins   in   the   flow-­‐‑through   fraction   were   likely   to   be   the   targets   of  
endogenous   SUMO2/3.   Finally,   the   immunoblot   image   of   SUMO2/3   confirmed   that  
modified   proteins   were   not   released   from   the   Ni2+-­‐‑NTA   agarose   matrix   during   the  
stringent  wash  procedure,  but  could  be  efficiently  eluted  with  imidazole  (Figure  3.9A).    
6His-­‐‑specific  Western   blot   analysis   illustrated   that   the   substrates   of   6His-­‐‑SUMO2T90K  




immunoblot,   the   amount   of   sumoylated   proteins   was   decreased   and   unconjugated  
6His-­‐‑SUMO2T90K   was   undetectable   in   the   flow-­‐‑through   fraction.   However,   a  
considerable   amount   of   antibody-­‐‑reactive   proteins   were   still   detected   among   the  
unbound  proteins  (Figure  3.9B;  lane  2).  Therefore,  another  experiment  was  performed  
to  investigate  whether  these  were  substrates,  which  could  be  recovered  by  conducting  
repeated   Ni2+-­‐‑NTA   purifications.   This   set-­‐‑up   mimicked   the   conditions   created   by  
adding  twice  as  much  resin  to  the  cell  lysate  protein,  but  diminished  the  probability  of  
rendering   the   samples   unsuitable   for   further   investigation   by   co-­‐‑purifying   extensive  
quantities  of  nonspecifically-­‐‑bound  contaminants.  
This   time,   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   were   treated   with   an   agent   GRE010,   which   is   a  
suspected   inhibitor   of   Ubl   proteases,   including   SENPs.   As   predicted,   the   amount   of  
SUMO2-­‐‑bound   substrates   in   the   high-­‐‑molecular-­‐‑weight   area   of   the   protein   gels  was  
increased   in   response   to   the   treatment  with   20  µμM  GRE010   for   8  hours,  whereas   the  
cells   mock-­‐‑treated   with   0.2  %   dimethyl   sulfoxide   (DMSO)   were   not   affected   (Figure  
3.10;   lanes   1   and   2).   Similarly   to   the   nickel   affinity   chromatography  with   the   lysate  
protein  of  heat-­‐‑stressed  cells,  a  considerable  amount  of  residual  SUMO  substrates  were  
detected   from   the   flow-­‐‑through   fraction   of   the   first   nickel   affinity   chromatography  
procedure   (Figure   3.10;   flow-­‐‑through   α).   However,   submission   of   this   fraction   of  
unbound  proteins  into  second  purification  cycle  did  not  lead  to  a  considerable  amount  
of  additionally  enriched  substrates  of  6His-­‐‑SUMO2T90K  (Figure  3.10;  elution  β,  1−3).  





Figure  3.10  |  Sumoylated  or  polyhistidine-­‐‑containing  proteins   in   the   flow-­‐‑through  fraction  
are  not  efficiently  retained  during  the  second  cycle  of  nickel  affinity  chromatography.    
HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  were  either  incubated  with  20  µμM  GRE010  for  8  hours  (GRE010;  +)  or  
mock-­‐‑treated   with   0.2  %   DMSO   (GRE010;   −).   Both   cell   cultures   were   harvested   and   equal  
amount   of   each   cell   pellet   (wt/wt)   was   mixed   (GRE010;   M).   6His-­‐‑SUMO2T90K-­‐‑conjugated  
proteins   were   extracted   from   the   combined   sample   utilising   two   Ni2+-­‐‑NTA   chromatography  
procedures  in  tandem  (α  and  β).  Equivalent  proportion  (~0.02  %;  vol/vol)  of  each  fraction  was  
subjected  to  western  blot  analysis  for  the  detection  of:  (A)  SUMO2/3  or  (B)  6His.  Approximately  
0.02  %  of  each  cell  lysate  (GRE010)  corresponds  to  15  µμg  of  protein.    
  
Overall,   comparisons   between   the   cell   lysate   and   nickel   affinity   chromatography  
elution   fraction   revealed   that   the   enrichment   of   6His-­‐‑SUMO2T90K   conjugates   using   a  
single  procedure  resulted  in  ~20-­‐‑fold  and  ~130-­‐‑fold  reduction  in  sample  volume  or  the  




 Depletion   of   endoproteinases   Lys-­‐‑C   and   Glu-­‐‑C   from   the  3.2.7.
solution  of  peptides  
As  the  6His-­‐‑SUMO2T90K-­‐‑modified  proteins  are  cleaved  prior  to  the  second  enrichment  
of  sumoylated  peptides,  it  is  crucial  to  separate  the  samples  from  the  proteases  to  avoid  
digesting   the   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody.   Filter-­‐‑aided   sample   preparation   (FASP)  
protocols   employing   ultrafiltration   devices  with   specified   nominal  molecular  weight  
cutoff   limits   have   been   widely   used   to   separate   proteins   and   peptides   from   low-­‐‑
molecular-­‐‑weight   compounds  or  high-­‐‑molecular-­‐‑weight   substances   that   can   interfere  
with  MS  analyses  (Manza  et  al.,  2005;  Wisniewski  et  al.,  2009b).  The  molecular  weights  
of  endoproteinases  Lys-­‐‑C  and  Glu-­‐‑C  are  ~28  kDa  or  ~30  kDa,  respectively  (The  UniProt  
Consortium,   2015).   It   was   thus   anticipated   that   both   of   these   proteases   might   be  
retained   on   an  ultrafiltration  device  with   a   nominal  molecular  weight   cutoff   limit   of  
30  kDa   or   smaller.   However,   previous   comparative   studies   have   shown   that  
ultrafiltration   devices   with   larger   nominal   cutoff   limits   (30  kDa   or   50  kDa)   produce  
peptides   with   higher   yield   (Wisniewski   et   al.,   2011).   For   these   reasons,   a   30  kDa  
ultrafiltration   device   was   selected   and   comprehensively   investigated   for   the  
compatibility  with  the  SUMOKGG  workflow.    
The   retention   of   Lys-­‐‑C   and   Glu-­‐‑C  was   examined   by   placing   15  µμg   of   bovine   serum  
albumin   (BSA)   tryptic   peptides   either   alone   or   combined  with   5  µμg   of   Lys-­‐‑C   (Figure  
3.11A)   or   5  µμg   of  Glu-­‐‑C   (Figure   3.11B)   onto   a   30  kDa   ultrafiltration   device   in   a   final  
volume  of  50  µμl  of  IAP  buffer.  Each  of  these  mixtures  was  then  processed  and  passed  
through   the   filter  using   identical  experimental   conditions   to   the  SUMOKGG  workflow,  






Figure  3.11  |  Endoproteinases  Lys-­‐‑C  and  Glu-­‐‑C  are  sufficiently  separated  from  a  mixture  of  
BSA  peptides  using  30  kDa  filter  units.    
A   solution   of   BSA   tryptic   peptides   either   alone,   or   mixed  with   Lys-­‐‑C   (A)   or   Glu-­‐‑C   (B)   was  
passed  through  30  kDa  cutoff  filter  unit.  Proteins  and  peptides  retained  on  the  filter  (lanes  4  and  
6),   collected   from   the   flow-­‐‑through   fraction   (lanes   3   and   5),   or   without   fractionation   (Input;  
lanes  1  and  2)  were  analysed  using  Coomassie  brilliant  blue-­‐‑stained  SDS-­‐‑PAGE  protein  gels.  
  
retrieved  by  the  addition  of  IAP  buffer  and  reverse  centrifugation  of  the  ultrafiltration  
device.  As  a  control,  a   second  collection  of  mixtures  was  produced  by  dissolving   the  
individual   components   directly   into   IAP   buffer,  which  were   then   examined  without  
passing  through  the  30  kDa  ultrafiltration  device.  Finally,  all  generated  samples  were  
concentrated,   dissolved   in   1  ×  Laemmli   sample   buffer   (125  mM  Tris-­‐‑HCl   pH  6.7,   2  %  
SDS,  15  %  glycerol,  300  mM  DTT)  and  analysed  by  SDS-­‐‑PAGE  (Figure  3.11).    
Images  of  Coomassie  brilliant  blue-­‐‑stained  SDS-­‐‑PAGE  protein  gels  indicated  that  both  
proteases,   Lys-­‐‑C   and  Glu-­‐‑C,  were   retained   on   the   30  kDa   filter   device,  while   tryptic  




3.11).  Upon   the   supplementation  of  Glu-­‐‑C,  BSA  peptides  present   in   the   sample  were  
truncated  and  thus  remained  unresolved  on  the  SDS-­‐‑PAGE  protein  gel  (Figure  3.11B;  
lanes   3   and   5).   Interestingly,   Coomassie   brilliant   blue-­‐‑stainable   material   with  
significantly  smaller  molecular  weight  than  the  30  kDa  cutoff  limit  was  detected  from  
“input”  and  “retained”   fractions,  which  also  contained  either  Lys-­‐‑C  or  Glu-­‐‑C  (Figure  
3.11;   lane   6).   As   BSA  was   successfully   separated   from   the   Lys-­‐‑C   containing   sample  
(Figure   3.11A;   lane   5),   it   is   likely   that   the   fragments   emerged   from   the   autolytic  
digestion   of   the   protease   during   the   relatively   slow   solvent   evaporation   procedure  
immediately  before  SDS-­‐‑PAGE  analysis.  However,  alternative  hypotheses,  such  as  the  
possibility  that  these  low-­‐‑molecular-­‐‑weight  substances  were  selectively  retained  on  the  
30  kDa  ultrafiltration  device,  cannot  be  rejected.  Nevertheless,  a  30  kDa  ultrafiltration  
device   can  be  utilised   for   the   removal   full-­‐‑length  proportion  of  proteolytically   active  
Lys-­‐‑C  and  Glu-­‐‑C  from  the  peptide  mixtures.    
 Characterisation   of   Lys-­‐‑C   and   Glu-­‐‑C   substrate   specificity  3.2.8.
and  proteolytic  efficiency  in  IAP  buffer  
As  illustrated  in  Chapter  3.2.7,  utilisation  of  30  kDa  ultrafiltration  device  is  required  for  
the  depletion   of   Lys-­‐‑C   and  Glu-­‐‑C   from  peptide  mixtures   to  prevent   the  digestion   of  
subsequently  supplemented  K-­‐‑ε-­‐‑GG-­‐‑specific  antibody.  In  principle,   this  ultrafiltration  
device   acts   as   a   storage   chamber   for   the   proteins,   while   the   wash   solutions   can   be  
passed   through   the   filter.   Likewise,   this   container   could   be   utilised   to   exchange   the  
protein   solution   to   IAP   buffer.   Proteolysis   in   IAP   buffer   would   integrate   sample  
handling  and   thus   increase   the   recovery  of  peptides,   as   the  arising   solution  could  be  




Previous   studies   have   shown   that   both,   Lys-­‐‑C   and   Glu-­‐‑C   are   highly   specific  
endoproteinases   that  hydrolyse  peptide  bonds  from  the  C-­‐‑terminal  side  of   lysines,  or  
glutamic  and  aspartic  acids,  respectively  (Drapeau  et  al.,  1972;  Raijmakers  et  al.,  2010).  
Nevertheless,  the  performance  of  these  proteases  can  be  affected  by  the  components  of  
the  IAP  buffer.  Notably,  the  apparent  preferential  selectivity  of  Glu-­‐‑C  towards  Glu  or  
Asp   residues   appears   to   depend   on   the   concentration   of   ammonium   bicarbonate   or  
ammonium   acetate   that   have   inhibitory   effects   on   the   activity   of   the   protease  
(Houmard   and   Drapeau,   1972;   Sorensen   et   al.,   1991).   To   characterise   the   enzymatic  
activities  and  substrate  specificities  of  both  proteases   in   IAP  buffer,  HEK293  N3S  cell  
lysate   proteins   were   processed   using   the   developed   workflow.   Digestion   was  
performed  on  a  30  kDa  filter  device  using  Lys-­‐‑C,  either  alone  or  in  tandem  with  Glu-­‐‑C  
in   two   alternative   buffer   conditions:   IAP   buffer,   or   widely-­‐‑utilised   and   well-­‐‑
characterised   ammonium   bicarbonate   (NH4HCO3).   Peptides   from   all   four   conditions  
were  then  individually  analysed  by  LC-­‐‑MSMS.    
The   specificity   of   proteases   in   the   described   experimental   set-­‐‑up  was  determined   by  
evaluating   the   occurrences   of   individual   amino   acids   at   the   C-­‐‑termini   of   identified  
peptide  sequences  (Figure  3.12A).  To  avoid  bias  in  the  identified  sequences,  all  MSMS  
peak  lists  were  searched  using  unspecific  enzyme  settings  with  the  Andromeda  search  
engine   integrated   into  MaxQuant   software  package   (Cox  and  Mann,  2008;  Cox  et  al.,  
2011).  Approximately  91.5  %  of  the  peptides  identified  from  the  sample  digested  with  
Lys-­‐‑C   alone   in   NH4HCO3   contained   a   lysine   at   the   C-­‐‑terminus   (Figure   3.12A;   light  
blue).   Interestingly,   this   proportion   increased   to   94  %   when   the   digestion   was  






Figure  3.12  |  Digestion  of  proteins  in  immunoaffinity  purification  buffer  does  not  alter  the  
efficiency  or  specificity  of  endoproteinases  Lys-­‐‑C  and  Glu-­‐‑C.    
HEK293  cell  lysate  proteins  were  prepared  according  to  the  FASP  protocol  using  30  kDa  cutoff  
filter   units   and   protein   buffer   solution   was   exchanged   either   to   immunoaffinity   purification  
(IAP)   buffer   or   to   25  mM   ammonium   bicarbonate   (NH4HCO3).   Proteins  were   digested   either  
with  Lys-­‐‑C  only,  or  using  Lys-­‐‑C  and  Glu-­‐‑C  in  tandem.  Corresponding  peptides  were  analysed  
by   LC-­‐‑MSMS   and   raw   MS   files   were   searched   with   MaxQuant   software   package   using  
nonspecific   enzyme   settings.   (A)   Stacked   bar   graph   showing   the   proportion   of   identified  
peptide   sequences   in   each  of   the   samples   terminating  with   lysine   (K;   light  blue),   arginine   (R;  
dark  blue),  glutamic  acid  (E;  red),  aspartic  acid  (D;  pink),  or  any  other  residue  (Residual;  grey).  
(B)  Stacked  bar  graph  demonstrating  the  proportion  of  identified  peptide  sequences  in  each  of  
the  protein  digests   containing  either  0   (dark  grey),   1   (red),   2   (orange),   3   (yellow),   4   (green),   5  
(blue)  or  more  than  five  (light  grey)  sites  of  missed  enzyme  cleavages.  
  
identified  from  IAP  buffered  sample  terminated  with  an  arginine  (Figure  3.12A;  dark  
blue)   and   the   proportion   of   sequences   finishing  with   any   other   amino   acid  was   less  
than   5  %.   These   results   confirmed   that   Lys-­‐‑C   digestion   could   be   performed   in   IAP  
buffer,  as  the  enzyme  remained  highly  specific  towards  the  peptide  bonds  C-­‐‑terminal  




Similarly,  the  combined  specificity  of  Lys-­‐‑C  and  Glu-­‐‑C  enzymes  was  slightly  improved  
in  IAP  buffer  with  ~95.1  %  of  the  identified  peptide  sequences  terminating  with  lysine  
or   glutamic   acid   (Figure   3.12A;   light   blue   and   red).   This   was   3  %   greater   than   the  
proportion   of   Lys   and   Glu   at   the   C-­‐‑termini   of   peptides   cleaved   in   ammonium  
bicarbonate.   Interestingly,   irrespective   of   the   components   of   the   digestion   buffer,   an  
average   of   ~2.6  %   (±  0.5  %)   of   the   sequences   contained   an   Asp   at   their   C-­‐‑terminus  
(Figure  3.12A;  pink).  Thus,  the  C-­‐‑termini  of  most  double-­‐‑cleaved  peptides  appeared  to  
be  occupied  either  by  Lys  or  Glu,  or  to  a  smaller  extent  by  Asp  (Figure  3.12A).  
Next,   the   activity   of   each   enzyme   in   IAP   buffer   was   evaluated   by   counting   the  
occurrences   of   missed   cleavages   in   the   sequences   of   identified   peptides,   while  
considering   the   established   enzyme   specificities   (Figure   3.12B).   Irrespective   of   the  
buffer   environment,   more   than   94.8  %   of   the   sequences   cleaved   with   Lys-­‐‑C   alone  
contained  no   internal   lysine   residues.  An   average   of   4  %  of   the  peptides   carried   one  
missed  cleavage  site  and  this  proportion  was  only  0.9  %  higher  in  samples  digested  in  
IAP  buffer   (Figure   3.12B).  However,   ~74.8  %   (±  1.3  %)  of  peptides   emerging   from   the  
samples   digested   with   Lys-­‐‑C   and   Glu-­‐‑C   in   tandem   contained   one   or   more   missed  
cleavage  sites,  whereas  only  a  quarter  (~25.2  %  ±  1.3  %)  of  the  identified  peptides  were  
digested  completely.  Furthermore,  the  proportion  of  sequences  with  up  to  four  missed  
cleavages  was  ~95.8  %  (±  0.2  %).  However,  similarly  to  the  Lys-­‐‑C  digested  sample,  the  
effect  of  the  buffer  solution  on  the  activities  of  both  enzymes  when  utilised  in  tandem,  
was  negligible  (Figure  3.12B).    
In   general,   peptide   sequences   are   identified   by   comparing   their   masses   and   MSMS  




spectra   (Sadygov   et   al.,   2004;   Steen   and  Mann,   2004).   Therefore,   the   identification   of  
any  peptide  sequence  relies  on  the  presence  of  a  corresponding  theoretical  spectrum  in  
the   computer-­‐‑modelled   database.   This   database   should   thus   be   constructed   while  
taking   into   account   the   activities   and   specificities   of   utilised  proteases,   to   ensure   the  
maximal   resemblance   between   the   collections   of   theoretical   and   in   vivo-­‐‑produced  
peptides.   Characterisation   of   both   enzymes,   Lys-­‐‑C   and   Glu-­‐‑C,   demonstrated   their  
incomplete   activity   (Figure   3.12B).   In   these   situations,   allowing   up   to   two   missed  
cleavages   for   the   creation   of   in   silico   database   is   widely   accepted   (Giansanti   et   al.,  
2016).  However,   increasing   the  number  of  missed  cleavages  even   further   is  generally  
not   recommended,  as   it  will  generate  a  greater  number  of   theoretical  peptide  masses  
and   thus   increase   the  probability  of  observing  a  peptide-­‐‑to-­‐‑spectrum  match   (PSM)  at  
random   (Eidhammer   et   al.,   2007).   To   this   end,   up   to   two   missed   cleavages   were  
allowed   for   the   analysis   of   peptides   digested  with   Lys-­‐‑C   alone.   On   the   other   hand,  
utilisation  of  these  search  settings  would  identify  only  79.6  %  (±  1.5  %)  of  the  peptides  
previously   discovered   from   the   double-­‐‑digested   test   sample   (Figure   3.12B).   Despite  
increasing  the  search  space  and  the  probability  of  random  matching,  it  was  considered  
that  allowing  up  to   four  missed  cleavages  would   increase   the  proportion  of  expected  
identifications   to   at   least   95  %.   Interestingly,   these   observations   are   consistent   with  
another  independent  study  (Giansanti  et  al.,  2016).    
Finally,  the  inability  of  Lys-­‐‑C  to  cleave  C-­‐‑terminal  to  methylated  or  acetylated  lysines  
has   been   observed   (Giansanti   et   al.,   2016).   Sumoylation   is   another   lysine-­‐‑specific  
modification   and   a   covalent   attachment   to   SUMO   is   likely   to   render   the   modified  
lysines   resistant   to   Lys-­‐‑C   cleavage.   However,   to   avoid   increasing   the   search   space  




subsequent  analyses  of  raw  MS  files  were  thus  performed  by  allowing  up  to  three  or  
five  missed  cleavages   for  samples  digested  with  Lys-­‐‑C  alone,  or   in  combination  with  
Glu-­‐‑C,  respectively.    
 Evaluating   the   impact   of   tandem   protein   digestion   on   the  3.2.9.
sequence  coverage  of  the  proteome  
To   measure   whether   a   sufficient   proportion   of   the   proteome   is   covered   by   the  
identified   peptide   sequences,   acquired   MS   files   were   re-­‐‑analysed   with   MaxQuant  
using   enzyme   specificity   settings   as   established   in   Chapter  3.2.8.   Additionally,   a  
sample   of   peptides   produced   by   trypsin   digestion   in   NH4HCO3   was   included   as   a  
control   to   determine   the   proportion   of   the   proteome   identified   when   samples   were  
processed  according  to  a  well-­‐‑established  approach  (Wisniewski  et  al.,  2009b).    
On  average,  ~57  500  MSMS  scans  were  acquired  per  peptide  sample  by  the  Q  Exactive  
mass   spectrometer   (Figure   3.13A),   and   this   value   differed   by   less   than   2500   events  
between  the   individual  LC-­‐‑MSMS  runs.  However,  despite   the  comparable  number  of  
acquired  MSMS  scans,  a  considerable  protease-­‐‑dependent  discrepancy   in   the  amount  
of   peptide-­‐‑to-­‐‑spectrum   matches   (PSMs)   was   observed   (Figure   3.13A;   white).   As  
expected,   the   digestion   with   trypsin   led   to   a   maximum   number   of   PSMs   (~35  000).  
Irrespective   of   the   composition   of   the   digestion   buffer,   the   number   of   matched  
sequences  from  samples  cleaved  with  Lys-­‐‑C  alone  was  only  4000  less  (~31  000).  When  
Lys-­‐‑C   digested   peptides   were   subsequently   treated   with   Glu-­‐‑C   in   NH4HCO3   the  
number  of  PSMs  decreased  by  ~20  %  (to  ~25  000).  However,  this  substantial  decrease  in  
PSMs  was  not  observed  when   the  digestion  was   carried  out   in   IAP  buffer,   as  almost  





Figure   3.13   |   In-­‐‑parallel   digestion   of   proteins   with   Lys-­‐‑C,   and   with   Lys-­‐‑C   and   Glu-­‐‑C  
contributes  to  the  cumulative  increase  in  proteome  sequence  coverage.    
HEK293   cell   lysate   proteins   with   buffer   solutions   exchanged   either   to   immunoaffinity  
purification  (IAP)  buffer  or  to  25  mM  ammonium  bicarbonate  (NH4HCO3)  were  digested  with  
Lys-­‐‑C,   Lys-­‐‑C   and   Glu-­‐‑C,   or   trypsin   according   to   the   FASP   protocol   (Manza   et   al.,   2005;  
Wisniewski   et   al.,   2009b).  Corresponding  peptides  were   analysed  by  LC-­‐‑MSMS  and   searched  
using   MaxQuant.   (A)  Stacked   bar   graph   illustrating   the   number   of   peptide-­‐‑to-­‐‑spectrum  
matches  (PSMs;  white)  and  unidentified  MSMS  scans  (grey)  from  each  of  the  peptide  mixtures.  
(B)  Bar  graph  demonstrating  the  number  of  identified  nonredundant  amino  acids  covering  the  
proteome   sequence   in   each   of   the   proteolytic   digests   (Lys-­‐‑C,   blue;   Lys-­‐‑C   and   Glu-­‐‑C,   red;  




The   sequence   coverage   of   each   proteome   originating   from   five   alternative  
combinations  of  proteolytic  digests  was  determined  by  calculating   the  proportions  of  
nonredundantly   identified   amino   acid   residues   (Figure   3.13B).   In   general,   a   positive  
correlation  between  these  results  and  the  number  of  PSMs  was  detected.  The  greatest  
proportion   of   the   proteome   was   covered   by   peptides   identified   from   the   trypsin-­‐‑
digested  sample,  which  contained  ~340  000  unique  amino  acid  residues  (Figure  3.13B;  
green).   Whilst   this   value   was   marginally   lower   when   proteins   were   digested   in  
NH4HCO3   with   Lys-­‐‑C   alone   (~310  000),   essentially   identical   results   to   trypsin   were  
obtained  by  proteolysis   in   IAP  buffer,   as   illustrated  by   the  ~340  000   identified  amino  
acid   residues   (Figure   3.13B;   yellow).   On   the   other   hand,   hydrolysis   with   Lys-­‐‑C   and  
Glu-­‐‑C   in   tandem  decreased   the   coverage   by   at   least   ~12  %   irrespective   of   the   buffer  
environment   (Figure   3.13B;   blue).  Analysis   of   individual   amino   acid   sequences   from  
each   proteolytic   digest   revealed   that   some   peptides   generated   by   alternative  
combinations   of   proteases   originated   from   distinct   segments   of   corresponding  
proteins.   Several   research   groups   have   reported   similar   observations   and   suggested  
utilising   alternative   proteases   in   parallel   to   improve   the   sequence   coverage   of   the  
proteome   (Swaney   et   al.,   2010;   Tsiatsiani   and  Heck,   2015).   Therefore,   the   previously  
acquired   raw   MS   files   were   re-­‐‑analysed   to   determine   the   cumulative   sequence  
coverage   of   the   proteomes,   when   individual   samples   are   combined   into   three  
experimental  groups  (Figure  3.13B;  dark  grey):    
1) Samples  digested  with  Lys-­‐‑C,  or  Lys-­‐‑C  and  Glu-­‐‑C  in  NH4HCO3    
2) Peptides  generated  by  cleavage  with  Lys-­‐‑C,  or  Lys-­‐‑C  and  Glu-­‐‑C  in  IAP  buffer    




As  anticipated,  irrespective  of  the  combination  of  enzymes  selected  for  the  experiment,  
joint   analysis   of   two   data   sets   resulted   in   an   approximately   1.5-­‐‑fold   increase   in  
additionally  identified  amino  acid  residues  (Figure  3.13B;  dark  grey).  Interestingly,  the  
proteome   sequence   coverage   acquired   by   the   aggregation   of   MS   files   of   peptides  
digested  with  Lys-­‐‑C  alone,  or  with  Lys-­‐‑C  and  Glu-­‐‑C  in  IAP  was  increased  compared  to  
the   samples   cleaved   in   ammonium   bicarbonate   and   thus   supported   the   decision   to  
carry  out  proteolytic  digestions  in  IAP  buffer.    
The   improved   sequence   coverage   achieved   by   cleaving   the   samples   with   multiple  
endoproteinases  in  parallel  demonstrates  the  importance  of  introducing  Glu-­‐‑C  into  the  
workflow.  As  the  yield  of  6His-­‐‑SUMO2T90K  conjugates  is  limited,  it  was  not  desirable  to  
split   the   sample   into   two.   Thus,   peptides   retained   on   the   30  kDa   ultrafiltration  
membrane  after  Lys-­‐‑C  cleavage  alone  were   subjected   to  an  additional  digestion  with  
Glu-­‐‑C   to   facilitate   their   efficient   elution   and   thus   improve   the   sequence   coverage  
without  the  requirement  to  subdivide  the  material.    
 Removal   of   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody   fragments   from   the  3.2.10.
mixture  of  purified  peptides  
As  explained  in  Chapter  3.1.1,  the  enrichment  of  SUMO  remnant-­‐‑containing  branched  
peptides  is  fundamental  to  enable  the  identification  of  modified  proteins  and  facilitate  
the  global  mapping  of  sumoylated  lysines.  A  selective  isolation  of  target  peptides  can  
be  achieved  by   immunoaffinity  chromatography  with  a  monoclonal  antibody  specific  
for   diglycine-­‐‑modified   lysines.   To   date,   two   K-­‐‑ε-­‐‑GG-­‐‑specific   antibodies   are  
commercially   available,   with   each   being   stored   in   a   different   condition:   lyophilised  




al.,   2010;   Kim   et   al.,   2011).   The   latter   product   was   considered   more   suitable   for  
incorporation   into   the   SUMOKGG   workflow,   as   the   agarose   matrix   can   facilitate  
straightforward  removal  of  the  antibody  from  the  solution  of  low  abundance  peptides.  
However,  upon  low-­‐‑pH  elution  of  diGly-­‐‑Lys-­‐‑containing  peptides,  a  large  proportion  of  
the   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody   fragments   were   also   released   from   the   resin.  
Surprisingly,  these  were  not  efficiently  removed  from  the  sample  by  conventional  C18-­‐‑
based  reversed-­‐‑phase  chromatography,  which  is  widely  implemented  for  the  desalting  
of  peptides  prior  to  the  LC-­‐‑MSMS  analysis,  and  would  normally  be  expected  to  retain  
large  polypeptides.  Consequently,   the  excessive  antibody  contaminants   in  the  sample  
compromised   the   detection   of   low   abundance   SUMO   remnant-­‐‑containing   peptides.  
Similar  findings  were  reported  by  Udeshi  et  al.  (Udeshi  et  al.,  2013b).    
To   reduce   the   impact   of   antibody-­‐‑derived   contamination   on   the   MS-­‐‑based  
identification   of   sumoylated   lysines,   the   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody   was   chemically  
cross-­‐‑linked   to   the   protein  A   agarose   matrix   using   a   freshly   prepared   solution   of    
bis(sulfosuccinimidyl)suberate   (BS3).   The   importance   of   this   cross-­‐‑linking   procedure  
was   examined   by   comparing   the   release   of   antibody   when   bound   to   the   resin  
non-­‐‑covalently   (conjugated)   or  when   cross-­‐‑linked   to   the   agarose   beads   (Figure   3.14).  
Both,   untreated   and   cross-­‐‑linked   resins   were   subjected   to   the   mock   immunoaffinity  
chromatography   procedure   without   the   addition   of   target   peptides.   TFA   (0.15  %,  
vol/vol)   was   added   to   mimic   the   process   of   peptide   elution   and   residual   unbound  
antibody   was   extracted   by   heating   the   resin   in   1  ×  Laemmli   buffer.   The   amount   of  
antibody   fragments   in   each   condition   was   analysed   by   SDS-­‐‑PAGE   followed   by  






Figure  3.14  |  Chemical  cross-­‐‑linking  of  K-­‐‑ε-­‐‑GG-­‐‑specific  antibody  to  protein  A  agarose  beads  
reduces  the  release  of  antibody  fragments  upon  low-­‐‑pH  elution.    
The  release  of  anti-­‐‑K-­‐‑ε-­‐‑GG  antibody  from  protein  A  agarose  beads  when  either  non-­‐‑covalently  
bound   (Conjugated;   left)   or   cross-­‐‑linked   (right)   was   evaluated   after   incubating   the   resin   in  
0.15  %  TFA.   Residual   unbound   antibody  was   then   extracted   by   heating   the   resin   at   95  °C   in  
1  ×  Laemmli   sample   buffer   (LB).   The   amount   of   antibody   released   with   each   procedure  
(0.15  %  TFA;   95  °C   1  ×  LB)   in   each   sample   (Conjugated;   cross-­‐‑linked)   was   determined   with  
Coomassie  brilliant  blue-­‐‑stained  SDS-­‐‑PAGE  protein  gel.  
  
the  binding,  a  substantial  proportion  of  antibody  light  and  heavy  chain  fragments  were  
extracted  from  the  commercially  supplied  protein  A  resin  (Figure  3.14;  conjugated).  In  
contrast,   the   amount   of   BS3-­‐‑cross-­‐‑linked   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody   eluting   with  
0.15  %  TFA  was   below   the   sensitivity   threshold   of   the  Coomassie   brilliant   blue   stain  
and   merely   a   marginal   proportion   was   released   upon   heating   the   resin   in   strong  
detergent-­‐‑based   1  ×  Laemmli   buffer   (Figure   3.14;   cross-­‐‑linked).   Thus,   BS3   can   be  
utilised   to   stabilise   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody   binding   and   prevent   the   excessive  
contamination   of   SUMO   remnant-­‐‑modified   peptide   samples.   These   findings   are  
consistent  with   a   study,  where  dimethyl  pimelimidate   (DMP)  was  used   to   cross-­‐‑link  




current   investigation,   BS3   gave   superior   retention   of   the   antibody   on   beads   when  
compared  to  DMP.    
 Improving   LC-­‐‑MSMS   settings   for   the   optimal   acquisition  3.2.11.
of  low  abundance  peptides  
After  optimisation  of  the  SUMOKGG  workflow  (Figure  3.8),  the  settings  of  the  LC-­‐‑MSMS  
system  were  investigated.  Two  small-­‐‑scale  purification  experiments  were  performed  in  
parallel   according   to   the   established   workflow.   Specifically,   the   generated  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   were   heat-­‐‑stressed   at   43  °C   for   30  minutes   to   enhance  
sumoylation   and   two   portions   of   approximately   45  mg   of   cell   lysate   protein   were  
subjected  to  nickel  affinity  chromatography.  A  small  proportion  (1  %)  of  each  isolated  
fraction   of   6His-­‐‑SUMO2T90K   conjugates   in   solution   was   then   cleaved   directly   with  
Lys-­‐‑C,   whereas   majority   of   the   substrates   (99  %)   were   subsequently   processed  
according   to   the   SUMOKGG   workflow   (Figure   3.8).   Half   of   each   sample   was   then  
analysed   by   LC-­‐‑MSMS   and   peptide   sequences   were   identified   with   the   MaxQuant  
software  package  (Cox  and  Mann,  2008).  
On   average,   ~4400   peptides   corresponding   to   1074   proteins   were   detected   per  
experiment  directly   after  nickel   affinity   chromatography   (Figure   3.15).  However,   less  
than   0.07  %   of   them   contained   a   SUMO   remnant-­‐‑modified   lysine.   Notably,   the  
proportion   of   identified   sumoylated   peptides   increased   by   more   than   400-­‐‑fold   to  
nearly  30  %  after  the  subsequent  K-­‐‑ε-­‐‑GG-­‐‑specific  enrichment  (Figure  3.15).    





Figure   3.15   |  Proteome-­‐‑wide   identification  of   sumoylation   sites   is   enabled  by   the   efficient  
enrichment  and  improved  acquisition  of  modified  peptides  by  MS.    
Number   of   Gly-­‐‑Gly-­‐‑modified   (grey)   or   all   nonredudant   peptide   sequences   (white)   identified  
after   nickel   affinity   chromatography   using   standard   MS   settings   (left),   or   after   subsequent  
diglycine-­‐‑lysine   (K-­‐‑ε-­‐‑GG)-­‐‑specific   immunoaffinity   enrichment   using   standard  MS   parameters  
(middle),  or  MS  settings  refined  for  the  optimal  acquisition  of  low  abundance  peptides  (right).  
The  number  of  SUMO  modification  sites  is  reported  in  brackets.  Data  points  are  a  mean  of  two  
replicate   purifications   from   the   same   biological   sample  with   standard   deviations   depicted   as  
error  bars.  
  
Surprisingly,   further  assessment  of   the  LC-­‐‑MSMS  performance  during  the  analysis  of  
diGly-­‐‑Lys-­‐‑enriched  samples  revealed  that  merely  8.2  %  of  the  acquired  MSMS  spectra  
were   matched   to   a   specific   amino   acid   sequence   (Table   3.1).   The   concept   of   low  
sumoylation  stoichiometry  was  reflected  in  multiple  stages  of  the  workflow.  First,  the  
yield  of  diGly-­‐‑Lys-­‐‑enriched  peptides  after  the  second  purification  stage  was  generally  
less   than   1  µμg,   although   ~45  mg   of   heat-­‐‑stressed   cell   lysate   protein   was   used   as   an  





Table  3.1  |  Summary  statistics  of  raw  files  acquired  with  standard  MS  settings  
     No.  of  MSMS  scans   23910a  
  
Isotope  patterns  sequenced  (%)   33.23a  
  
PSMs  (%)b   8.2a  
     Proportion  of  PSMs  with  IT  <60  ms  (%)c   0.42  
	  
a  Average  value;      b  Proportion  of  MSMS  scans  
	  
	  
c  IT,  ion  injection  time  of  the  MSMS  scan  
	    
revealed  that  the  MS  signal  intensities  of  most  peptide  ions  were  relatively  low,  despite  
the   extensive   enrichment   process.   It  was   thus   speculated   that   the  majority   of  MSMS  
spectra   remained   unidentified   due   to   the   small   amount   of   acquired   precursor   ions,  
which  then  produced  poor  fragment  ion  information.  In  support  of  this  hypothesis,  the  
median  Andromeda   score   of   all   PSMs  was   only   53.6   (Figure   3.16)   (Cox   et   al.,   2011).  
Furthermore,   nearly   all   ions   (>  99.5  %),   whose   MSMS   spectrum   was   matched   to   a  
sequence,   were   accumulated   in   the   C-­‐‑trap   for   the   maximal   allowed   time   of   60  ms  
(Table  3.1).    
  
Figure   3.16   |   Acquisition   of   LC-­‐‑MSMS   data   with   ultra   sensitive   instrument   settings  
improves  the  quality  of  MSMS  spectra.    
Box  plot  illustrating  the  distributions  of  Andromeda  scores  of  PSMs  of  MSMS  spectra  acquired  
with  standard  (top)  or  ultra  sensitive  (bottom)  MS  settings.  




To  address  this  issue,  two  solutions  could  be  envisaged:  either  preparing  and  loading  
more   sample   onto   the   instrument,   or   investigating   the   LC-­‐‑MSMS   settings   for   the  
optimal   acquisition   of   low   abundance   ions.   It   is   often   impractical   to   scale   up  
experiments   of   this   kind,   especially   considering   the   stoichiometry   of   protein  
sumoylation.   Instead,   the   latter   concept   was   examined   and   an   ultra   sensitive   MS  
workflow   was   designed   by   altering   mainly   two   parameters   of   the   data-­‐‑dependent  
MSMS  acquisition:  
1) The   maximum   injection   time   was   increased   from   60  ms   to   1000  ms,   to  
accumulate  more  precursor   ions  prior   to   their   fragmentation  and  detection   in  
Orbitrap.  
2) Instead   of   ten,   up   to   one  precursor   ion  per   full  MS   scan  was   selected   for   the  
data-­‐‑dependent  MSMS  analysis  to  reduce  the  overall  MS  cycle  time.  
To   assess   the   performance   of   this   ultra   sensitive  MS  workflow,   identical   amounts   of  
previously  described  SUMO  remnant-­‐‑containing  peptide  samples  were  re-­‐‑analysed  by  
LC-­‐‑MSMS.  Notably,  the  experiment  was  performed  on  the  same  day  with  as  few  other  
variables  as  possible  between  individual  runs  to  minimise  systematic  errors  that  could  
potentially   arise   from   altered   LC-­‐‑MSMS   instrumentation   set-­‐‑up   or   mass   calibration.  
The   impact   of   a   longer   ion   injection   time   was   clear,   as   more   than   twice   as   many  
diglycine-­‐‑modified   peptides   were   detected   and   efficiently   sequenced   from   the   same  
sample  (Figure  3.15).  Particularly,  acquisition  of  MSMS  spectra  with  settings  optimised  
for  the  detection  of  low  abundance  ions  enabled  the  identification  of  1857  peptides  per  
experiment   and   nearly   57  %   of   these   sequences   contained   a   site   of   Gly-­‐‑Gly  




Furthermore,  utilisation  of  ultra  sensitive  MS  settings  also  facilitated  the  acquisition  of  
better  quality  MSMS  data  and  thus  increased  the  reliability  of  the  identified  sequences.  
For  instance,  a  fragmentation  spectrum  of  a  diGly-­‐‑modified  peptide  of  a  human  DNA  
topoisomerase   2-­‐‑α   was   acquired   with   both,   standard   and   optimised   MS   settings  
(Figure   3.17).   However,   advanced   inspection   of   the   two   spectra   revealed   that   the  
fragment   ion  coverage  of  the  peptide  was  significantly   improved  upon  the  utilisation  
of  ultra  sensitive  MS  parameters  (Figure  3.17;  bottom  panel).  The  higher  quality  of  the  
MSMS   spectra   was   also   apparent   in   the   Andromeda   scores,   as   the   median   score   of  
PSMs  identified  and  detected  with  optimised  MS  settings  increased  from  53.6  to  115.7  
(Figure  3.16).    
The  SUMOKGG  workflow   is   thus  suitable   for   the  high-­‐‑throughput  mapping  of   sites  of  
sumoylation.   In  particular,   two   small-­‐‑scale   experiments  with   ~45  mg  of  heat-­‐‑stressed  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cell   lysate   protein   enabled   the   identification   of   1468   diGly-­‐‑
modified   lysines   from   784   proteins   (Figure   3.18).   Although   the   majority   (83.1  %)   of  
these  sumoylated  lysines  were  mapped  by  utilising  MS  acquisition  settings  optimised  
for   the   detetion   of   low   abundance   ions,   the   remaining   16.9  %   were   identified   by  
standard   LC-­‐‑MSMS   analysis   alone.   Surprisingly,   only   9.3  %   of   the   detected   isotope  
patterns  were  sequenced  by  tandem  MS  during  the  ultra  sensitive  LC-­‐‑MSMS  analysis  
(Table   3.2),   which   demonstrates   the   incomplete   efficiency   of   the   method   to   provide  
deep  sequencing  and  could  thus  explain  the  absence  of  some  sumoylated  peptides.  On  
the   other   hand,   as   the   data   acquired   with   standard   MS   settings   was   generally   less  
reliable,   a   proportion   of   these   uniquely   identified  modification   sites   could   also   arise  





Figure  3.17  |  Acquisition  of  MSMS  spectra  with  ultra  sensitive  instrument  settings  increases  
the   number   of   precursor   ions   injected   into   the   Orbitrap,   and   improves   peptide   sequence  
coverage.    
››  




‹‹  Figure   3.17   |   Acquisition   of   MSMS   spectra   with   ultra   sensitive   instrument   settings  
increases   the   number   of   precursor   ions   injected   into   the   Orbitrap,   and   improves   peptide  
sequence  coverage.    
Representative   annotated   MSMS   spectra   of   a   Gly-­‐‑Gly   remnant-­‐‑containing   peptide   of   DNA  
topoisomerase   2-­‐‑α   acquired   by  MS   with   standard   (top)   or   ultrasensitive   instrument   settings  
(bottom).   Peptide   acquisition  with   refined   ultrasensitive  MS   settings   results   in   an   increase   in  
Andromeda   score   from   36.679   to   191.78   with   a   posterior   error   probability   of   5.05  ×  10-­‐‑29.  
Fragment  ions  extending  from  the  N-­‐‑  or  C-­‐‑terminus  of  the  peptide  are  named  as  b-­‐‑  (dark  blue)  
or  y-­‐‑ions  (red),  respectively.  Peptide  internal  fragments,  ions  with  a  loss  of  neutral  molecule  or  
immonium   ions   are   illustrated   in   purple,   yellow   or   green,   respectively.   Ions   diagnostic   for  




Figure   3.18   |   The  majority   of   the   6His-­‐‑SUMO2T90K   modification   sites   are   identified   using  
ultra  sensitive  MS  settings  optimised  for  the  acquisition  of  low  abundance  peptides.    
A   Venn   diagram   demonstrating   the   overlap   in   the   identified   sumoylated   lysines   between  
samples   acquired   using   either   standard   or   optimised   ultra   sensitive   MS   settings.   The   total  
number  of  sites  mapped  by  either  of  the  LC-­‐‑MSMS  analyses  is  displayed  in  brackets.  




Table  3.2  |  Summary  statistics  of  raw  files  acquired  with  ultra  sensitive  MS  settings  
     No.  of  MSMS  scans   3716a  
  
Isotope  patterns  sequenced  (%)   9.34a  
     PSMs  (%)b   38.52a  
 
a  Average  value;      b  Proportion  of  MSMS  scans  
   
These  observations  demonstrate  the  requirement  to  optimise  LC-­‐‑MSMS  settings  based  
on   the   properties   of   individual   samples.   For   instance,   the   critical   characteristics   of  
SUMO-­‐‑containing   samples,   such   as   the   abundance,   dynamic   range   or   diversity   of  
substrates,   is   often   inconsistent   between   samples   that   examine   distinct   biological  
phenomenons.   Consequently,   when   the   objective   is   to   analyse   SUMO   remnant-­‐‑
modified   branched   peptides,   it   is   recommended   to   follow   these   guidelines   of  
LC-­‐‑MSMS  analysis:  
a) A   preliminary   survey   analysis   should   be   performed  with   a   small   proportion  
(~10  %)   of   diGly-­‐‑Lys-­‐‑enriched   peptide   sample   using   standard   LC-­‐‑MSMS  
settings.    
b) The   complexity   of   the   sample   should   be   characterised   based   on   the   total   ion  
current  (TIC)  and  base  peak  LC  chromatograms.  If  required,  the  length  and  the  
configuration  of   the   linear  gradient   should  be  optimised   to  achieve  an  evenly  
dispersed   elution   of   peptides   from   the   reversed-­‐‑phase   column   with   an  
acceptable  chromatographic  peak  shape.  
c) The  performance  of   the   initial  LC-­‐‑MSMS  run  should  be  assessed  based  on  the  
summary  statistics  of  the  processed  raw  MS  files.  
d) The   settings   of   the   subsequent   data-­‐‑dependent   MSMS   analyses   should   be  




Longer  ion  injection  time  improves  the  likelihood  of  peptide  identification,  but  
also   increases  overall  MS  cycle   time.   If   the   cycle   time  exceeds  peptide  elution  
time,   the   precursor   ion   selected   for   MSMS   might   no   longer   be   present.  
Decreasing  the  loop  count  will  decrease  the  MS  cycle  time,  but  should  also  be  
adjusted   according   to   the   number   of   co-­‐‑eluting   peptides   to   ensure   that   the  
precursor  ions  of  most  peptides  are  selected  for  fragmentation.  
e) Given   that   long   ion   injection   times   are   often   required,   one   could   consider  
increasing   the   transient   length   and   improve   the   resolving   power   of   the  mass  
detection,  provided  that  by  doing  so  the  overall  MS  cycle  time  is  not  increased  
excessively.  
These  guidelines  were  regularly  adopted  when  employing  the  SUMOKGG  workflow  to  
obtain   high-­‐‑quality   LC-­‐‑MSMS   data   for   the   global   analysis   of   SUMO2   modification  
sites.    
 Uncovering   the   false   discovery   rate   of   the   SUMOKGG  3.2.12.
workflow  
SUMOKGG   workflow   relies   on   the   assumption   that   endoproteinase   Lys-­‐‑C   has   an  
absolute   specificity   towards   lysines   (Raijmakers   et   al.,   2010).   Such   a   high   substrate  
specificity   is  of  utmost   importance,  as   the  proteolysis  of  peptide  bonds  N-­‐‑terminal   to  
the  Gly-­‐‑Gly  motif  at   the  C-­‐‑termini  of  other  human  Ubls   (Figure  3.1)  can  promote   the  
formation   of   diglycine   remnants   with   diverse   origin,   which   can   then   be   incorrectly  
assigned   as   the   sites   of   6His-­‐‑SUMO2T90K.   As   illustrated   in   Chapter  3.2.8,   Lys-­‐‑C   is  
remarkably  specific   in   IAP  buffer   (Figure  3.12A).  However,  despite   the  apparent   low  




(Figure  3.12A;  dark  blue),  their  occurence  is  higher  than  expected  based  on  the  natural  
distribution   of   amino   acids   in   a   human  proteome.   Three  members   of   the  Ubl   family  
(Ubiquitin,   ISG15  and  NEDD8)  contain  an  arginine  residue  at   the  equivalent  position  
to   the   T90K   in   6His-­‐‑SUMO2T90K   (Figure   3.1).   Therefore,   the   proportion   of   identified  
Gly-­‐‑Gly-­‐‑lysines  that  are  the  bona  fide  targets  of  6His-­‐‑SUMO2T90K  modification  should  
be  determined.    
To   establish   the   true   false   discovery   rate   (FDR)   of   the   SUMOKGG   workflow,   the  
substrate   specificity   of   Lys-­‐‑C   was   evaluated   by   identifying   the   incorrectly   assigned  
sites   of   Gly-­‐‑Gly   modification   produced   by   unspecific   Lys-­‐‑C   digestion   (Figure   3.19).  
Thus,   two   cultures   of   HEK293   cells   stably   expressing   either   6His-­‐‑SUMO2T90K   or  
6His-­‐‑SUMO2  were   incubated   in  a  growth  medium  supplemented  with  either  natural  
L-­‐‑lysine  (12C6,  14N2;  K0)  and  L-­‐‑arginine  (12C6,  14N4;  R0),  or  with  the  heavy  stable  isotope-­‐‑
containing   L-­‐‑lysine   (13C6,  15N2;   K8)   and   L-­‐‑arginine   (13C6,  15N4;   R10),   respectively.   Both  
metabolically-­‐‑labelled  cultures  were  then  incubated  for  30  minutes  at  43  °C  to  promote  
stress-­‐‑induced   protein   sumoylation.   After   harvesting,   equivalent   quantities   of   both  
cultures  were  mixed  based  on  the  weight  of  the  cell  pellets.  The  combined  sample  was  
then   processed   according   to   the   SUMOKGG   workflow   and   Gly-­‐‑Gly-­‐‑modified   lysines  
were  identified  by  LC-­‐‑MSMS  (Figure  3.19).    





Figure  3.19  |  Experimental  strategy  to  understand  the  FDR  of  the  SUMOKGG  workflow.    
HEK2936His-­‐‑SUMO2-­‐‑T90K   and  HEK2936His-­‐‑SUMO2   cells  were   cultured   in   growth  media   supplemented  
with   natural   (K0R0)   or   heavy   stable   isotope-­‐‑labelled   (K8R10)   L-­‐‑lysine   and   L-­‐‑arginine,  
respectively,   and   equivalent   amounts   of   heat-­‐‑treated   cells   were   mixed.   After   lysis,   ~5  %   of  
protein  was   subjected   to   in   solution  digestion  with  Lys-­‐‑C,  while  most   of   the  protein  mixture  
was   processed   using   SUMOKGG  workflow.   Peptides   corresponding   to   total   cell   lysate   or   after  
diGly-­‐‑Lys-­‐‑specific   enrichment  were  analysed  by  LC-­‐‑MSMS.  The   false  discovery   rate   (FDR)  of  
the  method  was  determined  by  measuring  the  relative  abundances  of  diGly  remnant-­‐‑containing  
peptides  in  human  cells  expressing  either  6His-­‐‑SUMO2  or  6His-­‐‑SUMO2T90K.  




If  Lys-­‐‑C  catalyses  the  hydrolysis  of  peptide  bonds  C-­‐‑terminal  to  lysine  residues  alone  
(Raijmakers   et   al.,   2010),   one   should   not   detect   any   Gly-­‐‑Gly   remnant-­‐‑containing  
peptides   from   K8R10-­‐‑labelled   sample   expressing   6His-­‐‑tagged   wild-­‐‑type   SUMO2.  
However,  the  occurence  of  SILAC  ratios  can  define  the  Gly-­‐‑Gly  modification  sites  that  
arise  from  incorrect  cleavage  and  thus  originate  from  other  human  Ubls  (Figure  3.19).  
In  total,  689  diglycine-­‐‑modified  lysines  were  identified  (Figure  3.20).  Remarkably,  only  
two   modification   sites   were   detected   from   K8R10-­‐‑labelled   6His-­‐‑SUMO2-­‐‑expressing  
cells   with   less   than   21-­‐‑fold   difference   compared   to   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (Figure  
3.20;  Table  3.3).  Interestingly,  both  of  these  falsely  assigned  sites  occured  on  Ubiquitin.  
However,   the   6His-­‐‑SUMO2-­‐‑to-­‐‑6His-­‐‑SUMO2T90K   ratio   of   K11-­‐‑containing   peptide   of  
Ubiquitin   was   noticeably   small   and   thus   suggested   that   this   lysine   can   act   as   a  
substrate  to  multiple  Ubls  (Table  3.3).    
  
  
Figure  3.20  |  Less  than  1  %  of  the  Gly-­‐‑Gly-­‐‑modified  peptides  identified  using  the  SUMOKGG  
workflow  arise  from  proteins  conjugated  to  a  different  Ubl.    
A  pie  chart  demonstrating  the  proportion  of  diGly  remnant-­‐‑containing  peptides  identified  from  
6His-­‐‑SUMO2T90K-­‐‑expressing   cells   only   (SUMO2T90K  modification   sites;   light   grey)   or   also   from  
those   expressing   6His-­‐‑SUMO2   (False   positive   identifications;   dark   grey).   The   false   discovery  
rate  (FDR)  of  the  SUMOKGG  workflow  is  ~0.29  %.  




Table  3.3  |  False  positive  identifications  











K48   0.93814   1.1  
2   K11   0.04758   21.0  
  
In  conclusion,  as   indicated  by  the  very   low  FDR  of   the  SUMOKGG  workflow  (<  1.0  %),  
this  highly  reliable  biochemical  approach  can  be  utilised  for  the  global  identification  of  
Gly-­‐‑Gly  modification  sites  that  originate  solely  from  6His-­‐‑SUMO2T90K  (Figure  3.20).    
 Benchmarking  the  SUMOKGG  workflow  3.2.13.
First   trial   experiments   with   the   HEK293   cells   stably   expressing   6His-­‐‑SUMO2T90K  
according   to   the   SUMOKGG   workflow   enabled   the   identification   of   a   few   hundred  
SUMO2  modification   sites.   The   extensive   optimisation   process   described   throughout  
this  chapter  improved  the  method  significantly  and  ~1000  sumoylated  lysines  are  now  
routely  identified  from  ~1.75  ×  108  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  corresponding  to  ~22.5  mg  
of  cell  lysate  protein  (Figure  3.15).    
To   estimate   the   reproducibility   of   the   SUMOKGG   workflow,   duplicate   cultures   of  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   were   processed   in   parallel   according   to   the   SUMOKGG  
workflow   and   analysed   using   the   ultra   sensitive   LC-­‐‑MSMS   settings.   In   total,   1220  
sumoylation   sites   were   identified   and   52.7  %   of   them   were   common   between   the  
replicate   purifications   (Figure   3.21).   However,   despite   adequate   reproducibility,   one  
should   consider   performing   multiple   replicate   experiments   or   LC-­‐‑MSMS   runs   to  





Figure  3.21  |  Reproducibility  of  the  SUMOKGG  workflow.    
A  Venn  diagram  illustrating  the  overlap  in  the  identified  SUMO  modification  sites  between  two  
replicate   purifications   of   6His-­‐‑SUMO2T90K-­‐‑modified   proteins   and   corresponding   Gly-­‐‑Gly  
remnant-­‐‑containing  peptides.  The  values  in  brackets  show  the  total  number  of  sites  identified  in  
each  sample.  
  
A  combined  analysis  of  18  LC-­‐‑MSMS  raw  files  acquired  during  the  development  stage  
of   the   SUMOKGG   workflow   produced   a   comprehensive   list   of   2034   SUMO2  
modification   sites   from  990  proteins   extracted   from  heat-­‐‑stressed  HEK2936His-­‐‑SUMO2-­‐‑T90K  
cells   (Supplementary   table   S1;  Appendix   6.1).  Approximately   43.3  %   of   the  modified  
lysines  were  identified  only  from  samples  processed  additionally  by  Glu-­‐‑C  digestion.  
Furthermore,  the  majority  of  MSMS  fragmentation  spectra  of  diGly-­‐‑modified  branched  
peptides  were  manually  validated  according  to  the  following  stringent  criteria:    
a) Broad   coverage   of   b   and   y   fragment   ion   series   extending   from   the   N-­‐‑   or  
C-­‐‑terminus  of  the  peptide,  respectively.  
b) Extensive  identification  rate  of  intensive  fragment  ion  peaks.    
c) Precursor   ion   mass   error   less   than   2   parts   per   million   (ppm)   after   mass  




d) Preferential  fragmentation  N-­‐‑terminal  to  proline  or  C-­‐‑terminal  to  glutamic  and  
aspartic  acids.    
e) Existence   of   ions   diagnostic   for   diGly   modification   (GG+,   m/z  +115.0505  Th;  
KGG+,  m/z  +186.1237  Th).  
f) Presence  of  an   ion  series  with  a  neutral   loss  corresponding  to  a  single  glycine  
(m/z  57.0215  Th).  
Moreover,   the   localisation   probability   of   all   modified   lysines   was   confirmed   to   be  
greater   than   75  %   and  peptides   identified   based   on   the   reverse  decoy  database  were  
removed.   Finally,   identification   of   multiple   peptide   sequences   containing   the   same  
Gly-­‐‑Gly-­‐‑modified   lysine   was   considered   beneficial   for   the   validity   of   the   assigned  
SUMO2  modification  site.  
Overall,  this  list  of  2034  SUMO2  modification  sites  was  ~20-­‐‑fold  larger  than  the  biggest  
site-­‐‑specific  study  published  prior  to  this  research  (Figure  3.22)  (Matic  et  al.,  2010).  In  
addition,   the   current   study   increased   the   number   of   all   known   sites   of   sumoylation  
determined  by  MS-­‐‑based  methods  by  more  than  12-­‐‑fold  (Hornbeck  et  al.,  2012).    





Figure  3.22  |  The  SUMOKGG  workflow  increases  the  known  number  of  sumoylation  sites  by  
more  than  tenfold.    
A  Venn  diagram  showing  the  comparison  among  SUMO2  modification  sites   identified   in   this  
study  and  two  data  sets  published  prior  to  the  completion  of  this  study:  (1)  an  MS-­‐‑based  study  
using  Lys-­‐‑deficient  6His-­‐‑SUMO2Q87R/T90R-­‐‑expressing  HeLa  cells   (Matic  et  al.,  2010),   (2)  all  other  
studies  using  MS  as  annotated  in  the  PhosphoSitePlus  database  as  of  January  2014  (Hornbeck  et  
al.,  2012).  The  total  numbers  of  sumoylation  sites  are  shown  in  brackets.  
  
In   summary,   these   improvements   in   the   detection   and   identification   of   sumoylated  
peptides   were   achieved   through   number   of   technical   and   methodological  
enhancements,   including   the   use   of   T90K   version   of   SUMO2   and   K-­‐‑ε-­‐‑GG-­‐‑specific  
antibody,   chemical   cross-­‐‑linking   of   the   antibody,   utilisation   of   additional   in-­‐‑tandem  






 SUMOKGG  workflow  for  the  global  identification  of  SUMO2  3.3.1.
modification  sites  
Prior   to   the  development  of   the  SUMOKGG  workflow,   experimental   strategies  utilised  
for  the  identification  of  sites  of  sumoylation  in  human  cells  employed  overexpression  
of  SUMO  with  an  amino-­‐‑terminal  affinity  tag  and  mutations  in  the  C-­‐‑terminal  region  
to  shorten  the  sequence  of  the  remnant  peptide  after  trypsin  digestion  (Blomster  et  al.,  
2010;  Matic   et   al.,   2010;  Galisson   et   al.,   2011;   Lamoliatte   et   al.,   2013;   Schimmel   et   al.,  
2014).   Isolation   of   sumoylated   proteins   was   thus   achieved   through   an   affinity  
purification.  However,   lack   of   enrichment   procedures   specific   for  modified   peptides  
hindered  the  MS-­‐‑based  detection  and  identification  of  low  abundance  SUMO  remnant-­‐‑
containing   sequences.   Two   previous   studies   acknowledged   the   requirement   for  
efficient   purification   of   modified   peptides,   but   the   applied   approaches   enabled   the  
mapping  of  a  maximum  of  103  sumoylated  lysines  only  (Blomster  et  al.,  2010;  Matic  et  
al.,  2010).  This  number,  however,  was  at  least  tenfold  less  than  expected  based  on  the  
amount  of  proteins  published  as  SUMO  substrates  (Golebiowski  et  al.,  2009;  Bruderer  
et   al.,   2011;   Tatham   et   al.,   2011;   Becker   et   al.,   2013).   Alternatively,   sophisticated  
bioinformatic   tools   were   developed   to   remove   the   requirement   of   C-­‐‑terminal  
mutations   by   facilitating   database   search   engine-­‐‑based   identification   of   chimeric  
MSMS   spectra   of   large   branched   peptides   (Pedrioli   et   al.,   2006;   Hsiao   et   al.,   2009;  
Lamoliatte  et  al.,  2013).  However,   these   tools  had   little   success  with  complex  peptide  




In   this   chapter,   a   SUMOKGG   workflow   was   developed   to   enable   global,   high-­‐‑
throughput,   and   unbiased   identification   of   SUMO2  modification   sites   from   complex  
samples   (Figure   3.8).   A   stable   HEK293   cell   line   expressing   6His-­‐‑SUMO2T90K   was  
generated   to   act   as   an   in  vivo  model   for   sumoylation.  The   enrichment  of   sumoylated  
proteins   followed   by   the   affinity   purification   of   SUMO  Gly-­‐‑Gly   remnant-­‐‑containing  
peptides  after  Lys-­‐‑C  digestion  provided  material  from  which  modification  sites  could  
be  identified.  Notably,  nearly  all  Gly-­‐‑Gly-­‐‑lysines  produced  through  Lys-­‐‑C  proteolysis  
originated   from   6His-­‐‑SUMO2T90K,   as   demonstrated   by   ~0.29  %   false   discovery   rate   of  
the  workflow  (Figure  3.20).  A  number  of  steps  of  the  SUMOKGG  workflow  were  critical  
to   this   enhanced   sensitivity,   efficiency   and   robustness.   As   anticipated,   a   major  
improvement   in  sensitivity  was  achieved  through  the  use  of   the  antibody  specific   for  
diGly-­‐‑lysines.  This  increased  the  proportion  of  SUMO  remnant-­‐‑containing  peptides  in  
the  final  samples  by  more  than  430-­‐‑fold  (Figure  3.15).  The  sensitivity  of  the  SUMOKGG  
workflow  was  also  improved  by  altering  MS  settings  for  the  optimal  acquisition  of  low  
abundance   diGly-­‐‑Lys-­‐‑containing   peptide   ions.   Improved   coverage   of   the   human  
proteome   was   achieved   by   the   introduction   of   an   additional   cleavage   step   using  
endoproteinase   Glu-­‐‑C,   which   nearly   doubled   the   number   of   identified   sumoylation  
sites.   Streamlining   sample   handling   increased   the   yield   and   robustness   of   the  
SUMOKGG   workflow.   All   abovementioned   enhancements   thus   supported   the  
development  of  a  workflow  that  can  be  utilised  to  routinely  identify  ~1000  sumoylated  
lysines   from   ~1.75  ×  108   heat-­‐‑stressed   HEK2936His-­‐‑SUMO-­‐‑T90K   cells.   In   conclusion,   the  
SUMOKGG  workflow  was   the   first  method   to  enable  high-­‐‑throughput   identification  of  
the  sites  of  sumoylation  and  demonstrated  the  depth  of  the  human  proteome  sequence  
that  can  be  conjugated  to  SUMO2  (Appendix  6.2)  (Tammsalu  et  al.,  2014;  Tammsalu  et  




 Additional  applications  of  the  SUMOKGG  workflow  3.3.2.
A  common  feature  of  Ubls  is  the  C-­‐‑terminal  Gly-­‐‑Gly  motif  (Flotho  and  Melchior,  2013).  
The   developed   SUMOKGG   workflow   could,   in   principle,   be   adapted   for   the   global  
identification   of   the   sites   of   any  Ubl.  Many   key   questions   of   the   biology   of   the   Ubl  
family  proteins  could  thus  be  addressed  with  this  workflow.  Such  as,  which  lysines  are  
unique   or   which   are   shared   among   Ubls?   Is   there   a   site   specificity   in   the   Ubl  
conjugation   in   response   to   cellular   stresses?   Moreover,   current   SUMOKGG   workflow  
could  be   tailored   to  compare   the   relative  abundances  of  distinct  Ubls  attached   to   the  
same   target   lysine   and   measure   the   extent   of   site-­‐‑specific   Ubiquitin-­‐‑like   protein  
crosstalk.    
The   C-­‐‑terminal   diGly  motif   of   the  mature   SUMO  molecule   is   also   conserved   across  
species  (Saitoh  and  Hinchey,  2000).  The  developed  SUMOKGG  workflow  could  thus  be  
applied   to   map   the   sites   of   SUMO   modification   in   other   model   organisms.   In  
collaboration   with   a   research   group   led   by   Genevieve   Thon   (University   of  
Copenhagen),   the   workflow   was   utilised   for   the   global   identification   of   SUMO  
modification   sites   in   S.  pombe   (Appendix   6.2)   (Kohler   et   al.,   2015).   In   this   study,   the  
single  gene  encoding  SUMO  in  fission  yeast  (pmt3)  was  replaced  with  6His-­‐‑SUMOL109K  
to   generate   an   organism   compatible   with   the   SUMOKGG   workflow.   Thus,   the  
6His-­‐‑SUMOL109K   was   expressed   from   the   endogenous   locus   and   served   as   the   sole  
source  of  cellular  SUMO.  Unlike  the  severe  growth  defects  of  SUMO-­‐‑deficient  S.  pombe  
(Δpmt3)   (Tanaka   et   al.,   1999),   6His-­‐‑SUMOL109K   did   not   compromise   the   survival   nor  
growth   rate   of   the   fission   yeast   (Figure   3.23A  and  B).   With   MS-­‐‑based   quantitative  






Figure   3.23   |   The   phenotype   of   S.  pombe   strain   expressing   solely   6His-­‐‑SUMOL109K   is  
indistinguishable  from  wild-­‐‑type  counterpart.    
››  




‹‹  Figure   3.23   |   The   phenotype   of   S.  pombe   strain   expressing   solely   6His-­‐‑SUMOL109K   is  
indistinguishable  from  wild-­‐‑type  counterpart.    
(A–B)  Growth   curves   (A;   dark   blue   and   red)   or   tenfold  dilution   series   (B)   of  S.  pombe   strains  
expressing   either   SUMO   or   6His-­‐‑SUMOL109K.   (C)   Scatter   plot   illustrating   the   log-­‐‑transformed  
(base  2)  relative  abundances  of  2266  proteins  between  S.  pombe  strains  expressing  either  SUMO  
or  6His-­‐‑SUMO  (abscissa),  or  6His-­‐‑SUMOL109K  (ordinate).  (D)  Micrographs  of  strains  expressing  
either   SUMO   or   6His-­‐‑SUMOL109K.   (E)  Western   blot   images   of   cell   lysate   proteins   of   S.  pombe  
strains  expressing  either  SUMO  or  6His-­‐‑SUMOL109K  detected  using  antibodies  recognising  either  
SUMO  (top)  or  Tubulin  (bottom).  Nonspecific   immunoreactions  are   indicated  by  asterisks.   (F)  
Western   blot   images   of   cell   lysate   proteins   from   unperturbed   (–)   or   heat-­‐‑stressed   (+;   42  °C,  
20  min)  S.  pombe  strains  expressing  either  SUMO  or  6His-­‐‑SUMOL109K  detected  using  antibodies  
recognising  either  SUMO  (top)  or  Tubulin  (bottom).  Figure  is  adapted  from  (Kohler  et  al.,  2015).  
  
to   achieve   the   observed   phenotype   (Figure   3.23C).   Furthermore,   the   morphology   of  
S.  pombe   cells   expressing   either   SUMO   or   6His-­‐‑SUMOL109K   was   indistinguishable  
(Figure  3.23D).  Finally,  Western  blot  analyses  demonstrated  that  6His-­‐‑SUMOL109K  was  
efficiently   conjugated   to   target   proteins   and   responded   to   cellular   stress   in   a   similar  
manner  to  the  wild-­‐‑type  counterpart  (Figure  3.23E  and  F).  Utilisation  of  the  SUMOKGG  
workflow   in   this   context   enabled   the   identification   of   1028   SUMO  modification   sites  
from   468   fission   yeast   proteins.   The   system  was   also   used   to  measure   the   effect   on  
sumoylated  proteome   in  S.  pombe   cells  deficient   in   the   function  of  SUMO-­‐‑targeted  E3  
Ubiquitin-­‐‑protein  ligase  subunit  Slx8  or  Ubiquitin  fusion  degradation  protein  1  (Ufd1).  
This  revealed  that  several  telomere-­‐‑  and  centromere-­‐‑associated  proteins  of  fission  yeast  
were   coordinately   processed   by   the   combined   actions   of   the   Cdc48-­‐‑Ufd1-­‐‑Npl4  
segregase   and   SUMO-­‐‑targeted   E3   Ubiquitin-­‐‑protein   ligases   Rfp1/Slx8   and   Rfp2/Slx8  
(STUbLs;  Appendix   6.2)   (Kohler   et   al.,   2015).   The   SUMOKGG  workflow  has   also   been  
applied  for  the  global  identification  of  sumoylated  lysines  from  C.  elegans  germline  and  




Although  heat  stressed  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  were  utilised  during  the  development  
of   SUMOKGG   workflow,   the   protocol   could   be   used   to   investigate   the   sites   of  
sumoylation   involved   in   other   cellular   processes,   such   as   cell   division,   DNA  
replication,   transcription,   or   in   cells   exposed   to   various   stress-­‐‑inducing   stimuli.   For  
instance,  SUMOKGG  workflow  has  been  used   to   reveal   the  dynamic  proportion  of   the  
more  than  600  SUMO2  modification  sites  identified  from  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  after  
a   treatment  with   a   suspected  Ubl   protease   inhibitor   GRE010   (collaboration  with   the  
research  group  of  Professor  Angus  Lamond).    
 Comparison   of   the   SUMOKGG   workflow   with   alternative  3.3.3.
methods  
In   recent  years,   the  ability   to  globally  determine   the   sites  of   SUMO  modification  has  
been   one   of   the   central   objectives   of   the   field   of   protein   sumoylation.  Consequently,  
several  independent  research  groups  have  focused  on  developing  methods  for  the  high  
throughput   identification   of  modified   lysines.   Since   the   publication   of   the   SUMOKGG  
workflow,   four   additional   protocols   enabling   the   mapping   of   more   than   a   hundred  
sumoylation  sites  have  thus  been  developed  (Hendriks  et  al.,  2014;  Impens  et  al.,  2014;  
Lamoliatte  et  al.,  2014;  Hendriks  et  al.,  2015a).  The  foundations  of  all  these  techniques,  
including  the  SUMOKGG  workflow,  are  surprisingly  similar.  For  instance,  all  published  
protocols  depend  on  an  affinity-­‐‑tagged  variant  of  SUMO  and  most  of  them  utilise  both  
protein-­‐‑   and   peptide-­‐‑level   enrichments.   However,   several   key   technical   distinctions  
exist   and   should   thus   be   taken   into   consideration,   when   analysing   the   archives   of  





Similarly  to  the  SUMOKGG  workflow,  the  method  published  by  Impens  et  al.  utilised  a  
6His-­‐‑tagged   variant   of   SUMO  allowing   the   affinity   purification   of  modified  proteins  
(Impens   et   al.,   2014).   Furthermore,   the   residue   preceding   the   C-­‐‑terminal   diGly  
sequence   was   mutated   to   enable   the   enrichment   of   proteolytically   digested   SUMO  
branched   peptides   with   K-­‐‑ε-­‐‑GG-­‐‑specific   antibody.   However,   in   contrast   to   the  
SUMOKGG   workflow,   the   residue   was   mutated   to   Arg   and   trypsin   digestion   was  
utilised  to  generate  peptides.  As  more  members  of  the  Ubl-­‐‑family  contain  an  arginine  
in   the   equivalent   position,   additional   measures   had   to   be   taken   to   discriminate  
between  the  sites  of  SUMO,  Ubiquitin,  NEDD8,  and  ISG15.  This  was  accomplished  by  
comparing   the   MS   signal   intensities   of   diGly-­‐‑Lys-­‐‑containing   peptides   derived   from  
SILAC-­‐‑labelled  cells  expressing  either  wild-­‐‑type  or  engineered  SUMO.  Only  peptides  
with   an   MS   signal   detected   exclusively   from   mutant   cells   were   acknowledged   as  
genuine  substrates  (Impens  et  al.,  2014).  This  type  of  analysis  is  prone  to  type  II  errors  
(“false   negatives”),   as   lysines  modified   by   various   Ubls,   including   SUMO,   could   be  
incorrectly   rejected.   Furthermore,   co-­‐‑purification   of   modified   peptides   originating  
from   multiple   Ubls   increases   the   complexity   of   samples,   and   can   thus   hamper   the  
identification  of  low  abundance  sumoylated  substrates.  As  a  result,  less  than  a  third  of  
the   acquired   peptides   contained   a   SUMO-­‐‑derived   remnant   sequence   (Impens   et   al.,  
2014;  Hendriks  and  Vertegaal,  2016a).  On  the  other  hand,  this  is  the  only  method  that  
to  date  has  been  applied   to  simultaneously  analyse   the  sites  of  SUMO1  and  SUMO3,  
identifying  295  or  167  modified  lysines,  respectively  (Impens  et  al.,  2014).  
A  6His-­‐‑SUMO  construct  was  also  utilised  for  the  method  developed  by  Lamoliatte  et  
al.   and   the   enrichment   of   sumoylated   conjugates   was   achieved   by   nickel   affinity  




introduced  to  the  C-­‐‑terminal  region  of  SUMO2  to  create  an  additional  cleavage  site  for  
trypsin.   However,   the   mutation   was   introduced   to   the   sixth   position   from   the  
carboxyl-­‐‑terminus  of  the  mature  molecule  to  distinguish  between  the  tryptic  remnants  
of   SUMO   and   other   Ubls.   Additionally,   Gln88   was   replaced   by   an   asparagine   to  
potentially   analyse   the   redundancy   between   the   targets   of   SUMO2   and   SUMO3,  
although   the   topic  was  not   addressed.  After   trypsin  digestion,   the  NQTGG-­‐‑modified  
branched   peptides   from   SUMO2Q87R/Q88N   conjugates   were   enriched   with   a   rabbit  
monoclonal  antibody  UMO  1-­‐‑7-­‐‑7,  which  to  date  is  not  available  to  the  wider  scientific  
community.   Surprisingly,   identification   of   the   MSMS   spectra   of   NQTGG-­‐‑Lys-­‐‑
containing  peptides  required  utilisation  of  a  specialist  software  application  developed  
in-­‐‑house   (Lamoliatte   et   al.,   2014).   In   total,   Lamoliatte   et   al.  were   able   to   identify   954  
sites  of  SUMO2  modification  in  response  to  proteasome  inhibition  with  MG132.    
The   third  protocol  was   an   optimised  version   of   the  most   efficient  method  published  
prior   to   SUMOKGG   workflow   (Matic   et   al.,   2010;   Hendriks   et   al.,   2014).   As   before,   a  
mutant   of   SUMO2   completely   lacking   lysine   residues   was   utilised   to   render   the  
molecule  resistant  to  Lys-­‐‑C  digestion  and  Gln87  was  mutated  to  Arg  to  generate  trypsin  
digested  branched  peptides  with  a  shorter  SUMO2  remnant   (QQTGG).  However,   the  
6His-­‐‑tag  was  replaced  with  a  decahistidine  (10His)  stretch  to  allow  for  more  stringent  
affinity   chromatography   procedure,   which   generated   samples   of   higher   purity.  
Furthermore,   the   affinity   purification   was   utilised   twice:   before   Lys-­‐‑C   digestion   to  
enrich  for  sumoylated  proteins,  and  after  proteolysis  to  isolate  target  peptides  attached  
to  Lys-­‐‑C  resistant  SUMO2K0/Q87R.  After  subsequent  trypsin  digestion,  branched  peptides  
were   identified   utilising   new   MS   instrumentation.   Altogether,   these   adjustments  




from  human  cells  exposed  to  various  cellular  stresses  (Hendriks  et  al.,  2014;  Hendriks  
and   Vertegaal,   2016b).   Importantly,   Lys-­‐‑deficient   10His-­‐‑SUMO2K0/Q87R   cannot   form  
polymeric   SUMO   chains,   which   can   have   a   distinct   function   compared   to   mono-­‐‑
sumoylation   (Tatham   et   al.,   2008),   and   the   phenotype   and   viability   of   cells   with  
10His-­‐‑SUMO2K0/Q87R  as  their  sole  copy  is  yet  to  be  addressed  (Hendriks  et  al.,  2014).    
The   most   recent   method,   named   as   protease-­‐‑reliant   identification   of   SUMO  
modification   or   “PRISM”,   enabled   sumoylation   site   identification   using   wild-­‐‑type  
SUMO  sequence  (Hendriks  et  al.,  2015a).  Expression  of  exogenously  introduced  10His-­‐‑
tagged   SUMO   was   still   essential   to   facilitate   the   affinity   purification   of   conjugates.  
After   enrichment,   unmodified   lysine   residues   of   denatured   purified   proteins   were  
acetylated   using   sulfosuccinimidyl   acetate   (sulfo-­‐‑NHS-­‐‑acetate)   and   conjugates   were  
desumoylated  with  SENP2.  Deconjugated  substrate  proteins  were   then  digested  with  
trypsin  and  analysed  by  LC-­‐‑MSMS.  Location  of  target  sites  was  inferred  indirectly  via  
the   identification   of   peptides   containing   unmodified   lysines   (Hendriks   et   al.,   2015a).  
The   major   weakness   of   this   approach   is   the   reliance   on   the   sulfo-­‐‑NHS-­‐‑acetate  
acetylation   reaction   to   go   to   completion,   as   residual   unmodified   lysines   could   be  
misassigned  as  SUMO  target  sites.  Furthermore,  potential  side  reactions  of  sulfo-­‐‑NHS-­‐‑
acetate   can   introduce   unknown   modifications   and   complicate   the   identification   of  
peptide  sequences.  In  vitro,  SENP2  has  been  reported  to  deconjugate  SUMO1,  SUMO2  
and   SUMO3   (Nishida   et   al.,   2001),   which   suggests   that   paralog-­‐‑specific   sites   of  
sumoylation  can  only  be  determined  utilising  protein-­‐‑level  enrichment  prior  to  SENP2  
treatment.  Therefore,  lysines  of  (co-­‐‑)purified  substrates  modified  by  a  different  SUMO  




In  practice,  SUMOKGG  workflow  is  comparable  to  all  abovementioned  methods  in  terms  
of  protocol  duration  (~5  versus  3–7  days)  and  the  amount  of  cell  culture  required  per  
LC-­‐‑MSMS   analysis   (90   million   versus   20–200   million   cells)   (Hendriks   et   al.,   2014;  
Impens  et  al.,  2014;  Lamoliatte  et  al.,  2014;  Tammsalu  et  al.,  2014;  Hendriks  et  al.,  2015a;  
Tammsalu   et   al.,   2015;   Hendriks   and   Vertegaal,   2016b).   Moreover,   the   number   of  
identified   SUMO2   modification   sites   is   proportionate   with   the   highest   performer  
among   the   other  methods   (2034   versus   2307   sites   after   heat   stress)   (Hendriks   et   al.,  
2014).   However,   as   illustrated   by   the   large   proportion   of   Gly-­‐‑Gly-­‐‑Lys-­‐‑containing  
peptides   present   in   enriched   samples   (Figure   3.15),   the   purification   efficiency   of   the  
SUMOKGG   workflow   is   superior   to   all   other   techniques   (~60  %   versus   2–30  %)  
(Tammsalu   et   al.,   2014;   Hendriks   and   Vertegaal,   2016a).   Furthermore,   the   SUMOKGG  
workflow   utilises   a   form   of   SUMO   with   a   single   amino   acid   substitution   near   the  
C-­‐‑terminus,   thus  reducing   the  risk  of  non-­‐‑wild-­‐‑type  behaviour  of   the  SUMO  protein.  
Mutating  the  residue  preceding  the  diGly  motif  to  lysine  and  using  Lys-­‐‑C  assures  that  
all  modified  peptides  originate  exclusively   from  SUMO2T90K.  Moreover,   the   relatively  
small  SUMO-­‐‑derived  Gly-­‐‑Gly  modification  on  target  lysines  is  identifiable  by  standard  
database   search   engines,   thus   preventing   the   requirement   for   specialist   software  
applications  or  add-­‐‑ons.    
 Future  directions  of  SUMO  site  proteomics  3.3.4.
Hitherto,  all   available  methods   for   the  high-­‐‑throughput   identification  of   sumoylation  
sites   rely   on   the   expression   of   exogenously   introduced   versions   of   SUMO   paralogs.  
Ultimately,  mapping  of  lysines  modified  by  endogenous  SUMO  would  be  the  ideal,  as  




approach   could  be   applied   to   tissues  or   clinical   samples.  The  ultimate   incarnation  of  
SUMO  proteomics  is  a  method  that  allows  the  identification  and  quantification  of  the  
sites  of  endogenous  sumoylation,  while  distinguishing  between  the  three  paralogs.    
Despite   the   substantial   advancements   in   LC-­‐‑MSMS   instrumentation,   with   present  
technology   the   requirement   to   enrich   for   low   abundance   sumoylated   molecules   is  
inevitable.   However,   a   methodology   for   the   purification   of   endogenous   SUMO  
remnant-­‐‑containing   peptides   after   proteolysis   is   lacking.   To   date,   the   majority   of  
sumoylation   site   analyses   have   focused   on   the   identification   of   SUMO   remnant-­‐‑
modified   lysines   after   trypsin   digestion,   and   required   SUMO   mutations   to   allow  
peptide-­‐‑specific  enrichment  (Hsiao  et  al.,  2009;  Blomster  et  al.,  2010;  Matic  et  al.,  2010;  
Lamoliatte   et   al.,   2013).   However,   investigation   into   the   suitability   of   alternative  
proteases   has   been   limited.   Thus,   a   comprehensive   assessment   of   biochemical  
properties  of  SUMO  remnant-­‐‑containing  branched  peptides  after  proteolytic  digestions  
with  various  endopeptidases  either  alone  or  in  combination  would  be  beneficial.  This  
type  of  analysis  could  reveal  SUMO  branch-­‐‑specific  features,  such  as  suitable  fixed  size  
or  chemical  characteristics  that  could  enable  their  efficient  separation  from  unmodified  
peptides.  Alternatively,  these  branched  peptides  could  serve  as  an  epitope  to  generate  
novel  SUMO  remnant-­‐‑specific  antibodies.    
Recently,   the   application   of   a   wild-­‐‑type   α-­‐‑lytic   protease   (WaLP)   in   bottom-­‐‑up  
proteomics  experiments  was  demonstrated  (Silen  et  al.,  1989;  Meyer  et  al.,  2014).  WaLP  
cleaves  peptide   bonds  predominantly   from   the  C-­‐‑terminal   side   of  Val,  Ala,   Thr,   and  
Ser.   Therefore,   the   protease   could   be   utilised   to   generate   Gly-­‐‑Gly-­‐‑Lys-­‐‑containing  




utilised   to  map  paralog-­‐‑specific   sites  of  modification,  as  all  SUMO  molecules  contain  
Thr   in   the   equivalent   position   (Figure   3.1).   Furthermore,   with   lower   affinity,   WaLP  
digests   peptides   C-­‐‑terminal   to   Gly,   Leu   and  Met   (Meyer   et   al.,   2014).   Ubiquitin-­‐‑like  
protein  FUBI  contains  leucine  in  the  equivalent  position  to  Thr90  in  SUMO,  and  WaLP-­‐‑
generated   Gly-­‐‑Gly-­‐‑Lys-­‐‑containing   peptides   could   thus   originate   from   substrate  
proteins   modified   by   multiple   Ubls.   Moreover,   WaLP-­‐‑specificity   towards   peptide  
bonds  C-­‐‑terminal   to  glycines  could  shorten  the  Gly-­‐‑Gly  remnant  and  thus  render   the  
branched   peptides   unsuitable   for   the   subsequent   enrichment   with   K-­‐‑ε-­‐‑GG-­‐‑specific  
antibody.  However,  despite   all   these   limitations,  WaLP-­‐‑based  method   could  validate  
the   sites   of   SUMO  modification   identified   with   currently   available   approaches.   But  
until  such  a  method  becomes  available,  techniques  like  the  SUMOKGG  workflow  can  be  






Global  reprogramming  of  SUMO  signalling  









Protein   posttranslational  modification   by   SUMO2/3   is   enhanced   in   cells   subjected   to  
various   protein-­‐‑damaging   stimuli,   such   as   oxidative   stress,   addition   of   ethanol,  
inhibition   of   protein   degradation,   or   exposure   to   severe   temperature   fluctuations  
(Saitoh  and  Hinchey,  2000).  The  dynamics  of  sumoylation  appears  to  correlate  with  the  
accumulation  of  mis-­‐‑  and  unfolded  proteins.  For  instance,  conjugation  to  SUMO2/3  in  
response  to  proteasome  inhibition  depends  on  the  accumulation  of  newly  synthesised  
misfolded   polypeptides   (Tatham   et   al.,   2011).   Exposure   to   elevated   temperature,  
however,   triggers   a   fast   translation-­‐‑independent   substrate   sumoylation,   which  
correlates  with   the  rapid  and  widespread  aggregation  of  denatured  proteins   (Tatham  
et   al.,   2011;  Wallace   et   al.,   2015).   Importantly,   conjugation   to  SUMO2/3  promotes   the  
survival  of  cells  after  a  severe  heat  shock  (Golebiowski  et  al.,  2009).    
Hundreds  of  proteins  are  sumoylated   in  response   to  hyperthermic  cellular  stress  and  
many   of   them   can   bind   chromatin   (Golebiowski   et   al.,   2009;   Niskanen   et   al.,   2015;  
Seifert  et  al.,  2015).  In  particular,  an  exposure  to  elevated  temperature  induces  a  rapid  
SUMO2   conjugation   to   proteins   associated   with   promoters   and   enhancers   of   active  
genes.   Modification   of   these   chromatin-­‐‑binding   proteins   appears   to   require   the  
transcriptional   activity   of   target   genes   (Niskanen   et   al.,   2015;   Seifert   et   al.,   2015).  
Similarly   to   the  heat   shock   response   in  general,   sumoylation  of   chromatin-­‐‑associated  
proteins  is  induced  by  the  accumulation  of  either  un-­‐‑  or  misfolded  proteins.  (Seifert  et  
al.,   2015).  However,   the   general   function   of   SUMO2   recruitment   to   chromatin   is   still  




maintains  or  restricts  the  expression  of  target  genes  (Niskanen  et  al.,  2015;  Seifert  et  al.,  
2015).    
Subcellular   fractionation-­‐‑based   studies   have   revealed   that   the   unconjugated   form   of  
SUMO2/3   is   preserved   in   the   cytoplasm,   whereas   sumoylated   substrates   are   almost  
exclusively   nuclear.   After   the   exposure   to   protein-­‐‑damaging   stimuli,   the  majority   of  
SUMO-­‐‑bound  conjugates  are  associated  with  the  detergent-­‐‑insoluble  fraction  upon  cell  
lysis   (Tatham   et   al.,   2011;   Seifert   et   al.,   2015).   Interestingly,   this   insoluble   material  
appears   to   consist   of   large   protein   complexes   that   are   tightly   associated  with   DNA.  
Preliminary   experiments   have   suggested   that   multiple   components   of   these   protein  
complexes  could  act  as  substrates  of  SUMO2  modification  (Seifert  et  al.,  2015).    
The   aim  of   this   project  was   to   uncover   the   global   dynamics   of   SUMO2   signalling   in  
heat-­‐‑stressed   cells   by   providing   an   extensive   quantitative   resource   of   sumoylated  
proteins   together   with   the   exact   SUMO2   modification   sites.   A   direct   quantitative  
comparison   of   normal   and   heat-­‐‑stressed   cells   would   enable   the   verification   of   the  
major  targets  of  proteotoxic  stress-­‐‑induced  sumoylation  by  demonstrating  the  extent  of  
modification  of  individual  substrates  in  each  condition.  The  generated  comprehensive  
knowledgebase   of   SUMO2  modification   sites   could   also   be   utilised   by   the   scientific  
community  to  uncover  the  physiological  functions  of  sumoylation.    
Considering   that   the   predominantly   cytoplasmic   pool   of   unconjugated   SUMO2  
decreases   rapidly   upon   heat   stress,   and   the   emerging   sumoylated   conjugates   are  
mainly   nuclear,   it   was   anticipated   that  many   other   proteins  might   be   under   similar  




Surprisingly,   the  global  changes   to   the  spatial  distribution  of   the  human  proteome   in  
response  to  hyperthermic  stress  have  not  been  addressed.    
To   this   end,   a   quantitative   SILAC   (stable   isotope   labelling   by   amino   acids   in   a   cell  
culture)-­‐‑based  workflow  was  devised   (Ong   et   al.,   2002).   The  developed  method  was  
designed   to   enable   direct   comparison   between   individual   protein   abundances   in   the  
cytoplasmic   or   nuclear   fraction   of   either   normal   or   heat-­‐‑stressed  HEK2936His-­‐‑SUMO2-­‐‑T90K  
cells.  Furthermore,  the  SUMOKGG  workflow  was  utilised  to  identify  the  sites  of  SUMO2  
modification   and   to   determine   the   extent   of   sumoylation   of   each   substrate   in  
unperturbed  cells  or  after  the  exposure  to  heat  stress.    





 Time   course   of   6His-­‐‑SUMO2T90K   conjugation   to   substrate  4.2.1.
proteins  in  response  to  hyperthermic  stress  
In  response  to  heat-­‐‑activated  cellular  stress,  available  SUMO2  is  covalently  attached  to  
substrate  proteins   (Saitoh  and  Hinchey,  2000;  Golebiowski  et  al.,   2009).  To  determine  
the  dynamics  of  heat-­‐‑induced  sumoylation,  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  were  exposed  to  
0,  15,  30,  60,  or  120  minutes  of  hyperthermic  stress  at  43  °C.  Cell  pellets  were  disrupted  
in  a  buffer  containing  100  mM  2-­‐‑chloroacetamide  to  inhibit  desumoylation  (Bruderer  et  
al.,   2011),   and   proteins   were   segregated   into   nuclear   and   cytoplasmic   fractions.  
Equivalent  amount  of  each  subcellular   fraction   (protein  wt/wt)  was   then   loaded  onto  
SDS-­‐‑PAGE  gels  and  subjected  to  Western  blot  analyses  for  the  detection  of  SUMO2/3,  
6His,  Tubulin,  or  Lamin  A/C  (Figure  4.1).    
Immunoblot  images  of  SUMO2/3  and  6His  indicated  that  the  conjugation  of  SUMO2/3  
to  target  proteins  was  maximal  after  30–60  minutes  of  heat  stress  (Figure  4.1A  and  B).  
Consistent   with   previously   published   observations,   the   sumoylated   substrates  
resolved  in  the  high-­‐‑molecular-­‐‑weight  area  of  the  protein  gel  and  were  predominantly  
detected  in  the  nuclear  fraction  (Tatham  et  al.,  2011;  Seifert  et  al.,  2015).  Meanwhile,  the  
majority   of   unconjugated   SUMO2  monomers  were   found   in   the   cytoplasmic   fraction  
(Figure  4.1A  and  B).  





Figure   4.1   |   The   apex   of  
6His-­‐‑SUMO2T90K   conjugation   is  
reached   in   30–60   minutes   of  
exposure  to  acute  heat  stress.    
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells  
cultured   at   37  °C  were   shifted   to  
43  °C   and   cells   were   harvested  
either   before   (0  min)   or   after   15,  
30,   60,   and   120   minutes   of  
treatment.   Proteins   from   each  
sample   were   separated   into  
cytoplasmic   and   nuclear  
fractions,   and   equivalent  
amounts   were   subjected   to  
Western   blot   analyses   for   the  
detection   of:   (A)   SUMO2/3,   (B)  
6His,   (C)   Tubulin,   and   (D)  
Lamin  A/C.   (E)   Coomassie  
brilliant   blue-­‐‑stained   PVDF  
membrane   validating   the  
equivalent  loading  and  consistent  
transfer  of  proteins.  
  




Western   blot   images   of   Tubulin   and   Lamin  A/C   demonstrated   the   efficiency   of   the  
protein   separation   and   served   as   loading   controls   for   the   corresponding   fractions  
(Figure   4.1C   and   D).   As   expected,   Tubulin   was   detected   predominantly   in   the  
cytoplasmic   fraction   (Figure   4.1C),   and   Lamin  A/C   was   found   exclusively   from   the  
nuclear  material  (Figure  4.1D).  Coomassie  brilliant  blue  staining  of  the  polyvinylidene  
difluoride  (PVDF)  membrane  showed  the  equality  in  protein  loading  and  the  efficiency  
of  transfer  onto  PVDF  membrane  across  the  protein  gel  (Figure  4.1E).    
Based  on   these   results,   the   subsequent  proteomics   experiment   exploring   the   SUMO2  
signalling   in   response   to   heat-­‐‑activated   proteotoxic   stress   was   performed   with  
HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  incubated  at  43  °C  for  30  minutes.  
 Overview  of  the  experimental  strategy  4.2.2.
To   investigate   the   alterations   in   global   protein   sumoylation   in   response   to   heat-­‐‑
induced  proteotoxic  stress,  a  SILAC  quantitative  MS-­‐‑based  approach  was  undertaken  
(Figure  4.2)  (Ong  et  al.,  2002).  For  this  purpose,  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  were  cultured  
in  a  growth  medium  supplemented  with  natural  L-­‐‑lysine  (12C6,  14N2;  K0)  and  L-­‐‑arginine  
(12C6,  14N4;  R0)  (Figure  4.2;  grey).  The  K0R0-­‐‑labelled  culture  was  divided  into  two  equal  
portions  and  one  of  the  subcultures  was  subjected  to  hyperthermic  stress  by  elevating  
the   incubation   temperature   to   43  °C   for   30  minutes   (Figure   4.2;   orange).   After  
harvesting,   both   subcultures   were   disrupted   in   a   buffer   containing   100  mM  
2-­‐‑chloroacetamide,  and  separated  into  nuclear  and  cytoplasmic  fractions.  Nuclei  were  
collected   by   centrifugation   and   washed   to   reduce   the   amount   of   cytoplasmic  






Figure  4.2  |  Experimental  strategy.    
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   cultured   in   natural   L-­‐‑Lys   and   L-­‐‑Arg-­‐‑containing   growth   medium  
(K0R0;  grey)  were  divided  in  two,  and  one  of  the  subcultures  was  exposed  to  heat  stress  (43  °C,  
30  min;   orange).  Both   subcultures  were   then  harvested   and  maintained   separately  during   the  
subcellular  fractionation  procedure  (top-­‐‑down  flowchart).  In  parallel,  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  
were   cultured   in  heavy   stable   isotope-­‐‑containing  growth  medium  at   37  °C   (K8R10;   blue)   and  
lysed   directly  without   fractionation   (bottom-­‐‑up   flowchart).   An   equivalent   amount   of   K8R10-­‐‑
labelled  untreated  unfractionated   cell   lysate  protein  was   then  mixed  with   each  K0R0-­‐‑labelled  
sample  and  downstream  processing  was  performed  according  to  the  SUMOKGG  workflow.  




and  protein  structures   in  each  analytical   fraction  were  disrupted  by   the  addition  of  a  
strong   chaotropic   agent   Gu-­‐‑HCl,   and   the   concentration   of   proteins   was   determined  
using  a  bicinchoninic  acid  (BCA)  assay  (Figure  4.2;  top-­‐‑down  flowchart).    
In  parallel,  another  culture  of  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  was  metabolically  labelled  with  
heavy  stable  isotope-­‐‑containing  L-­‐‑lysine  (13C6,  15N2;  K8)  and  L-­‐‑arginine  (13C6,  15N4;  R10),  
and  cultured  at  37  °C  (Figure  4.2;  blue).  The  K8R10-­‐‑labelled  cells  were  harvested  under  
strong  denaturing  conditions  without  fractionation  and  the  protein  concentration  was  
determined  using  BCA  assay  (Figure  4.2;  bottom-­‐‑up  flowchart).  This  sample  of  heavy-­‐‑
labelled   proteins   extracted   from   unstressed   unfractionated   cells   was   to   serve   as   an  
internal   standard   that   ultimately   allowed   direct   comparison   of   individual   protein  
abundances  between  all  four  fractions  (subsequently  termed  analytes).    
The  internal  standard  was  then  spiked  into  each  of  the  analytes  according  to  a  specific  
mixing  strategy,  which  was  designed  to  prevent  systematic  errors  that  could  arise  from  
the  inequality  in  the  initial  number  of  cells  cultured  either  at  37  °C  or  43  °C  (Equation  
4.1).   The   set-­‐‑up   was   devised   to   understand   the   reproducibility   of   the   fractionation  
process,   and   to   enable   direct   quantitative   comparisons   of   individual   protein  
abundances  between  all  four  analytes.  Therefore,  each  fractionated  sample  was  spiked  
with  the  amount  of  K8R10-­‐‑labelled  standard  that  corresponded  to  a  half  of  the  absolute  
protein   extracted   from   either   unperturbed   or   heat-­‐‑stressed  HEK2936His-­‐‑SUMO2-­‐‑T90K   cells,  
respectively  (Equation  4.1).    




Equation  4.1  |  Strategy  for  the  spiking  of  standard  protein.    
HS  =  (LN  +  LC)/2  
HS,  K8R10-­‐‑labelled  standard  protein  to  be  mixed  with  each  analyte  (mg)  
LN,  nuclear  analyte  of  a  K0R0-­‐‑labelled  cell  culture  (mg)  
LC,  cytoplasmic  analyte  of  the  same  K0R0-­‐‑labelled  cell  culture  (mg)  
  
Next,  all  generated  mixtures  of  proteins  were  examined  twice  essentially  as  illustrated  
in   (Figure   3.19).   The   first   analysis   was   aimed   to   describe   the   changes   in   protein  
abundance   or   localisation   within   human   cells   after   the   exposure   to   elevated  
temperature.   Thus,   a   small   proportion   of   each   sample   was   subjected   directly   to   in  
solution  digestion  with  Lys-­‐‑C,   either   alone  or   in   tandem  with   trypsin.  The   emerging  
mixtures   of   peptides   were   fractionated   offline   by   strong   anion   exchange   (SAX)  
chromatography  and  analysed  by  LC-­‐‑MSMS.  Finally,   four  analyte-­‐‑to-­‐‑standard  SILAC  
ratios   were   acquired   by   comparing   the   relative   abundances   of   individual   proteins  
between   the   K8R10-­‐‑labelled   standard   and   the   K0R0-­‐‑labelled   cytoplasmic   or   nuclear  
fraction   of   cells   cultured   either   at   37  °C   or   43  °C.   Ultimately,   these   SILAC   ratios  
represented   the   subcellular   distribution   of   the   human   proteome   in   normal   or   heat-­‐‑
stressed  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells.  These  ratios  were  also  used  to  confirm  the  equality  
in   the   amount   of   internal   standard   spiked   into   each   analyte   and   when   required,   to  
reduce  the  systematic  errors  by  normalisation.    
The   remaining   mixtures   of   proteins   were   processed   according   to   the   SUMOKGG  
workflow  developed  in  Chapter  3.  Analogously  to  the  abovementioned  samples,   four  
analyte-­‐‑to-­‐‑standard   SILAC   ratios   were   acquired.   However,   these   were   designed   to  




sumoylation   in   response   to   heat-­‐‑activated   proteotoxic   stress.   Importantly,   the   entire  
workflow  was  performed  in  duplicate  to  improve  data  reliability.    
 Preliminary   examination   of   the   quality   of   fractionated  4.2.3.
protein  samples  
Prior   to   mixing,   all   analytes   were   subjected   to   the   Western   blot   analyses   for   the  
detection  of  SUMO2/3,  6His,  Tubulin,  or  Lamin  A/C  to  ensure  the  efficiency  of  the  heat  
shock   and   the   subcellular   fractionation   procedure   (Figure   4.3).   As   anticipated,   the  
sumoylated   substrates  were  predominantly  detected   from   the  high-­‐‑molecular-­‐‑weight  
area  of  the  nuclear  fraction,  whereas  the  unconjugated  form  of  SUMO2/3  was  mainly  in  
the  cytoplasmic  material  (Figure  4.3A  and  B;  cytoplasmic;  nuclear).  Also,  an  extensive  
heat-­‐‑induced   increase   in   substrate-­‐‑bound   SUMO2/3   was   observed   in   the   nuclear  
analyte.  The  separation  of   sumoylated  proteins  and  unconjugated  SUMO2/3  between  
the  subcellular   fractions  was  remarkably  clear-­‐‑cut,  and  only   low  levels  of  monomeric  
SUMO2/3   were   detected   in   the   wash   (Figure   4.3A   and   B;   wash).   Heavy-­‐‑labelled  
proteins   from  unstressed   and   unfractionated   cells   contained   both,   unconjugated   and  
substrate-­‐‑bound  SUMO2/3  (Figure  4.3A  and  B;  unfractionated).    
The   distribution   of   Lamin  A/C   or   Tubulin   verified   the   efficient   fractionation   (Figure  
4.3C   and   D).   As   expected,   Tubulin   was   mainly   cytoplasmic,   whereas   Lamin   A   and  
Lamin   C   were   predominantly   nuclear.   Out   of   the   four   immunoblot   images,   only  
Tubulin   was   consistently   detected   from   the   wash   fraction,   and   illustrated   the  
importance   of   washing   the   extracted   nuclei   to   eliminate   potential   contamination  
(Figure  4.3C;  wash).  However,  less  than  7.5  %  of  the  protein  extracted  per  cell  culture  





Figure  4.3  |  Increased  SUMO2  conjugation  in  the  nuclear  fraction  of  heat-­‐‑stressed  cells.    
Fractions   of   cellular   proteins   generated   according   to   the   experimental   strategy   presented   in  
Figure  4.2  were  subjected  to  Western  blot  analyses  for  the  detection  of:  (A)  SUMO2/3,  (B)  6His,  
(C)  Tubulin,   and   (D)  Lamin  A/C.   (E)  Ponceau  S   staining   of   a   PVDF  membrane   validating   the  
equal  loading  and  consistent  transfer  of  proteins.    




The  detection  of  both  Tubulin  and  Lamin  C   in   the  heavy-­‐‑labelled  material  confirmed  
the  unfractionated  nature  of  the  internal  standard  (Figure  4.3C  and  D;  unfractionated).  
The   Ponceau-­‐‑stained   PVDF   membrane   verified   the   equal   loading   and   efficiency   of  
transfer  (Figure  4.3E).    
The   analytes  were   then  mixed  with   the   heavy-­‐‑labelled   standard   and   the   experiment  
was  conducted  according  to  the  devised  protocol  (Figure  4.2).  Ultimately,  four  SILAC  
ratios   reflecting   the   subcellular   distribution   of   either   6His-­‐‑SUMO2T90K-­‐‑modified   or  
overall  human  proteome,  were  obtained  in  duplicate:  
• “Cytoplasmic  fr.  at  37  °C”-­‐‑to-­‐‑“Internal  standard”  
• “Nuclear  fr.  at  37  °C”-­‐‑to-­‐‑“Internal  standard”  
• “Cytoplasmic  fr.  at  43  °C”-­‐‑to-­‐‑“Internal  standard”  
• “Nuclear  fr.  at  43  °C”-­‐‑to-­‐‑“Internal  standard”  
 A   comprehensive   validation   of   the   sample   preparation  4.2.4.
workflow    
As   described   in   Chapter  4.2.2,   all   four   analytes   generated   in   duplicate   were   spiked  
with   an   unfractionated   internal   standard   to   enable   direct   comparison   of   individual  
protein   abundances   between   each   subcellular   fraction   of   normal   or   heat-­‐‑stressed  
human  cells.  However,  a  specific  mixing  scenario  had  to  be  devised  to  compensate  for  
the   potential   inequalities   in   the   number   of   cells   utilised   per   experimental   condition  
(Equation   4.1).   Consequently,   various   amounts   of   internal   standard   were   combined  




this   mixing   strategy   had   thus   to   be   evaluated   to   assure   its   completion   without  
systematic  errors,  or  if  required,  to  assist  with  normalisation.    
The  accuracy  and  precision  of  the  spiking  procedure  were  thus  assessed  by  comparing  
the  quantities  of  individual  proteins  in  the  analytical  or  standard  sample  according  to  
Equation   4.2.   Given   that   no   systematic   errors   were   introduced   and   the   absolute  
abundances   of   most   proteins   remained   unaltered   in   response   to   hyperthermia,   the  
median  value  of  these  calculated  relative  abundances  should  be  equal  between  cultures  
incubated  at   37  °C  or   43  °C.  On  average,   this  median  value  varied  by  merely   ~2.9  %,  
illustrating   the   high   precision   of   the   spiking   procedure   (Table   4.1;   coefficient   of  
variation).   However,   small   imperfections   in   the   accuracy   were   observed,   as   the  
geometric   averages   of   the  median   relative   abundances  within   duplicate   experiments  
were  either  1.3  (±  0.5  %)  or  0.7  (±  5.4  %),  instead  of  the  anticipated  value  of  one  (Table  
4.1;  median  of  relative  abundances).  The  analyte-­‐‑to-­‐‑standard  ratios  of  all  proteins  were  
thus  normalised  to  diminish  the  introduced  spiking-­‐‑related  systematic  errors.  
    
Equation  4.2  |  Strategy  for  the  assessment  of  the  spiking  accuracy.    
(LN  +  LC)/(2  ×  HS)  =  1  
HS,  K8R10-­‐‑labelled  standard  protein  mixed  with  each  analyte  (mg)  
LN,  nuclear  analyte  of  a  K0R0-­‐‑labelled  cell  culture  (mg)  
LC,  cytoplasmic  analyte  of  the  same  K0R0-­‐‑labelled  cell  culture  (mg)  
  




Table  4.1  |  Precision  and  accuracy  of  spiking  procedure.    
     Statistic          First  study        Second  study  
  
Culturing  temperature  (°C)   37   43  
  
37   43  
  
Median  of  relative  abundancesa   1.3   1.3  
  
0.7   0.7  
     Coefficient  of  variation  (%)b   0.5        5.4  
  
a  Calculated  according  to  Equation  4.2;  the  measurement  is  based  on  50  %  of  proteins  with  highest  
MS  signal  intensity  
  
b  Measured  between  the  cultures  within  each  study  
  
The   reproducibility   of   the   fractionation   procedure   was   evaluated   using   the   four  
analyte-­‐‑to-­‐‑standard  SILAC  ratios  acquired  in  duplicate.  Consistency  in  the  distribution  
of   individual  proteins  between  two  subcellular   fractions  was  measured  by  determing  
the  cell  culture-­‐‑specific  “Nuclear  fr.”-­‐‑to-­‐‑“Cytoplasmic  fr.”  relative  protein  abundances  
according   to   (Equation   4.3).   This   was   compared   between   the   duplicate   experiments  
performed  with  cells  either  cultured  at  37  °C  or  heat-­‐‑stressed  at  43  °C  (Figure  4.4).  As  
with  all  SILAC  ratios,  the  computed  “Nuclear  fr.”-­‐‑to-­‐‑“Cytoplasmic  fr.”  ratios  followed  
a   lognormal   distribution   and  were   characterised   by   a   positive   skew.   Therefore,   each  
calculated   ratio  was   log-­‐‑transformed   (base  2)   to   follow   a   normal   distribution,  which  
ultimately   supported   the   straightforward   visualisation   of   data   and   interpretation   of  
relationships.  The  same  approach  was  undertaken   throughout   this  study  and  protein  
ratios  were  reported  as  log-­‐‑transformed  (base  2)  values.    
  
Equation  4.3  |  Calculation  of  culture-­‐‑specific  "ʺNuclear  fr."ʺ-­‐‑to-­‐‑"ʺCytoplasmic  fr."ʺ  protein  ratios.    




Cytoplasmic  fr.       
     Cytoplasmic  fr.   Internal  standard   Internal  Standard       





Figure  4.4  |  Reproducibility  of  subcellular  fractionation.    
The  consistency  in  the  segregation  of  proteins  into  subcellular  fractions  was  compared  between  
the   duplicate   experiments   performed  with   either   unperturbed   (A;   37  °C)   or   heat-­‐‑stressed   (B;  
43  °C)   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells.   Both   scatter   plots   were   fitted   with   a   least   squares   linear  
regression  curve.  
  
Two   scatter   plots   were   generated   by   comparing   the   log-­‐‑transformed   relative  
subcellular   abundances   of   individual   proteins   between   the   duplicate   experiments  




(r2)   were   computed   to   assess   the   goodness   of   the   fitted   models.   Considering   that  
SILAC  is  particularly  suitable   for  measuring  relatively  small  protein  changes  and  the  
less  precise  extreme  outliers  can  have  major  impact  on  the  linear  regression  line,  only  
proteins   with   less   than   20-­‐‑fold   relative   difference   between   two   subcellular   fractions  
were  utilised  to  evaluate  the  reproducibility  of  the  fractionation  procedure  (Bantscheff  
et  al.,  2007).    
In   general,   both   linear   regression   lines   reflecting   the   relationships   between  duplicate  
experiments  were  characterised  by  high  R  squared   (r2)  values   (Figure  4.4).  Therefore,  
most  of  the  observed  variances  between  the  duplicate  experiments  were  explained  by  
the  modelled   linear  regression  curves,  which  thus  demonstrated  the  high  consistency  
of   the   fractionation   technique.   Furthermore,   the   infinitesimal   intercept   value   of   the  
regression   line   modelled   based   on   the   subcellular   distribution   of   proteins   in   cells  
cultured   at   37  °C   (Figure   4.4A)   illustrated   the   precision   in   the   amplitude   of   protein  
segregation   achieved.   In   contrast,   the   systematic   variance   between   duplicate  
fractionation  procedures  performed  with  heat-­‐‑stressed  cells  was  ~27.4  %  (Figure  4.4B).  
Whether   this  variance  was   introduced  by  disproportionate   fractionation   efficiency  or  
marginally   different   magnitude   of   hyperthermic-­‐‑stress   response   cannot   be   resolved  
using   the   available   information.   Thus,   elimination   of   this   systematic   variance   by  
normalisation   was   not   justified.   Furthermore,   it   was   speculated   that   the   less   than  
1.3-­‐‑fold   systematic   variance   between   duplicate   experiments   would   not   impair   the  
general  accuracy  of  quantification.    
Finally,   the   performance   of   the   workflow   to   represent   the   genuine   snapshot   of   the  




immunofluorescence  microscopy  (IF)-­‐‑based  subcellular  annotation  data  was  retrieved  
from   the   Human   Protein   Atlas   database   (HPA),   which   is   a   rich   resource   of  
complementary   localisation   information   collected   with   an   alternative   technology  
(Uhlen  et  al.,  2015).  Every  protein  in  the  HPA  database  has  been  classified  based  on  the  
reliability  of  the  annotation.  Only  “Supportive”  entries,  whose  immunostaining  pattern  
has   been   validated   either   by   multiple   antibodies   or   by   the   protein   characterisation  
information   available   in   the   UniProt   database,   were   used   for   the   comparisons   (The  
UniProt   Consortium,   2015).   Finally,   the   concurrency   of   the   annotations   assigned   by  
either  immunofluorescence  microscopy  or  mass  spectrometry  was  evaluated.    
Considering   the   continuous   nature   of   MS-­‐‑based   data,   a   frequency   histogram   was  
generated  to  reflect  the  subcellular  distribution  of  all  proteins  quantified  in  this  study  
(Figure   4.5).   In   particular,   the   quantified   proteome   of   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   was  
partitioned   into   40   bins   based   on   the   individual   “Nuclear  fr.”-­‐‑to-­‐‑“Cytoplasmic  fr.”  
ratios,  and  the  number  of  proteins  in  each  bin  was  counted.  The  histogram  bins  were  
then   coloured   according   to   the   porportion   of   proteins   with   a   primary   IF-­‐‑based  
annotation  as  cytoplasmic  (green),  mitochondrial  (blue),  nuclear  (maroon),  or  multiple  
locations  (light  grey)  (Figure  4.5).    
As   illustrated  by  the  stacked  histogram  (Figure  4.5),   the  overall  MS-­‐‑based  subcellular  
allocation  of  the  proteome  of  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  followed  a  bimodal  distribution,  
suggesting  that  most  proteins  have  a  distinct  primary  location  either  in  the  cytoplasmic  
or  nuclear  compartment.  On  the  other  hand,   less  than  1.5-­‐‑fold  difference  between  the  
compartment-­‐‑specific  abundances  was  observed  for  15.9  %  of   the  quantified  proteins,  





Figure  4.5  |  Efficiency  of  subcellular  fractionation.    
Stacked  frequency  histogram  of  the  subcellular  distribution  of  HEK2936His-­‐‑SUMO2-­‐‑T90K  proteome  at  
37  °C.   Coloured   areas   represent   the   proportion   of   proteins   with   cytoplasmic   (green),  
mitochondrial   (blue),   nuclear   (maroon),   or   unambiguous   (grey)   immunofluorescence  
microscopy  (IF)-­‐‑based  location  annotation  retrieved  from  Human  Protein  Atlas  database  (Uhlen  
et  al.,  2015).  Two  pie  charts  were  created  to  analyse  the  distribution  of  each  IF-­‐‑based  annotation  
among   proteins,   whose   relative   abundances   between   the   compartments   differed   by   at   least  
fivefold.  
  
In   general,   the   IF-­‐‑based   annotations   were   in   agreement   with   the   MS-­‐‑based   spatial  
allocation.  As  expected,  proteins  with  mainly  cytoplasmic  IF  pattern  had  a  tendency  to  
segregate   into   the   cytoplasmic   subcellular   fraction   (Figure   4.5;   green),   and   no  




4.6A−C).  Surprisingly,   the  subcellular   localisation  of  proteins  with  a  mitochondrial   IF  
pattern   was   similar   to   the   global   histogram   and   was   characterised   by   a   bimodal  
distribution   (Figure   4.5   and   Figure   4.6D;   blue).   However,   multiple   independent  
research   groups   have   claimed   that   the   phenomenon   is   a   fractionation   technique-­‐‑
specific  artifact  and  the  separation  of  mitochondria  from  nuclei  is  inefficient  (Boisvert  
et  al.,  2012;  Raychaudhuri  et  al.,  2014).  Nevertheless,  ~89.9  %  of  the  388  proteins  with  at  
least  5-­‐‑fold  greater  abundance  in  the  nuclear  fraction  were  in  agreement  with  their  IF-­‐‑
based   annotation,   thus   demonstrating   the   high   purity   of   the   fraction   of   nuclear  
proteins  (Figure  4.5;  second  pie  chart).    
In  contrast,  a  significant  amount  of  proteins  with  mainly  nuclear  IF  signal  were  more  
abundant  in  the  cytoplasmic  subcellular  fraction  of  the  MS-­‐‑based  study  (Figure  4.5  and  
Figure  4.6E−G;  maroon).  In  particular,  nuclear  IF  annotation  was  retrieved  for  25.3  %  of  
the   612   proteins,   whose   MS-­‐‑based   abundance   was   more   than   5-­‐‑fold   greater   in   the  
cytoplasmic   fraction   (Figure   4.5;   first   pie   chart).   A   detailed   inspection   revealed   that  
many   of   those   155   proteins,   such   as   the   12   subunits   of   the   proteasome   or   six  
components   of   the   Constitutive   photomorphogenesis   9   (COP9)   signalosome,   are  
present   in  both   compartments.  Moreover,   their   subcellular   stoichiometry   is  often   cell  
line-­‐‑specific  (Rivett  et  al.,  1992;  Palmer  et  al.,  1996;  Fuzesi-­‐‑Levi  et  al.,  2014).  However,  
this   type   of   annotation   discrepancy   was   observed   for   many   other   proteins   and   the  
reasons   for   those   are   still   unclear.   Therefore,   caution   should   be   applied   when  
interpretating  data,  which  is  based  on  proteins  with  ambiguous  subcellular  location.    





Figure   4.6   |   Spatial   distribution   of   the   HEK2936His-­‐‑SUMO2-­‐‑T90K   proteome   grouped   by   the   IF-­‐‑
based  location  annotation.    
››  




‹‹  Figure   4.6   |  Spatial  distribution  of   the  HEK2936His-­‐‑SUMO2-­‐‑T90K  proteome  grouped  by   the   IF-­‐‑
based  location  annotation.    
Frequency   histograms   of   the   subcellular   distribution   of   the   HEK2936His-­‐‑SUMO2-­‐‑T90K   proteome  
coloured  according   to   the   IF-­‐‑based   location  retrieved  from  the  Human  Protein  Atlas  database  
(Uhlen  et  al.,  2015).  Coloured  area  of  each  distribution  represents  the  proportion  of  proteins  that  
according   to   the   HPA   annotation   are   predominantly   located   in:   (A)   cytoplasm,   (B)   golgi  
apparatus   or   endoplasmic   reticulum,   (C)   vesicles,   (D)  mitochondria,   (E)   nucleus,   (F)   nucleus,  
but  are  excluded  from  nucleoli,  (G)  nucleoli.  The  colour  code  is  linked  to  Figure  4.5  with  green,  
blue  and  maroon  representing  subcellular  compartments  that  were  combined  into  cytoplasmic,  
mitochondrial  or  nuclear  IF-­‐‑based  annotation  groups,  respectively.  
  
 Uncovering   the   dynamics   of   the   human   proteome   in  4.2.5.
response  to  heat-­‐‑induced  proteotoxic  stress  
To  reveal  the  acute  heat  shock-­‐‑induced  global  changes  to  the  spatial  distribution  of  the  
human   proteome,   a   small   proportion   of   each   SILAC-­‐‑labelled   mixture   of   proteins  
(Figure  4.2)  was  processed  and  analysed  by  LC-­‐‑MSMS  as  described  in  Chapter  4.2.2.  In  
total,   8024   proteins   were   identified   and   63.5  %   of   them   were   quantified   in   every  
analyte.   Using   the   acquired   SILAC   ratios,   “Nuclear  fr.”-­‐‑to-­‐‑“Cytoplasmic  fr.”   values  
were   calculated   (Equation   4.3)   and   the   subcellular   distribution   was   determined   for  
5099   proteins   expressed   in   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (Supplementary   table   S2;  
Appendix   6.1).   Furthermore,   as   each   of   these   proteins  was  measured   in   all   analytes,  
potential   changes   to   their   location   or   absolute   abundance   in   cells   exposed   to   heat-­‐‑
induced  proteotoxic  stress  could  be  assessed.    
First,   the   fluctuations   in   the   absolute   amount   of   individual   proteins   in   response   to  
hyperthermia   were   examined.   To   this   end,   the   internal   standard-­‐‑normalised  




compared   between   samples   extracted   from   either   normal   or   heat-­‐‑stressed  
HEK2936His-­‐‑SUMO2-­‐‑T90K  cells.  After  a  30-­‐‑minute  treatment,  the  absolute  quantity  of  nearly  
all   proteins   remained   unaltered   (Figure   4.7;   Table   4.2).   Notably,   the   observation   is  
consistent   with   the   study   based   on   TAP-­‐‑SUMO2-­‐‑expressing   HeLa   (human   cervix  
epitheloid  carcinoma)  cells,  which  were  cultured  at  43  °C   for  an  equal  period  of   time  
(Golebiowski  et  al.,  2009).    
  
  
Figure  4.7  |  The  abundance  of  proteins  remains  unaltered  in  cells  exposed  to  heat  stress.    
Scatter   plot   of   log-­‐‑transformed   (base  2)   relative   protein   abundances   in   heat-­‐‑stressed   or  
unperturbed   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (43  °C/37  °C)   with   y-­‐‑axis   representing   the   log-­‐‑
transformed   (base  10)   summed  MS   signal   intensity.   Each   data   point   corresponds   to   a   single  
protein   and   is   displayed   using   a   colour   gradient   from   black   to   orange   according   to   the  
variability  of  its  relative  ratio  in  replicate  experiments  in  an  increasing  order.  










Log2  protein  abundance  






NME4   1.44350   3.68  




CCDC14   1.24918   26.53  
4  
HAUS  augmin-­‐‑like  complex  
subunit  2  
HAUS2   1.24670   13.76  
5   Centromere  protein  J   CENPJ   1.11334   56.22  
6   Protein  KHNYN   KHNYN   1.05692   4.21  
7   Sugar  phosphate  exchanger  3   SLC37A3   1.04173   42.93  
8  
Short-­‐‑chain  specific  acyl-­‐‑CoA  
dehydrogenase,  mitochondrial  




DUS1L   1.03051   12.19  
10  
Cytochrome  b-­‐‑c1  complex  
subunit  8  
UQCRQ   1.00845   15.09  




JMY   1.00566   26.88  
13   RILP-­‐‑like  protein  1   RILPL1   -­‐‑1.26435   18.99  
14  
Geranylgeranyl  transferase  
type-­‐‑1  subunit  beta  
PGGT1B   -­‐‑1.27096   39.82  
15  
E3  ubiquitin-­‐‑protein  ligase  
MARCH6  
MARCH6   -­‐‑1.38700   16.30  
16  
Arf-­‐‑GAP  with  SH3  domain,  
ANK  repeat  and  PH  domain-­‐‑
containing  protein  2  




ASH1L   -­‐‑1.60220   9.55  
  
a  Each  protein  quantification  is  based  on  at  least  three  peptides  
	  
b  Includes  proteins  with  coefficient  of  variation  up  to  59.35  %  




To  determine  the  subcellular  compartment-­‐‑specific  abundances  of  individual  proteins,  
two  complementary  methods  were  employed.  First,   the   internal   standard-­‐‑normalised  
abundances   of   proteins   either   in   the   nuclear   or   cytoplasmic   fraction   of   normal   cells  
were  compared  with  their  heat-­‐‑stressed  counterparts.  Thus,  the  analysis  was  designed  
to   reveal   the   temperature-­‐‑induced   subcellular   compartment-­‐‑specific   fold   changes   to  
individual   protein   abundances   (Figure   4.8   and   Figure   4.9;   abscissa).   Secondly,   the  
“Nuclear  fr.”-­‐‑to-­‐‑“Cytoplasmic  fr.”   ratios  were  utilised   to  define   the  proportion  of   the  
total   pool   of   each   protein   in   the   two   subcellular   compartments   in   normal   cells.   This  
distribution  was   then  compared   to   the  heat-­‐‑stressed  cells,  and   thus   the  proportion  of  
each   protein   pool,   whose   location   was   affected   by   the   elevated   temperature,   was  
uncovered  (Figure  4.8  and  Figure  4.9;  ordinate).    
Surprisingly,  a  substantial  movement  of  proteins  from  cytoplasmic  to  nuclear  fraction  
was  observed  (Figure  4.8  and  Figure  4.9).  In  particular,  more  than  twofold  increase  in  
the  nuclear  analyte  was  reproducibly  measured  for  1129  proteins  (Figure  4.8;  abscissa).  
As   expected,   all   SUMO   paralogs   shuttled   in   response   to   hyperthermic   stress,   as   the  
nuclear   abundance   of   SUMO1   and   SUMO2/3   increased   by   approximately   3.3-­‐‑   or  
4.4-­‐‑fold,  respectively  (Figure  4.8;  Supplementary  table  S2;  Appendix  6.1).  In  eukaryotic  
cells,  the  activation  of  heat  shock  response  is  mediated  by  a  transcription  factor  HSF1  
(Heat   shock   factor   protein  1)   that   regulates   the   expression   of   a   subset   of   genes  
encoding  molecular   chaperones   (Hartl   et   al.,   2011;   Solis   et   al.,   2016).   In   normal   cells,  
HSF1   is  held  as   an   inactive  monomer   in   the   cytoplasm  and  nucleus.  However,  upon  
cellular  stress  the  monomeric  molecules  of  HSF1  are  converted  into  high-­‐‑affinity  DNA-­‐‑






Figure  4.8  |  The  abundance  of  1129  proteins  is  increased  in  the  nuclear  fraction  by  more  than  
twofold  in  response  to  heat  shock.  
Scatter   plot   of   log-­‐‑transformed   (base  2)   relative   protein   abundance   in   the   nuclear   subcellular  
fraction   of   heat-­‐‑stressed   or   unperturbed  HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (x-­‐‑axis;   43  °C/37  °C).   Y-­‐‑axis  
represents  the  percentage  of  the  absolute  pools  of  individual  proteins  that  shuttle  in  response  to  
acute  heat  shock.  The  distributions  of  x  and  y  values  are  represented  by  frequency  histograms.  
Each   data   point   is   displayed   using   a   colour   gradient   from   black   to   orange   according   to   the  
increasing  variability  of  replicate  relative  abundance  values.  
  
genes   encoding   heat   shock   proteins   (HSPs)   (Baler   et   al.,   1993;   Sarge   et   al.,   1993;  
Akerfelt  et  al.,  2010).  In  agreement  with  these  characteristics,  the  nuclear  abundance  of  
HSF1  was  increased  by  approximately  8.2-­‐‑fold  in  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  cultured  at  





Figure  4.9  |  The  cytoplasmic  abundance  of  1231  proteins  decreased  by  more  than  twofold  in  
heat-­‐‑stressed  human  cells.  
Scatter  plot  of  log-­‐‑transformed  (base  2)  relative  protein  abundance  in  the  cytoplasmic  fraction  of  
heat-­‐‑shocked   or   normal   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (x-­‐‑axis;   43  °C/37  °C).   Y-­‐‑axis   illustrates   the  
percentage  of  individual  protein  pools  that  shift  in  response  to  heat  stress.  The  distributions  of  
both  data  sets  are  represented  by  frequency  histograms.  Each  data  point  corresponds  to  a  single  
protein   and   is   displayed   using   a   colour   gradient   from   black   to   orange   according   to   the  
increasing  variability  of  relative  abundances  between  replicate  experiments.  
  
In  contrast  with  the  general  increase  of  proteins  in  the  nuclear  subcellular  fraction,  an  
expected   global   reduction   in   the   individual   protein   quantities   was   detected   in   the  
cytoplasmic   subdivision   of   the   heat-­‐‑stressed   cells   (Figure   4.9).   Specifically,   the  
abundance  of  1231  proteins  was   reproducibly   reduced   in   the   cytoplasmic   fraction  by  




was  observed  for  11.6  %  of  quantified  proteins,  which  were  simultaneously   increased  
in   the   nuclear   and   decreased   in   the   cytoplasmic   fraction.   This   suggests   that   the  
proportion   of   proteins,   which   substantially   translocate   between   the   two   subcellular  
fractions   in   response   to   acute  heat   stress   is   low.   Indeed,   the   observation  was   further  
confirmed   by   the   second   analysis,   which   specifically   measured   the   proportions   of  
individual  protein  pools  that  shift  between  the  cell  fractions  in  response  to  heat  shock  
(Figure   4.8   and   Figure   4.9;   ordinate).   Although   the   subcellular   compartment-­‐‑specific  
abundances   of   many   proteins   were   altered   by   more   than   twice,   these   fold   changes  
were   mostly   created   by   minor   proportions   of   the   entire   protein   pools.   However,   at  
least   14.4  %   of   the   total   pool   of   2550   quantified   proteins   was   shifted   into   nuclear  
fraction   in   response   to   hyperthermia.  Moreover,   245   proteins  were   substantially   and  
reproducibly   translocated,  with  at   least  50  %  of   their  entire  pool  moving   into  nuclear  
compartment   (Figure   4.8   and   Figure   4.9).   However,   within   this   group   there  was   no  
obvious  enrichment  of  proteins  with  distinct  molecular  activity,  or  an  affiliation  with  
specific   biological   pathways   or   macromolecular   complexes   (Ashburner   et   al.,   2000;  
Ruepp  et  al.,  2008;  The  Gene  Ontology  Consortium,  2015).    
 Spatial  distribution  of  HSF1  and  SUMO2  4.2.6.
As  discovered   in  Chapter  4.2.4,   the   assigned   subcellular   annotation   of   some  proteins  
can   be   ambiguous.   One   of   these   proteins  with   inconclusive   location  was   the   critical  
regulator  of  heat  stress  response:  transcription  factor  HSF1.  As  this  project  investigates  
the  spatial  distribution  of  the  human  proteome  in  response  to  hyperthermia,  the  bona  





According   to   this  study,  nearly  85  %  of   the  HSF1  molecules  were  segregated   into   the  
cytoplasmic   fraction   of   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   cultured   at   37  °C   (Supplementary  
table   S2;   Appendix   6.1).   Conversely,   the   immunofluorescence   microscopy-­‐‑based  
annotation   retrieved   from   the   Human   Protein   Atlas   database   suggests   that   HSF1   is  
mainly   nuclear   (Uhlen   et   al.,   2015).   To   resolve   this   discrepancy,   an  
immunofluorescence  microscopy  experiment  was   conducted  using  HeLa   cells,  which  
considering  their  size,  morphology  and  better  adherence  are  more  suitable  for  the  IF-­‐‑
based  studies  than  the  HEK2936His-­‐‑SUMO2-­‐‑T90K  N3S  cells.    
Surprisingly,   under   normal   conditions,   the  majority   of   HSF1  was   detected   in   nuclei  
and   was   characterised   by   a   diffused   IF   pattern   (Figure   4.10;   37  °C).   However,   the  
immunostaining   of   HSF1   changed   considerably   in   response   to   heat-­‐‑induced  
proteotoxic   stress,   as   large   intense   foci  were   formed   (Figure   4.10;   43  °C).   These   foci,  
known   as   the   nuclear   stress   bodies,   have   been   described   to   appear   transiently   in  
stressed   human   cells   and   are   considered   to   be   the   predominant   location   of   HSF1  
accumulation  upon  heat  shock  (Cotto  et  al.,  1997).  The  generated  images  were  thus  in  
agreement  with  the  IF-­‐‑based  annotation  of  the  location  of  HSF1.    





Figure  4.10  |  HSF1  accumulates  in  subnuclear  foci  in  response  to  heat  stress.    
Unperturbed  (37  °C)  or  heat-­‐‑stressed  (43  °C)  HeLa  cells  were  analysed  by  immunofluorescence  
microscopy  with  HSF1-­‐‑specific  rabbit  polyclonal  antibody  (green).  DNA  was  stained  with  DAPI  
(maroon).  Scale  bar  represents  10  µμm.  
  
According  to  the  Western  blot  images  of  cellular  fractions,  the  unconjugated  molecules  
of   SUMO2/3   were   predominantly   segregated   into   the   cytoplasmic   fraction   of   the  
HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  (Figure  4.3A  and  B).  Although  the  protein  is  not  annotated  in  
the  Human  Protein  Atlas  database,  the  IF-­‐‑based  information  on  SUMO2/3  localisation  
can  be  found  from  the  literature,  which  suggests  that  the  protein  is  mainly  nuclear  and  
accumulates  in  the  subnuclear  PML  bodies  (Vertegaal  et  al.,  2004;  Tatham  et  al.,  2008;  
Uhlen   et   al.,   2015).   Another   immunofluorescence   microscopy   experiment   was   thus  
performed   to   resolve   this   apparent  discrepancy  and  pinpoint   the  genuine   location  of  
SUMO2/3  in  normal  and  heat-­‐‑stressed  human  cells.  
Consistent   with   the   previous   IF-­‐‑based   studies,   predominantly   nuclear   SUMO2/3-­‐‑




the   recruitment  of   SUMO2/3   to   subnuclear  bodies  was   illustrated  by   the   existence  of  
SUMO2/3-­‐‑containing   foci.   However,   similarly   to   the   HSF1,   the   image   was   also  
characterised  by  a  diffused  IF  pattern.  Interestingly,  most  of  the  diffuse  SUMO2/3  was  
decreased   and  many   small   subnuclear   foci   were   formed   after   the   activation   of   heat  
shock  response  (Figure  4.11;  43  °C).    
  
Figure  4.11  |  SUMO2/3  accumulates  in  subnuclear  foci  in  response  to  heat  stress.    
The   localisation   of   SUMO2/3   in   unperturbed   (37  °C)   or   heat-­‐‑stressed   (43  °C)   human   cells  
assessed  by  immunofluorescence  microscopy  using  a  rabbit  monoclonal  antibody  (green).  DNA  
was  stained  with  DAPI  (maroon).  Scale  bar  represents  10  µμm.  
  
The   produced   immunofluorescence   microscopy   images   thus   suggest   that   HSF1   and  
SUMO2/3  are  predominantly  nuclear   irrespective  of   the   culturing   temperature  of   the  
human   cells.   Moreover,   both   proteins   accumulate   in   subnuclear   foci   in   response   to  
hyperthermic  stress.  Interestingly,  this  recruitment  into  subnuclear  foci  correlates  with  
the   increased   amount   of   SUMO2/3   and   HSF1   measured   in   the   nuclear   fraction   of  




 Subcellular   localisation   and   functional   characterisation   of  4.2.7.
targets  of  SUMO2  
There  is  a  consensus  that  sumoylation  occurs  predominantly  in  the  nucleus  (Kamitani  
et   al.,   1997;   Rodriguez   et   al.,   2001).   However,   a   comprehensive   high-­‐‑throughput  
comparison  between  the  spatial  distributions  of  sumoylated  or  unmodified  molecules  
of  individual  proteins  has  not  been  conducted.  Furthermore,  the  equilibrium  of  protein  
localisation,  either  SUMO-­‐‑conjugated  or  unmodified,  could  be  affected  in  response  to  
stress-­‐‑inducing  stimuli,  such  as  the  heat  shock.    
To   quantitatively   compare   the   spatial   distributions   of   sumoylated   proteins   between  
unperturbed   and   heat-­‐‑stressed   human   cells,   the   analytical   samples   generated   in  
Chapter  4.2.2   (Figure   4.2)   were   processed   according   to   the   SUMOKGG   workflow  
developed   in   Chapter  3   (Figure   3.8).   The   SUMO   remnant-­‐‑modified   Gly-­‐‑Gly-­‐‑Lys-­‐‑
containing   peptides  were   then   analysed   by   LC-­‐‑MSMS  with   settings   adjusted   for   the  
optimal   detection,   identification   and   quantification   of   low   abundance   sumoylated  
sequences.    
In   total,   612   SUMO2   modification   sites   from   383   proteins   were   identified   from  
HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  cultured  at  37  °C  (Supplementary  table  S3;  Appendix  6.1).  As  
anticipated,  approximately  88.5  %  of  the  sumoylated  lysines  were  detected  solely  from  
the   nuclear   fraction   (Figure   4.12;   abscissa).   This   is   consistent   with   the  Western   blot  
analyses   described   in   Chapter  4.2.3   (Figure   4.3).   Functional   characterisation   of   these  
383  modified  proteins  revealed  that  nearly  40.0  %  of  them  are  involved  in  transcription  






Figure  4.12  |  6His-­‐‑SUMO2T90K  conjugates  localise  to  the  nuclear  fraction  of  unstressed  cells.    
Scatter  plot  with  subcellular  localisations  of  individual  sumoylated  proteins  (x-­‐‑axis)  compared  
to   the   spatial   distributions   of   the   total   pools   of   corresponding   proteins   (y-­‐‑axis)   in  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   cultured   at   37  °C.   The   kernel   density   plots   display   the   probability  
density   function   of   the   subcellular   distribution   of   either   SUMO-­‐‑modified   (top;   filled   area)   or  
total   (right;   filled  area)  pool  of   the   sumoylated  proteome.  The  probability  density   function  of  
the   localisation   of   all   5099   proteins   quantified   in   cells   cultured   at   37  °C   is   illustrated   by   the  
dashed  line  (right).    
  
proteins  linked  with  fundamental  cellular  mechanisms,  such  as  cell  cycle  progression,  
RNA  processing,  or  DNA  replication,  recombination  and  repair  (Figure  4.13).    





Figure  4.13  |  Substrates  of  6His-­‐‑SUMO2T90K  are  functionally  related.    
Bar   chart   showing   the   significantly   overrepresented   biological   functions   of   383   or   2311  
sumoylated  proteins  identified  from  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  cultured  at  37  °C  (grey)  or  43  °C  
(orange),   respectively.   The   number   of   proteins   in   each   functionally   related   group   is   depicted  
above  the  bars.  Triplicate  sets  of  383  (black)  or  2311  (red)  randomly  selected  proteins  served  as  a  
control.  Error  bars  correspond  to  standard  deviations.  
  
Direct   comparisons  between   the   locations  of   sumoylated  or  unmodified   counterparts  
of   the   corresponding   proteins   revealed   a   diverse   spatial   positioning   of   the   non-­‐‑
modified   molecules,   despite   the   predominantly   nuclear   localisation   of   the   SUMO-­‐‑
bound  counterparts  (Figure  4.12;  ordinate).  For  instance,  the  non-­‐‑modified  versions  of  
more   than   a   quarter   of   SUMO   substrates   were   segregated   predominantly   into   the  
cytoplasmic   fraction   (Figure   4.12;   bottom   right   section).   Interestingly,   ~42  %   of   these  
proteins   were   components   of   ribosomal   subunits.   The   ribosome   is   a   large,  
cytoplasmically  located,  macromolecular  complex  that  carries  out  protein  synthesis  in  




a   tightly   regulated   process,   in   which   the   maturation   and   assembly   of   individual  
components   is   accompanied   by   the   transport   of   these   pre-­‐‑ribosomal   particles   from  
nucleoli   to   cytoplasm   (Kressler   et   al.,   2010).   Interestingly,   a   connection   between   the  
early   assembly   of   pre-­‐‑ribosomes   and   sumoylation   has   been   recognised   in   yeast   and  
human  cells,   thus  explaining  the  distinct  partitioning  of  SUMO-­‐‑conjugated  molecules  
into  the  nuclear  subcellular  fraction  (Panse  et  al.,  2006;  Haindl  et  al.,  2008;  Finkbeiner  et  
al.,  2011).  
In   response   to  heat   shock,   the  number  of   lysines   conjugated   to  SUMO2   increased  by  
more   than  13-­‐‑fold.   In   total,   8262  modification   sites  were  detected   from  2311  proteins  
extracted   from   heat-­‐‑stressed   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (Supplementary   table   S3;  
Appendix  6.1).  Surprisingly,  ~93.7  %  of  these  Gly-­‐‑Gly-­‐‑conjugated  lysines  were  detected  
exclusively  after  heat  shock.  Similarly  to  the  distribution  of  the  sumoylated  proteome  
in   unperturbed   cells,   nearly   all   SUMO2   remnant-­‐‑containing   branched   peptides  were  
identified  from  the  nuclear  fraction  (Figure  4.14;  abscissa).  However,  the  distributions  
of   the   non-­‐‑modified   counterpart   proteins   were   also   shifted   towards   the   nuclear  
compartment   in   response   to   cellular   stress   (Figure   4.14;   ordinate).   In   particular,   the  
spatial   partitioning   of   the   non-­‐‑modified   pool   of   the   heat-­‐‑induced   sumoylated  
proteome  was  bimodal,  with  more  than  65  %  of  the  proteins  locating  into  the  nuclear  
fraction   and   nearly   a   quarter   of   them   being   balanced   between   the   two   subcellular  
compartments   (Figure   4.14;   ordinate).   Furthermore,   a   subtle   overrepresentation   of  
SUMO2  substrates  was  observed  among  the  245  proteins,  whose  location  was  affected  
the  most  in  response  to  heat  shock  (Figure  4.8  and  Figure  4.9).  In  particular,  ~48.6  %  of  





Figure  4.14  |  SUMO2-­‐‑modified  proteins  segregate   into   the  nuclear  fraction  of  heat-­‐‑stressed  
human  cells.    
Scatter  plot  with  subcellular  localisations  of  individual  sumoylated  proteins  (x-­‐‑axis)  compared  
to  the  spatial  distributions  of  the  total  pools  of  corresponding  proteins  (y-­‐‑axis)  in  heat  shocked  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells.  The  kernel  density  plots  display   the  probability  density   function  of  
the   subcellular   distribution   of   either   SUMO-­‐‑conjugated   (top;   filled   area)   or   total   (right;   filled  
area)  pool  of   the  sumoylated  proteome.  The  probability  density   function  of   the   localisation  of  
all  5099  proteins  quantified  in  cells  cultured  at  43  °C  is  illustrated  by  the  dashed  line  (right).  
  
Characterisation  of  the  2311  proteins  conjugated  to  SUMO2  in  response  to  heat  shock  
revealed  an  enrichment  of  protein  groups  associated  with  the  same  biological  functions  
as   identified   for   unstressed   human   cells   (Figure   4.13).   However,   the   number   of  
proteins   in   each   functionally   related   group   was   increased   on   average   by   fourfold.  
These   findings   suggest   that   protein   sumoylation   functions   in   specific   fundamental  
cellular   processes   and   the   importance   of   SUMO   conjugation   is   highlighted   in   cells  




 Extent   of   SUMO2   modification   of   individual   proteins   in  4.2.8.
human  cells    
Gel   electrophoretic   pattern   of   many   purified   sumoylated   conjugates   has   led   to   the  
suggestion   that  proteins  can  contain  multiple  SUMO  modification  sites   (Psakhye  and  
Jentsch,   2012).   Indeed,   nearly   a   third   (31.8  %)   of   the   sumoylated   proteins   extracted  
from  unperturbed  HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   contained  multiple   lysines,  which   can   be  
conjugated   to   SUMO2   (Figure   4.15A;   grey).   For   instance,   eleven   lysines   of   ZNF451  
were   modified   in   cells   cultured   at   37  °C   (Figure   4.15B).   Recently,   structural   and  
biochemical  studies  have  revealed  that  ZNF451  is  a  SUMO  E3  ligase,  and  can  undergo  
extensive  automodification  (Cappadocia  et  al.,  2015b;  Eisenhardt  et  al.,  2015).  Likewise,  
seven   Gly-­‐‑Gly-­‐‑lysines   were   identified   from   another   putative   SUMO   E3   ligase:  
Transcription   intermediary   factor   1-­‐‑β   (TRIM28),   which   can   also   undergo  
autosumoylation   (Figure   4.15B)   (Ivanov   et   al.,   2007).  Many   other   components   of   the  
SUMO  conjugation  machinery,  such  as  the  SUMO-­‐‑activating  enzyme  subunit  2  (SAE2)  
and  all  SUMO  paralogs,  contained  at  least  four  modification  sites  at  37  °C  (Matunis  et  
al.,   1996;   Johnson   et   al.,   1997;   Lapenta   et   al.,   1997;   Desterro   et   al.,   1999).   The   list   of  
proteins   containing   multiple   SUMO2   modification   sites   was   also   enriched   in   well-­‐‑
established   SUMO   target   proteins,   such   as   Non-­‐‑POU   domain-­‐‑containing   octamer-­‐‑
binding  protein  (NONO)  with  ten,  Scaffold  attachment  factor  B2  (SAFB2)  with  seven,  
and  General   transcription   factor   II-­‐‑I   (GTF2I)  with   five  Gly-­‐‑Gly-­‐‑lysines   (Figure   4.15B)  
(Becker   et   al.,   2013).   Furthermore,   four   heterogenous   nuclear   ribonucleoproteins  
(hnRNPs):   M   (HNRNPM),   C1/C2,   (HNRNPC),   A0   (HNRNPA0)   and   A2/B1  
(HNRNPA2B1)  contained  at   least   four  sites,  with  hnRNP  M  and  hnRNP  C1/C2  being  





Figure   4.15   |  Number   of   SUMO2  modification   sites   identified  per   target   protein   increases  
after  acute  heat  stress.    
(A)  Bar  chart  displaying  the  number  6His-­‐‑SUMO2T90K  acceptor   lysines   identified  per  substrate  
protein   from   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   cultured   either   at   37  °C   (grey)   or   43  °C   (orange).   (B)  
Scatter   plot   illustrating   the   number   of   Gly-­‐‑Gly-­‐‑lysines   modified   per   target   protein   in  
unperturbed  (x-­‐‑axis)  or  heat-­‐‑stressed  (y-­‐‑axis)  human  cells.  Proteins  with  no  heat-­‐‑induced  effect  
on   the   amount   of   SUMO2   modification   sites   map   onto   grey   dashed   line.   Total   number   of  
sumoylated  or  unmodified  proteins  in  each  condition  are  shown  above  (37  °C)  or  next  to  (43  °C)  
the  scatter  plot.  
  
In  general,  a  greater  number  of  SUMO2  modification  sites  per  protein  was  observed  in  
heat-­‐‑stressed   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (Figure   4.15B)   and   the   proportion   of   proteins  
accommodating   multiple   Gly-­‐‑Gly-­‐‑lysines   increased   to   ~61  %   (Figure   4.15A;   orange).  
For   instance,   GTF2I   contained   60,   Poly   [ADP-­‐‑ribose]   polymerase   1   (PARP1)   had   59,  
and  ZNF451  contained  44  sumoylation  sites.  PARP1   is  also  a  well-­‐‑established  SUMO  




al.,   2009;   Martin   et   al.,   2009;   Messner   et   al.,   2009).   Moreover,   73   proteins   with   no  
detectable  Gly-­‐‑Gly-­‐‑lysines  at  37  °C  contained  more  than  ten  SUMO2-­‐‑modified  residues  
after  heat  shock,  and   for  1969  proteins   the  SUMO  modification  was  detected   in  heat-­‐‑
stressed   cells   only   (Figure   4.15B).   The   number   of   SUMO2   modification   sites   was  
decreased  in  51  proteins  corresponding  to  less  than  2.2  %  of  the  sumoylated  proteome.  
For   instance,   the  seven  SAFB2  lysines  modified   in  unperturbed  cells  were  reduced  to  
five   in   response   to   proteotoxic   stress.   This   is   consistent   with   proteomic   studies  
demostrating   decreased   sumoylation   of   SAFB2   in   human   cells   exposed   to   heat   or  
treated  with  MG132  (Golebiowski  et  al.,  2009;  Lamoliatte  et  al.,  2014).    
Given   the   methodological   limitations   of   bottom-­‐‑up   proteomics,   for   most   proteins   it  
was   not   possible   to   determine   whether   the   multisite   sumoylation   occurs  
simultaneously.   However,   as   Lys-­‐‑C   is   inhibited   by   posttranslational   modification   of  
target   residues,   71   unique   peptide   sequences   from   39   proteins   were   identified   to  
contain  concurrent  sumoylation  of  adjacent  lysines  (Supplementary  table  S4;  Appendix  
6.1).   Most   of   these   multiply   modified   peptides   were   detected   exclusively   after   heat  
shock,  and   from  proteins   that   contained  many  Gly-­‐‑Gly-­‐‑lysines,   such  as  hnRNPs   (A0,  
A2/B1,   C1/C2,   F,   L   and   M),   PARP1,   E3   SUMO-­‐‑protein   ligase   NSE2,   and   all   SUMO  
paralogs.  However,  multisite  modification  of  SUMO  molecules  was  also  detected  from  
cells  cultured  at  37  °C  (Supplementary   table  S4;  Appendix  6.1).  Lys11   is   the  major  site  
involved   in   chain   formation   on   SUMO2   and   SUMO3   (Tatham   et   al.,   2001),   and   the  
6His-­‐‑SUMO2T90K-­‐‑modified   Lys11   of   both   paralogs   was   found   in   all   four   analytes.   In  
addition,  several  combinations  of  multiply  modified  peptides  of  SUMO2  and  SUMO3  
were  detected,  including  two  doubly  modified  peptides  containing  Lys11  together  with  




suggesting   that   multiple   branching   patterns   may   occur   (Supplementary   table   S4;  
Appendix  6.1).    
 Sequence  context  of  SUMO2  modification  sites  4.2.9.
Initial   studies   inspecting   the   amino   acid   residues   targeted   for   SUMO   conjugation  
suggested   that   the   ability  of   a   lysine   to  be   sumoylated  depends  on   its   residence   in   a  
conserved  sequence  environment  ψKxE,  where  ψ  and  x  represent  hydrophobic  or  any  
residues,  respectively  (Rodriguez  et  al.,  2001).  Consequently,  subsequent  investigations  
focused   predominantly   on   these  motifs   and   the   determination   of   SUMO   target   sites  
was  strongly  biased  towards  lysines  residing  in  the  described  environment.  In  contrast,  
the   current   resource   of   SUMO2   modification   sites   was   compiled   using   high-­‐‑
throughput   MS-­‐‑based   proteomics   methodology   and   thus,   enabled   the   detection   of  
modified   lysines   without   previously   determined   sequence   context   bias   (Choudhary  
and  Mann,  2010).  Furthermore,  the  relatively  large  size  of  the  acquired  data  sets  made  
them  suitable  for  the  inspection  and  plausible  discovery  of  novel  sequence  consensuses  
utilising  robust  statistical  significance  tests.    
Therefore,   sequence   motifs   were   visualised   using   pLogo,   a   web-­‐‑based   software  
application   (O'ʹShea   et   al.,   2013).  Analysis   of   612   unique   diGly-­‐‑lysines   detected   from  
human   cells   cultured   at   37  °C   validated   the   preferential   modification   of   residues  
residing  in  the  consensus  motif  ψKxE  (Figure  4.16A)  (Rodriguez  et  al.,  2001).  However,  
Val   and   Ile   were   the   only   overrepresented   hydrophobic   residues   N-­‐‑terminal   to   the  
target   lysine   (position   -­‐‑1).   Intriguingly,   despite   the   apparent   high   frequency   of  






Figure  4.16  |  Lysines  residing  in  two  distinct  sequence  motifs  are  preferentially  targeted  for  
SUMO2  conjugation  after  heat  shock.    
pLogo  representation  of  the  sequence  context  of:   (A)  612  lysines  modified  by  6His-­‐‑SUMO2T90K  
in   cells   cultured   at   37  °C,   or   (B)   7815   Gly-­‐‑Gly-­‐‑lysines   that   increased   in   abundance   or   were  
detected  exclusively  from  cells  exposed  to  heat  stress.  Y-­‐‑axes  correspond  to  the  log-­‐‑odds  of  the  
binomial   probability   (π)  with   significance   threshold   values   of   3.68   (p   <   0.05)  marked   by   red  
horizontal  lines.  Note  the  different  scales  of  y-­‐‑axes.  
  
26.8  %  of   the   identified   lysines  matched   strictly   to   this   pattern   (Figure   4.17A  and  B).  
Another   29.6  %   of   the   Gly-­‐‑Gly-­‐‑Lys-­‐‑containing   sequences   were   characterised   by   a  
partial   consensus   motif,   which   accommodated   either   a   valine   or   an   isoleucine   in  
position  -­‐‑1,  or  a  glutamic  acid  two  amino  acids  C-­‐‑terminal  to  the  target  lysine  (position  
+2).  Surprisingly,  nearly  a  quarter  of  the  sites  sumoylated  in  unperturbed  cells  did  not  
conform  to  any  significant  consensus,  thus  demonstrating  the  importance  of  unbiased  
identification  of  sites  of  SUMO2  modification  (Figure  4.17A  and  B).    
Analysis   of   the   7815   unique   Gly-­‐‑Gly-­‐‑Lys-­‐‑containing   sequences,   which   increased   in  
abundance  or  were  detected  exclusively  after  heat  shock,  uncovered  many  additional  
aspects   of   the   widely   accepted   core   motif   (Figure   4.16B).   Similarly   to   the   sequence  






Figure  4.17  |  Distribution  of  the  sequence  motifs  targeted  by  SUMO2  modification.    
››  




‹‹  Figure  4.17  |  Distribution  of  the  sequence  motifs  targeted  by  SUMO2  modification.    
(A)  Bar  chart  showing  the  numbers  of  Gly-­‐‑Gly-­‐‑lysines  identified  from  unstressed  (grey)  or  heat-­‐‑
shocked   (orange)   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   residing   in   sequence   contexts   conforming   to  
complete   (strictly   [V/I]KxE)   or   partial   (~[V/I]KxE)   conventional   consensus   motifs  
overrepresented   in   unperturbed   cells;   or   to   inverted   ([E/D]xK)   or   partial   conventional  
(~[V/I/L]Kx[E/D])  consensuses  preferred  exclusively  after  heat  shock.  SUMO2  sites  that  do  not  
conform   to   any   consensus   are   counted   separately   (Residual).   (B)   Stacked   bar   chart  
demonstrating   the   cumulative   percentage   of   SUMO2   modification   sites   conforming   to   the  
sequence   motifs   described   in   panel  A,   and   identified   either   from   unstressed   (37  °C)   or   heat  
shocked   (43  °C)   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells.   (C)   Box   plot   illustrating   the   distributions   of   the  
Andromeda   scores   of   Gly-­‐‑Gly-­‐‑modified   peptides   grouped   by   the   sequence   contexts   of   the  
target  lysines  as  in  panel  A.  
  
overrepresented.  However,  in  addition  to  Val  and  Ile,  the  occurrence  of  Leu  in  position  
-­‐‑1   was   also   significantly   frequent.   Furthermore,   the   presence   of   a   glutamic   acid   in  
position  +2  was  accompanied  by  Asp,  although,  the  occurrence  of  Glu  was  more  than  
threefold  greater  (Figure  4.16B).  
The   preferential   modification   of   lysines   in   an   inverted   sumoylation   consensus  
sequence  [E/D]xKψ  was  suggested  based  on  a  small-­‐‑scale  proteomic  study  (Matic  et  al.,  
2010).  The  proposed   inverted  consensus  was  overrepresented,  but  exclusively  among  
the   Gly-­‐‑Gly-­‐‑Lys-­‐‑containing   sequences   modified   after   the   exposure   to   elevated  
temperature.  Hydrophobic  residues  did  not  significantly  accompany  the  target  lysines  
at   their   C-­‐‑terminal   side.  Moreover,   the   frequency   of   acidic   residues  Asp   and  Glu   in  
position   -­‐‑2  was   nearly   equal,   in   contrast   to   the  more   prevalent   occurrence   of  Glu   in  
position   +2   of   the   conventional   sumoylation   consensus   motif.   Thus,   the   inverted  
sequence   environment,  which   is   preferentially  modified   in   heat-­‐‑stressed   cells   can   be  




the   target   lysines  with   sequence   environments   conforming   to   the   inverted   consensus  
motif   contained   a   glutamic   acid   in   position   +2.   This   is   consistent   with   a   mixed  
population   of   sumoylated   sequences   matching   either   to   conventional   or   inverted  
sumoylation  consensus  motif.    
Although   the   number   or   diGly-­‐‑modified   lysines   that   conformed   strictly   to   the  
consensus   motif   ψKxE   increased   by   more   than   threefold   in   response   to   heat   stress  
(Figure   4.17A;   strictly   [V/I]KxE),   these   548   target   sites   corresponded   to   only   7.0  %  of  
the  overall  heat-­‐‑induced  sumoylated  lysines  (Figure  4.17B).  Another  26.7  %  and  28.1  %  
of  the  modified  sites  conformed  to  either  partial  conventional  or  inverted  sumoylation  
consensus  motif,  respectively.  The  number  of  SUMO2-­‐‑modified  peptides  that  did  not  
conform  to  any  significant  consensus  was   increased  by  ~20-­‐‑fold,  constituting   to  more  
than  38  %  of  all  sequence  contexts  modified  in  heat-­‐‑stressed  cells.  (Figure  4.17A  and  B).  
Analysis  of  the  Andromeda  scores  (the  metric  for  quality  of  the  sequence  information)  
of   diGly-­‐‑modified   peptides   revealed   that   the   median   score   of   sequences   containing  
heat-­‐‑induced   SUMO2  modification   sites  was   considerably   lower   (Figure   4.17C).   This  
suggests   that   their  MSMS  spectra   contained   scarce   fragmentation   information,  which  
could   be   a   consequence   of   either   low   abundance   or   ionisation   efficiency.   In   normal  
cells,   a   similar   phenomenon  was   observed   only   for  Gly-­‐‑Gly-­‐‑Lys-­‐‑containing   peptides  
not  conforming  to  any  consensus  motif  (Figure  4.17C).    
Dependence   of   SUMO   modification   on   prior   protein   phosphorylation   has   been  
described   for   several   substrates,   such  as  HSF1   (Hietakangas   et   al.,   2003),  Peroxisome  
proliferator-­‐‑activated   receptor   gamma   (PPAR-­‐‑γ)   (Yamashita   et   al.,   2004),   or   MEF2  




a   phosphorylation-­‐‑dependent   sumoylation   motif   (PDSM),   which   accommodates   a  
conventional   SUMO   consensus   sequence   two   residues   N-­‐‑terminal   to   the   proline-­‐‑
directed  phosphorylation  site  (ψKxExxSP)  (Hietakangas  et  al.,  2006).  In  this  study,  191  
SUMO2  remnant  diGly-­‐‑containing  peptides  were  also  phosphorylated  (Supplementary  
table  S5;  Appendix  6.1).  The  phosphate-­‐‑modified  residue  could  be  found  at  nearly  any  
position  in  proximity  to  the  sumoylation  site,  but  was  most  prevalent  five  amino  acids  
C-­‐‑terminal   to   the  diGly-­‐‑lysine   (Figure  4.18;  position  +5).  Approximately  78.3  %  of   the  
sites   at   position   +5   conformed   to   serine-­‐‑proline   (SP)   or   threonine-­‐‑proline   (TP)  
phosphorylation   sequence   and   the   amino   acid   context   of   12   Gly-­‐‑Gly-­‐‑modified  
phosphorylated   peptides   matched   strictly   to   the   PDSM   motif.   A   doubly   modified  
peptide   of   a   Transcriptional   activator   Myb   was   sumoylated   at   Lys527   and  
  
  
Figure  4.18  |  Occurrence  of  phosphorylated  residues  in  proximity  to  the  sumoylated  lysine.    
Bar  chart   illustrating   the  number  unique  peptide  sequences  with  a  phosphorylated  residue  at  
the  designated  position  (-­‐‑11  to  -­‐‑1,  or  1  to  11)  relative  to  the  SUMO  Gly-­‐‑Gly-­‐‑remnant  modified  
lysine   (position   0).   Striped   area   represents   the   proportion   of   sequences   with   corresponding  
unphophorylated  Gly-­‐‑Gly-­‐‑Lys-­‐‑containing  peptides  also  identified  in  this  study.  




phosphorylated   at   Ser532   in   a   sequence   context   of   IKxExxSP,   suggesting  
phosphorylation-­‐‑dependent  sumoylation  (Figure  4.19;  top  panel).  The  observation  was  
further   confirmed   by   re-­‐‑analysing   MS   data   files   containing   high-­‐‑resolution   MSMS  
spectra   of   phosphopeptide-­‐‑enriched   samples   using   a   sequence   database   of   virtual  
linearised   branched  peptides   (Matic   et   al.,   2008;  Matic   and  Hay,   2012;  Mertins   et   al.,  
2013).   With   this   approach,   the   same   phosphorylated   peptide   was   also   shown   to   be  
modified  by  the  tryptic  remnant  of  the  wild-­‐‑type  SUMO2  (Figure  4.19;  bottom  panel).  
Furthermore,   several   independent   biochemical   studies   have   demonstrated   either   the  
sumoylation  of  Lys527  or  phosphorylation  of  Ser532  of  Myb  (Aziz  et  al.,  1995;  Bies  et  al.,  
2002;   Dahle   et   al.,   2003;   Sramko   et   al.,   2006;   Pani   et   al.,   2008).   Although,   the  
dependency   of   Lys527   sumoylation   on   prior   phosphorylation   of   Ser532   has   not   been  
explored.  Another   12  Gly-­‐‑Gly-­‐‑modified  peptides  were  phosphorylated  at  position  +2  
or   -­‐‑2   relative   to   the   sumoylated   lysine   (Figure   4.18).   Interestingly,   phosphate  
modification  of  either  of  these  residues  generates  a  negative  charge  at  a  position,  which  
in  sequences  conforming  to  conventional  or  inverted  sumoylation  consensus  motifs  are  
occupied  by  acidic  Glu  or  Asp  residues.    





Figure   4.19   |   Sequence   context   of   a   phosphate-­‐‑modified   sumoylated   peptide   of   Myb  
conforms  to  PDSM  motif.    
Annotated  MSMS  spectra  of  a  Ser532-­‐‑phosphorylated  peptide  of  Transcriptional  activator  Myb  
with  Lys527  modified  by  either  Gly-­‐‑Gly  remnant  of  6His-­‐‑SUMO2T90K  (top),  or  C-­‐‑terminal  tryptic  
fragment   of   endogenous   SUMO2   (bottom).   B-­‐‑   (dark   blue)   and   y-­‐‑   (red)   ions   correspond   to  
fragment   ion  series  extending  from  the  N-­‐‑  or  C-­‐‑terminus  of   the  peptide,  respectively.   Internal  
fragments,   and   ions   diagnostic   for   diGly  modification   or  with   a   loss   of   neutral  molecule   are  
illustrated  in  purple,  pink  or  yellow,  respectively.  
  




 Secondary  structure  context  of  the  sumoylated  lysines  4.2.10.
SUMO-­‐‑conjugating   enzyme  Ubc9   is   able   to  directly   recognise   and  bind   conventional  
sumoylation   consensus   motif   ψKxE,   if   presented   in   an   extended   conformation  
(Rodriguez  et  al.,  2001;  Sampson  et  al.,  2001;  Bernier-­‐‑Villamor  et  al.,  2002).  Consistent  
with   this   observation,   the   majority   of   Gly-­‐‑Gly-­‐‑modified   lysines   in   a   sequence  
environment   conforming   to   partial   conventional   consensus   motif   (~[V/I]KxE)   were  
predicted  to  reside  outside  the  regular  secondary  structure  elements,  such  as  α-­‐‑helices  
or  β-­‐‑strands   (Figure  4.20;   coil).  More   than  60  %  of  6His-­‐‑SUMO2T90K  modification  sites  
resided   in   coils   irrespective   of   the   sequence   environment   of   the   target   lysine   or  
culturing   temperature   of   the   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells.   However,   the   proportion   of  
acceptor  lysines  found  in  helices  was  increased  among  Gly-­‐‑Gly-­‐‑lysines  not  conforming  
to  any  known  consensus  sequence  or  in  cells  exposed  to  heat  stress  (Figure  4.20).    
Secondary   structure   elements   of   a   protein   can   affect   the   selection   between   lysines  
targeted  for  SUMO  conjugation.  For  instance,  Ubc9-­‐‑dependent  in  vitro  sumoylation  of  
Ubiquitin-­‐‑conjugating  enzyme  E2  K   (E2-­‐‑25K)  occurs   exclusively  on  Lys14,  despite   the  
non-­‐‑consensus  sequence  context  of  the  target  residue  (Pichler  et  al.,  2005).  This   lysine  
resides   in  an  α-­‐‑helix  and   is   located  between   two  non-­‐‑modified   consensus   sites:  Lys10  
and   Lys18.   An   unstructured   peptide   corresponding   to   the   N-­‐‑terminal   sequence   of  
E2-­‐‑25K,  however,  is  preferentially  modified  at  consensus  site  Lys10  (Pichler  et  al.,  2005).  
Confirming   these   in   vitro   observations,   Lys14   of   E2-­‐‑25K   alone   was   conjugated   to  
6His-­‐‑SUMO2T90K   in   the  unfractionated  sample  of  HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   cultured  at  
37  °C.   However,   both   Lys10   and   Lys14   were   sumoylated   in   cells   cultured   at   43  °C  
(Supplementary   table   S3),   suggesting   that   the   N-­‐‑terminal   α-­‐‑helix   of   a   proportion   of  





Figure   4.20   |   Majority   of   6His-­‐‑SUMO2T90K-­‐‑conjugated   lysines   reside   outside   regular  
secondary  structure  elements.    
Dot  chart  demonstrating  the  propensity  of  6His-­‐‑SUMO2T90K-­‐‑modified  lysines  to  reside  in  helical  
(blue),   beta   strand   (yellow)   or   coiled   (grey)   regions   of   the   protein   as   assigned   by   JPred4  
secondary  structure  prediction  server  (Drozdetskiy  et  al.,  2015).  Error  bars  correspond  to  95  %  
confidence  intervals.  
  
 SUMO2  modification  of  macromolecular  protein  complexes  4.2.11.
A   functional   SUMO   conjugation   pathway   is   required   for   the   viability   of   most  
eukaryotic   organisms   (Nacerddine   et   al.,   2005).   However,   lack   of   phenotypes   of  
particular   proteins   deficient   in   SUMO   modification   has   led   to   the   proposal   that  
sumoylation   may   target   macromolecular   groups,   instead   of   individual   proteins  
(Psakhye   and   Jentsch,   2012).   As   evidenced   in   Chapter  4.2.7,   most   SUMO   conjugates  
clustered   into   functionally   related  categories  and   the  number  of  modified  proteins   in  
each   class  was   increased   considerably   in   response   to  proteotoxic   stress   (Figure   4.13).  
Gene   Ontology   cellular   component-­‐‑based   annotation   of   these   substrates   using  
PANTHER   Classification   System   revealed   that   SUMO   conjugates   were  




Figure   4.22)   (The   Gene   Ontology   Consortium,   2015;   Mi   et   al.,   2016).   As   expected,  
several  of  these  protein  groups  process  RNA  or  function  in  DNA  transcription,  such  as  
the   spliceosomal   small   nuclear   ribonucleoproteins   (snRNPs)   or   RNA   polymerase   III  
transcription   factors   (Figure   4.21).   Moreover,   many   components   of   macromolecular  
complexes  involved  in  DNA  replication  and  repair,  or  remodelling  of  chromatin  were  
sumoylated  in  response  to  heat  stress  (Figure  4.22).  For  instance,  23  of  the  30  replisome  
complex  proteins   contained  Gly-­‐‑Gly-­‐‑lysines   in   cells   cultured   at   43  °C   (Figure   4.22A).  
Proliferating  cell  nuclear  antigen  (PCNA)  is  one  of  the  best-­‐‑studied  components  of  the  
replisome,   whose   sumoylation   at   Lys164   facilitates   the   suppression   of   unscheduled  
homologous   recombination   during   the   replication   of   S.  cerevisiae   or   human   DNA  
(Papouli   et   al.,   2005;   Pfander   et   al.,   2005;   Gali   et   al.,   2012;   Moldovan   et   al.,   2012).  
Interestingly,   Lys164-­‐‑modified   PCNA   was   one   of   the   few   members   of   the   replisome  
complex  conjugated   to  SUMO2   in  unperturbed  and  heat-­‐‑stressed  HEK2936His-­‐‑SUMO2-­‐‑T90K  
cells  (Figure  4.22A;  Supplementary  table  S3;  Appendix  6.1).  Approximately  72  %  of  the  
43  Polycomb  group   (PcG)   epigenetic   repressors  were   sumoylated   in   cells   cultured   at  
43  °C,   with   the   majority   of   components   containing   multiple   Gly-­‐‑Gly-­‐‑lysines   (Figure  
4.22B).   PcG   proteins   assemble   into   two   principal   multiprotein   polycomb   repressive  
complexes   (PRC1   and   PRC2)   that   collaborate   to   silence   the   expression   of   numerous  
target  genes  (Schwartz  and  Pirrotta,  2013).  Nearly  all  core  components  of  the  two  PRC  
complexes  were  conjugated  to  SUMO2  in  response  to  heat  stress  (Figure  4.22B).  Little  is  
known  how  SUMO  conjugation  influences  the  mammalian  PcG-­‐‑dependent  repression,  
except   that   sumoylated   E3   SUMO-­‐‑protein   ligase   CBX4   mediates   the   recruitment   of  
PRC1  to  murine  DNA  (Kang  et  al.,  2010).    





Figure   4.21   |   Multiple   members   of   macromolecular   protein   complexes   involved   in   DNA  
transcription  or  RNA  processing  are  conjugated  to  SUMO2T90K  in  response  to  heat  stress.  
Interaction   networks   of:   (A)  Spliceosomal   snRNP   complex   (accession   no.   GO:0097525;  
Bonferroni-­‐‑corrected   p-­‐‑value   2.37  ×  10-­‐‑12),   or   (B)  RNA   polymerase   III   transcription   factor  
complex   (accession   no.   GO:0090576;   Bonferroni-­‐‑corrected   p-­‐‑value   4.14  ×  10-­‐‑4).   Cellular  
component-­‐‑based   annotation   was   retrieved   from   Gene   Ontology   database   using   PANTHER  
Classification  System  (The  Gene  Ontology  Consortium,  2015;  Mi  et  al.,  2016).  As  indicated,  the  
colour  of  the  nodes  represents  the  number  of  sumoylation  sites  identified  from  cells  cultured  at  
43  °C  (no.  of  GlyGlyK  sites).  Proteins  modified  in  unperturbed  cells  are  underlined.  The  shape  
of   the   nodes   illustrates   the   functional   class   of   the   protein   as   provided   by  Qiagen’s   Ingenuity  
Pathway  Analysis  database  (protein  family;  www.qiagen.com/ingenuity).  
  





Figure   4.22   |   Multiple   members   of   protein   complexes   involved   in   DNA   replication   or  
chromatin  remodelling  are  conjugated  to  SUMO2T90K  in  response  to  heat  stress.    
Interaction  networks  of:  (A)  Replisome  (accession  no.  GO:0030894;  Bonferroni-­‐‑corrected  p-­‐‑value  
2.69  ×  10-­‐‑9),   (B)  PcG   protein   complex   (accession   no.   GO:0031519;   Bonferroni-­‐‑corrected   p-­‐‑value  
2.25  ×  10-­‐‑12),   or   (C)  MCM   complex   (accession   no.   GO:0042555;   Bonferroni-­‐‑corrected   p-­‐‑value  
7.94  ×  10-­‐‑3).  Cellular  component-­‐‑based  annotation  was  retrieved  from  Gene  Ontology  database  
using  PANTHER  Classification  System  (The  Gene  Ontology  Consortium,  2015;  Mi  et  al.,  2016).  
As   indicated,   the   colour   of   the   nodes   represents   the   number   of   sumoylation   sites   identified  
from  cells  exposed  to  heat  stress  (no.  of  GlyGlyK  sites).  Proteins  modified  in  unperturbed  cells  
are  underlined.  The  shape  of  the  node  illustrates  the  functional  class  of  the  protein  as  provided  
by   Qiagen’s   Ingenuity   Pathway   Analysis   database   (protein   family;   www.qiagen.com/  
ingenuity).  




Nine   out   of   11   proteins   of   the  Minichromosome  maintenance   (MCM)  DNA   helicase  
complex,   with   all   of   the   six   core   subunits   (Mcm2–7)   contained   Gly-­‐‑Gly-­‐‑lysines   in  
response   to   proteotoxic   stress   (Figure   4.22C).   In   budding   yeast,   sumoylation   of   all  
Mcm2–7  subunits  occurs  exclusively  upon  their  loading  onto  chromatin  and  regulates  
the  initiation  of  DNA  replication  by  preventing  premature  origin  firing  (Wei  and  Zhao,  
2016).   The   structure   of   S.  cerevisiae   heterohexameric   MCM   helicase   has   been  
determined   (Li   et   al.,   2015),   and  mapping   of   the   16   conserved   and   resolved   SUMO2  
modification   sites   onto   the   surface   of   the   complex   showed   that   none   of   the   SUMO2  
molecules  would  be  expected  to  project  into  the  central  channel  of  the  complex.  This  is  
consistent  with  the  observation  that  only  chromatin-­‐‑loaded  MCM  is  sumoylated  (Wei  
and  Zhao,  2016).  However,  several  SUMO2-­‐‑targeted  lysines  located  to  the  interface  of  
individual   subunits   (Figure   4.23),   suggesting   that   sumoylation  and   the  association  of  
the  subunits  are  mutually  exclusive.  The  proposal  that  desumoylation  is  required  prior  
to   the   initiation   of   eukaryotic   DNA   replication   is   thus   supported   by   the   combined  
analysis  of  proteomic  and  structural  data  sets  (Li  et  al.,  2015;  Wei  and  Zhao,  2016).  This  
example  demonstrates  how  site-­‐‑specific  proteomic  studies  of  sumoylation  can  support  
and  facilitate  the  discovery  of  the  function  of  SUMO2  modification.    





Figure   4.23   |  SUMO2T90K-­‐‑modified   lysines   locate   to   the   interface   of   individual   subunits   of  
MCM  complex.    
(A)  Molecular  interface  between  Mcm5  (blue)  and  Mcm2  (yellow)  with  three  SUMO2T90K  target  
lysines   highlighted   in   red.   (B)  Molecular   interface   between  Mcm4   (purple)   and  Mcm7   (cyan)  
with  two  SUMO2T90K  target  lysines  highlighted  in  red.  PDB  entry:  3JA8  (Li  et  al.,  2015).  
  





 Global  effects  of  heat  on  the  HEK2936His-­‐‑SUMO2-­‐‑T90K  proteome    4.3.1.
Exposure  of  cells  to  elevated  temperature  triggers  a  rapid  and  extensive  accumulation  
of  aggregation-­‐‑prone  mis-­‐‑  and  unfolded  proteins,  which  serve  as  stress  signals  for  the  
activation  of  a  cellular  programme  known  as  the  heat  shock  response  (Ananthan  et  al.,  
1986;   Wallace   et   al.,   2015).   Stress-­‐‑induced   expression   of   a   specific   group   of   genes  
encoding  molecular   chaperones   is   required   to  maintain   the   conformational   integrity  
and  the  homeostasis  of  the  proteome  (proteostasis)  (Lindquist,  1986;  Ellis,  1987;  Hartl,  
1996).   However,   the   global   production   of   proteins   is   repressed   at   multiple   levels   of  
gene   regulation   via   the   inhibition   of   posttranscriptional   splicing   of   RNA,   reduced  
initiation   of   translation,   or   halt   in   translation   elongation   (Bond,   1988;   Spriggs   et   al.,  
2010;   Shalgi   et   al.,   2013;   Shalgi   et   al.,   2014).   Meanwhile,   the   degradation   of   most  
eukaryotic   proteins   is   unaffected   by   hyperthermia   (Medicherla   and  Goldberg,   2008).  
Consistent   with   these   observations,   the   absolute   abundance   of   nearly   all   proteins  
remained   unaltered   in   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   during   a   30-­‐‑minute   heat   treatment  
(Figure  4.7).    
Exposure   of   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   to   elevated   temperature,   however,   induced   a  
substantial   localisation   reorganisation   of   the   proteome,   and   the   abundance   of   more  
than   a   thousand   proteins   increased   in   the   nuclear   or   decreased   in   the   cytoplasmic  
fraction  by  at  least  twofold  (Figure  4.8  and  Figure  4.9).  Interestingly,  these  fold  changes  
were   in   general   produced   by   a  minor   proportion   of   the   corresponding  protein   pool,  




prior   to   the   heat   treatment.   Using   SILAC-­‐‑based   quantitative   proteomics,   nuclear  
accumulation  of  chaperones,  co-­‐‑chaperones  and  subunits  of   the  26S  proteasome  have  
been  described  in  HeLa  cells  exposed  to  hyperthermia  for  2  hours  (Raychaudhuri  et  al.,  
2014).   In   the   current   study,   components   of   the   protein   ubiquitination   pathway  were  
also  significantly  overrepresented  among  the  1129  proteins  with  more  than  a  twofold  
increase   in   the   nuclear   fraction   (p-­‐‑value   9.65  ×  10-­‐‑27).   In   particular,   the   nuclear  
abundances   of   17   (co)-­‐‑chaperones   and   30   subunits   of   the   26S   proteasome   were  
increased   in   response   to   hyperthermia.   However,   the   spatial   distributions   of   the  
members  of   the   two  protein   families  were  remarkably  different   in  heat-­‐‑stressed  cells,  
as   chaperones   and   co-­‐‑chaperones   were   mostly   nuclear,   but   the   average   nuclear  
proportion   of   26S   proteasome   subunits   was   only   22  %   (Supplementary   table   S2;  
Appendix  6.1).    
Currently,   there   are   no   procedures   that   enable   to   obtain   subcellular   fractions   with  
proteins  derived  exclusively   from  nucleus  or  cytoplasm.  A  relatively  defined  fraction  
of   cytoplasmic   proteins   can   be   produced   through   gentle   disruption   of   cells   under  
hypotonic  conditions.  However,   the  nuclear   fraction  will  contain  substantial  amounts  
of   cytoplasmic   proteins.   Alternatively,   cells   can   be   disrupted   in   the   presence   of  
detergents,  and  the  stringent  isolation  of  nuclei  will  remove  most  of  the  contaminating  
cytoplasmic   material.   However,   soluble   nuclear   proteins   can   leach   out   into   the  
cytoplasmic   fraction.   In   this   study,   fractionation   of   HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   was  
optimised   to   produce   a   clean   preparation   of   nuclear   proteins,   including   SUMO-­‐‑
conjugated  substrates.  As  a  consequence,  the  cytoplasmic  fraction  was  less  defined  and  
contained   molecules   with   predicted   nuclear   localisation   (Figure   4.5   and   Figure   4.6).  




microscopy-­‐‑based   experiments   revealed   their   predominantly   nuclear   localisation  
irrespective  of   the  culturing   temperature   (Figure  4.10  and  Figure  4.11).  Notably,  both  
proteins  accumulated  in  subnuclear  foci   in  response  to  hyperthermia,  suggesting  that  
the   recruitment   of   HSF1   or   SUMO2/3   to   these   foci   could   facilitate   their   nuclear  
retention  during  the  subcellular  fractionation  procedure.  Therefore,  the  extensive  heat-­‐‑
induced   increase   of   proteins   in   the   nuclear   fraction   could   be   explained   by   two  
phenomena:  
1) Nuclear  proteins  could  be  maintained  in  the  compartment  through  recruitment  
to  components  of  the  nuclear  structure  such  as  chromatin,  as  observed  for  HSF1  
and  SUMO2/3.    
2) Cytoplasmic  proteins  could  be  translocated  to  the  nucleus.    
Importantly,   these   phenomena   are   not   mutually   exclusive.   Upon   heat   shock,   YTH  
domain-­‐‑containing   family  protein  2   (YTHDF2)   relocates   to   the  nucleus  of  HeLa  cells,  
where   it  promotes  N6-­‐‑adenosine-­‐‑specific  methylation  of   the  5’  untranslated   region  of  
mRNA   and   thus   assists   the   cap-­‐‑independent   translation   initiation   of   selected  
transcripts   (Zhou   et   al.,   2015).   In   agreement   with   this   observation,   the   nuclear  
proportion  of  YTHDF2  was  increased  from  30  %  to  nearly  75  %  in  HEK2936His-­‐‑SUMO2-­‐‑T90K  
cells  cultured  at  43  °C  (Supplementary  table  S2;  Appendix  6.1).    
 Heat-­‐‑induced  reprogramming  of  protein  sumoylation  4.3.2.
Similarly   to   the   rapid   aggregation   of   aberrant   proteins,   increased   conjugation   to  
6His-­‐‑SUMO2T90K   was   observed   within   minutes   of   heat   treatment,   occurring  




inhibits   heat-­‐‑induced   protein   sumoylation   and   correlates   with   the   increased  
production   of   various   heat   shock   proteins   (HSPs)   (Kurepa   et   al.,   2003;   Seifert   et   al.,  
2015).  Notably,  SUMO  conjugation  is  restored  by  pharmacological  inhibition  of  a  Heat  
shock  protein  HSP90,   suggesting   that   SUMO  modification   is   repressed   by  molecular  
chaperones   (Seifert   et   al.,   2015).   According   to   in   vitro   experiments,   Lys10   in   the  
N-­‐‑terminal   α-­‐‑helix   of   Ubiquitin-­‐‑conjugating   enzyme   E2  K   (E2-­‐‑25K)   is   sumoylated  
when  residing  in  an  unstructured  peptide  (Pichler  et  al.,  2005).  In  this  study,  Lys10  was  
conjugated  to  6His-­‐‑SUMO2T90K  only  in  cells  cultured  at  43  °C,  suggesting  heat-­‐‑induced  
denaturation   of   E2-­‐‑25K   (Supplementary   table   S3;   Appendix   6.1).   Interestingly,  
sumoylation   can   promote   the   solubility   of   aggregation-­‐‑prone   proteins,   such   as  
α-­‐‑synuclein,  Ataxin-­‐‑7  or  Androgen  receptor,  and  suggests  that  conjugation  to  SUMO2  
may  attenuate  aggregation  of  un-­‐‑  and  misfolded  proteins  accumulating  after  exposure  
to   proteotoxic   stress-­‐‑stimuli,   such   as   heat   (Mukherjee   et   al.,   2009;   Janer   et   al.,   2010;  
Krumova  et  al.,  2011).  
More   than   380   proteins   were   conjugated   to   SUMO2   in   unperturbed  
HEK2936His-­‐‑SUMO2-­‐‑T90K  cells.  Most  of  these  substrates  function  in  transcription,  processing  
of   RNA,   remodelling   of   chromatin,   or   DNA   replication,   recombination   and   repair  
(Figure  4.13).  The  rapid  increase  in  SUMO  conjugation  observed  in  heat-­‐‑stressed  cells  
(Figure  4.3)  resulted  in  a  substantial  group  of  2311  sumoylated  proteins.  Many  of  these  
substrates   contained  multiple   SUMO2-­‐‑modified   lysines  with   the   number   of   protein-­‐‑
specific   target   sites   reaching   as   many   as   60   (Figure   4.15).   Moreover,   the   concurrent  
modification  of  adjacent  lysines  was  confirmed  for  several  conjugates  (Supplementary  
table  S4;  Appendix  6.1).  Interestingly,  the  extensive  heat-­‐‑induced  SUMO2  modification  




affiliated   with   the   same   macromolecular   complexes   (Figure   4.21   and   Figure   4.22).  
Synchronous  sumoylation  of  entire  groups  of  either  physically  or  functionally-­‐‑related  
proteins   has   been   suggested   to   contribute   to   the   formation   of   macromolecular  
complexes   through   multiple   SUMO-­‐‑SIM   interactions   between   individual   binding  
partners  (Psakhye  and  Jentsch,  2012).  The  substrate  selectivity  could  thus  be  provided  
by   the   recruitment   of   a   limited   number   of   E3   SUMO-­‐‑protein   ligases   to   these  
multiprotein  complexes  (Jentsch  and  Psakhye,  2013).  Supporting  this  suggestion,  an  E3  
SUMO-­‐‑protein   ligase   CBX4   is   a   member   of   the   Polycomb   group   of   epigenetic  
repressors  that  were  extensively  modified  in  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  cultured  at  43  °C  
(Figure  4.22)   (Kagey  et  al.,  2003).  Likewise,  SUMO2  modification  of  chromatin-­‐‑bound  
proteins   depends   on   the   expression   of   four   genes   encoding   E3   SUMO-­‐‑protein   ligase  
PIAS   proteins,   for   which   the   heat-­‐‑induced   recruitment   to   active   DNA   regulatory  
elements  shows  a  similar  kinetics  to  SUMO2  (Seifert  et  al.,  2015).    
The   sequence   environment   of   ~56.4  %   of   the   612   lysines   sumoylated   in   unperturbed  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   conformed   partially   to   a   SUMO   consensus   motif   [V/I]KxE  
(Figure   4.16   and   Figure   4.17),   which   is   directly   recognised   by   SUMO-­‐‑conjugating  
enzyme   Ubc9   (Rodriguez   et   al.,   2001;   Sampson   et   al.,   2001;   Bernier-­‐‑Villamor   et   al.,  
2002).  Most  of  these  345  lysine  residues  were  found  outside  regular  protein  secondary  
structure   elements,   consistent   with   the   concept   of   Ubc9   binding   the   conventional  
consensus  motif  if  the  sequence  is  presented  in  an  unstructured  conformation  (Figure  
4.20).   The   number   of   target   lysines   with   either   increased   sumoylation   status   or  
modified  exclusively  after  heat  treatment  increased  to  7815  in  HEK2936His-­‐‑SUMO2-­‐‑T90K  cells  
cultured  at   43  °C   (Supplementary   table  S3;  Appendix  6.1).  The  amino  acid   context  of  




consensus  motif  (Figure  4.16  and  Figure  4.17;  ~[V/I/L]Kx[E/D]).  Approximately  22.6  %  
of   them   matched   to   an   inverted   SUMO   consensus   motif   [E/D]xK,   which   was  
overrepresented   among   the   sumoylation   sites   identified   from   heat-­‐‑stressed  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   alone.   However,   the   largest   heat-­‐‑induced   increase   was  
observed   among   Gly-­‐‑Gly-­‐‑lysines   not   conforming   to   any   known   consensuses   and  
constituted  to  a  nearly  40  %  of  the  SUMO2  modification  sites   identified  after  the  heat  
treatment   (Figure   4.17B).   In   addition,   the   proportion   of   sites   residing   in   predicted  
helical   secondary   structure   elements  was   increased   among   non-­‐‑consensus   sequences  
and  heat-­‐‑induced  SUMO2  modification  sites  (Figure  4.20).  Whether  these  alterations  to  
the   primary   and   secondary   structure   contexts   of   SUMO2   modification   sites   were  
promoted   by   the   relaxed   sequence   specificity   of   Ubc9,   recruitment   of   particular   E3  
SUMO-­‐‑protein   ligases,  denaturation  of   substrates,  or   all   three  events   simultaneously,  
requires  further  investigation.    
 Future  perspectives  4.3.3.
The  challenge  for  future  research  will  be  the  interpretation  of  large  databases  of  protein  
localisation  or  SUMO2  modification  sites  identified  from  unperturbed  or  heat-­‐‑stressed  
HEK2936His-­‐‑SUMO2-­‐‑T90K   cells   (Supplementary   table   S3;   Appendix   6.1).   The   current   study  
has  described  changes  in  protein  localisation  in  response  to  hyperthermia,  however  the  
biology   that   underpins   these   changes   has   not   been   explored   experimentally.   Further  
investigation,   potentially   using   other   technology,   should   be   carried   out   to   reveal  
whether  these  changes  are  induced  by  biological  phenomena,  such  as  nuclear  retention  




separation   of   potential   protein   aggregates   with   the   nuclear   fraction   or   diffusion   of  
nuclear  proteins  to  the  cytoplasmic  fraction.    
As  exemplified  in  this   investigation  (Chapter  4.2.11  and  Figure  4.23),  combined  usage  
of   MS-­‐‑based   proteomics,   structural   and   biochemical   studies   can   assist   to   formulate  
hypotheses   that   together  with   the   subsequent   in   vivo   experiments   could  uncover   the  
physiological   role   of   sumoylation   of   many   substrate   proteins.   Alternatively,   these  
analyses  could  reveal  the  instances  when  protein-­‐‑group  modification  is  preferred  over  
substrate-­‐‑specific   SUMO   modification.   The   extent   of   heat-­‐‑induced   sumoylation   of  
individual  members  of  the  SUMO  conjugation  machinery  suggests  the  hyperactivity  of  
the   pathway   in   heat-­‐‑stressed   cells.   Therefore,   distinguishing   between   the   relevant  
modifications  and  bystander  events  should  also  be  considered.    
A   number   of   age-­‐‑related   pathologies,   such   as   Huntington’s,   Parkinson’s   or  
Alzheimer’s   disease,   are   characterised   by   a   disruption   of   proteostasis.   SUMO   is  
conjugated   to   several  polypeptides   that   function   in   these  neurodegenerative  diseases  
(Sarge   and   Park-­‐‑Sarge,   2011).   The   comprehensive   database   of   proteotoxic   stress-­‐‑
induced  SUMO2  modification  sites,  provided  by   this   study,   could   thus  be  utilised  as  
an   in   vivo   model   system-­‐‑based   resource   to   uncover   the   physiological   role   of   the  
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6.1. Supplementary  files  and  tables  
The   mass   spectrometry   proteomics   data   associated   with   publications   provided   in  
Appendix  6.2  (Tammsalu  et  al.,  2014;  Kohler  et  al.,  2015;  Tammsalu  et  al.,  2015;  Pelisch  
et   al.,   2016)   have   been   deposited   to   the   ProteomeXchange   Consortium   (http://  
proteomecentral.proteomexchange.org)  via   the  PRIDE  partner   repository   (Vizcaino  et  
al.,  2016)  with  data  set  identifiers  PXD001281,  PXD002972  and  PXD005202.  
Unpublished   raw  MS   and  MaxQuant   output   files,   and   supplementary  materials   are  
available  upon  request.    
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